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Abstract
Following the publication of two large-scale randomised controlled trials in the early 1990s,
little doubt remains about the efficacy of carotid endarterectomy as a means of preventing
stroke in selected sub-groups of patients. However, the effectiveness and cost-effectiveness
of this intervention as a stroke prevention strategy are uncertain, as are the public health
implications when this strategy is applied to a population.
This thesis focuses on the effectiveness and cost-effectiveness of carotid endarterectomy as
a stroke prevention strategy in the Scottish population. The variation in uptake of carotid
endarterectomy by hospital and region between 1981 - 1996 is described by analysing a
unique set of patient linked data on hospital use and outcome following carotid surgery for
2892 patients. Stroke-free survival and overall survival before and after the publication of
the trial results for this cohort are also assessed. A systematic overview of studies
addressing the costs and benefits of carotid endarterectomy is conducted by critically
appraising the methodology and interpretation of previous cost and cost-effectiveness
estimates. Unlike previous studies, this thesis considers the resource implications of carotid
endarterectomy by estimating not only the procedure cost of carotid endarterectomy, but
also the overall NHS work-up costs for a large cohort of patients with transient ischaemic
attack referred to a Scottish teaching hospital for carotid endarterectomy assessment,
investigation and surgery. Finally, as part of the analysis of cost-effectiveness estimates for
Scottish patients, a novel use of the European Carotid Surgery Trial data has enabled
assessment of the transferability of efficacy results obtained in a randomised controlled trial




Carotid endarterectomy as a strategy for stroke prevention has evolved over many
decades since the first successful removal of a stenosed segment of the carotid artery
reported in 1954 (Eastcott et al., 1954). Two large randomised controlled trials
(European Carotid Surgery Trialists' Collaborative Group, 1991; (ECST) North
American Symptomatic Carotid Endarterectomy Trial Steering Committee, 1991
(NASCET) have showed that in selected patients with symptomatic internal carotid
artery stenosis of 70% or more, carotid endarterectomy (CEA) in addition to best
medical therapy is associated with a significant reduction in the rate of stroke
compared with best medical therapy alone. The number needed to treat to prevent
one stroke of any kind is estimated at seven to ten patients over a two to three year
follow-up.
Patients who have experienced a transient ischaemic attack (TIA) are at an increased
risk of stroke (Dennis et al., 1990). Some TIAs are due to carotid stenosis and as
mentioned, carotid endarterectomy has been shown to reduce the risk of stroke in
carefully selected symptomatic patients with carotid stenosis of 70% or more. The
identification and management of patients with TIAs is one of many strategies,
which might reduce the number of strokes further. Estimates suggest that if carotid
endarterectomy were performed on all eligible patients with transient ischaemic
attack in England, the annual incidence of first-ever strokes would decrease only by
0.5% (Dennis et al., 1991). Estimates of the economic implications of performing
carotid endarterectomy as a stroke prevention strategy are however not available.
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Chapter One: Introduction
Though there is now little doubt concerning the efficacy of carotid endarterectomy
for some selected subgroups, the cost implications and the outcome of this procedure
outside trial conditions have not yet satisfactorily been addressed.
1.1 Stroke
Stroke is the second most common cause of death worldwide accounting for nearly
4.5 million deaths per year (Murray and Lopez, 1997a), and the sixth most common
cause of premature disability (Murray and Lopez, 1997b). In Scotland about thirteen
percent of all deaths annually are attributed to stroke (Information and Statistics
Division, National Health Service, Scotland, 1995). This is the third most common
cause of death in Scotland after heart disease (30%) and cancer (25%) and one of the
most common causes of physical disability (Secretary of State for Health, London:
HMSO, 1991). The management of patients who have had a stroke is estimated to
consume about 4% of National Health Service resources in Scotland (Isard and
Forbes, 1992).
The epidemiology ofstroke.
With the exception of the available mortality statistics, very little is known about the
epidemiology and incidence of stroke in Scotland. Stroke is defined as a clinical
syndrome characterised by "rapidly developing symptoms and/or signs of focal and
at times global loss of cerebral function, lasting longer than 24 hours or leading to
death, with no apparent cause other than that of vascular origin" (Aho et al., 1980).
Stroke events can be classified as major, disabling, fatal or minor strokes. A major
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stroke is defined as symptoms lasting longer than seven days; a disabling stroke is a
stroke that after six months is still associated with disability as recorded on the
modified Rankin Scale of 3, 4 or 5. A fatal stroke is considered to have caused the
death of the patient (ECST Trialists' Collaborative Group, 1998) and a minor stroke
refers to an acute disturbance of focal neurological function with symptoms lasting
more than 24 hours and less than seven days. A minor stroke is by definition not
disabling after one week of onset.
The incidence of a disease quantifies the number of new cases that develop in a
population of individuals at risk during a specified time interval. The incidence of
stroke however appears to be relatively similar for Caucasians in most developed
countries where it has been studied. Stroke incidence rates rise exponentially with
increasing age, from about 30 per 100 000 population in the third and fourth decades
to almost 3000 per 100 000 in the eighth and ninth decades (Bonita, 1992; Malmgren
et al., 1987). The age-and-sex standardised incidence of first-ever stroke appears to
be somewhere between 200 and 400 per 100 000 per year in those aged between 45
and 84 years (Sudlow et al., 1997). The annual age-and-sex standardised incidence
reported in the Oxford Community Stroke Project, 1981 - 1985, the only true
incidence study from the United Kingdom, was 200 per 100 000 persons (Bamford et
al., 1988). Using these incidence rates as reference, between 10 000 and 20 000 first-
ever strokes per year can be expected in the Scottish population of about five million.
3
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The economic burden ofstroke.
The economic burden of stroke can be defined in terms of the direct cost of providing
medical care to patients and the indirect cost associated with lost productivity and
other intangible costs. A third of all strokes are fatal and another third will recover
and remain relatively independent. The remaining third however will be dependent
and will require long-term care. Murray and Lopez ranked cerebrovascular disease as
the sixth most common cause of premature disability worldwide using disability-
adjusted life-years (DALYs). The burden of premature mortality and disability
attributed to stroke and quantified in terms ofDALYs is not available for the Scottish
population neither is the economic impact of this disability. A fatal stroke may incur
a small cost. Those who recover will require acute stroke care and probably some
form of rehabilitation for a short period, but those left dependent will be using a
considerable amount of available health care resources. Hence the need to estimate
the lifetime cost of stroke using an incidence-based approach. Several early studies
using an incidence-based approach have estimated the lifetime cost of stroke (Mills
et al., 1978; Hartunian et ah, 1980). More recent studies from the United States and
the Netherlands have been published estimating the economic burden of stroke both
with regards to the individual and society and also distinguishing between the acute
care cost and the life-time cost of stroke (Taylor et al., 1996; Bergman et al., 1995).
Similar studies from the United Kingdom or Scotland have not been identified. Only
once the lifetime cost of stroke has been quantified, will it be possible to determine
the "total" economic burden of stroke and the cost-effectiveness of stroke prevention
strategies such as carotid endarterectomy.
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Prevalence-based studies estimating the cost of treating stroke in a given year have
been reported from Canada, Sweden, the United Kingdom, The Netherlands, New
Zealand and the United States (Smurawska et ah, 1994; Terent et al., 1994; Asplund
et ah, 1993; Persson et ah, 1990; Isard and Forbes, 1992; Evers et ah, 1997; Alberts
et ah, 1996; Scott et ah, 1994; Matchar et al, 1996). The cost of stroke using a
prevalence-based approach accounted for about 4.3 % of the total National Health
Service expenditure in Scotland (Isard and Forbes, 1992). Prevalence-based studies
are valuable in identifying the costs of stroke at a given time, however they provide
little insight into the lifetime cost associated with stroke incident cases.
The management ofstroke
One of the national targets in the United Kingdom is to reduce the mortality for
stroke in people between 65 and 75 years of age by at least 40% by the year 2000.
(Secretary of State for Health. HMSO, 1991). A more recently published Green
Paper on the future of the public health strategy, proposed to reduce the mortality
from heart disease and stroke and related illness amongst people younger than 65
years by at least one-third, from 66.2 to 44.1 per 100 000 population, by 2010. ("Our
Healthier Nation - A contract for Health" 1998) Two alternatives could be
considered to achieve this objective. Firstly strategies to prevent stroke and secondly




Optimal pharmacological treatment for acute stroke is not yet available, although
various treatment modalities are being investigated. The treatment of stroke patients
during the acute phase in dedicated stroke units has however showed benefits to a
"wide range of stroke patients in a variety of different ways" including a reduction in
death and a reduction in the need for institutionalised care as result of a reduction in
disability (Stroke Unit Trialists' Collaboration, 1997; Langhorne et al., 1995).
Strokeprevention, the decline ofstroke and the contribution of risk factors.
Time trends in stroke incidence have been observed, and it is possible that stroke is
becoming less common. These changes in the stroke incidence began more or less at
the same time as the control of hypertension improved in the community. Although
hypertension control in residents in Rochester, Minnesota continue to improve during
the 1970s and 1980s, the stroke incidence rates stabilised or even increased
(Broderick et ah, 1989). Changes in potential risk factors, other than hypertension,
could be contributing factors to the initial decline observed.
Data on trends in stroke incidence are limited. Small community-based cohort studies
have been identified in which incidence trends were studied over time (Broderick et
al., 1989; Terent, 1988; Ueda et al., 1981; Tuomiletho et al., 1991). From published
data, it is apparent that trends in stroke incidence in different countries do not follow
a similar pattern. The time trend information most widely quoted comes from
Rochester, Minnesota where the stroke incidence declined remarkably during the
1950s and 1960s. An overall average annual decline (3.1 per 100 000) in the
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incidence rate, adjusted for age and sex has been observed over time (1945 - 1949 to
1955 - 1959) in Rochester, Minnesota (USA), (Garraway et ah, 1979). However, this
trend did not continue into the 1980s, instead an increase in stroke incidence has been
reported (Broderick et al., 1989). The Framingham Study beginning in 1953 and
investigating the secular trends in stroke incidence, prevalence and fatality found a
significant decline in stroke severity over the three decades but no change in the
incidence of stroke. (Wolf et al., 1992). These two studies however, are not
representative of the American population as a whole. No overall decline was
reported in the incidence rate from Auckland over the study period of 1981 - 1991
(Bonita et al., 1993).
Studies from Denmark reported conflicting results: one study between 1972 and
1990 reported an increase in men (Jorgenson et al., 1992). A second study found no
significant change in men or women for the period 1976 to 1988 (Lindenstrom et al.,
1993). A decline in the stroke incidence in men and women aged 65 to 84 years was
reported in another study from Denmark for the period 1976 to 1993, but the decline
was only significant in men (Truelsen et al., 1997).
No change in stroke incidence was reported from one study in Goteborg Sweden
(Harmsen et al., 1992). An increase in the stroke incidence has however been
reported from Soderhamn, Sweden in women, but the over 85-year age group was
responsible for most of the increase. A decline in stroke incidence has been reported
from studies in Finland and Japan (Tuomiletho et al., 1991; Ueda et al., 1981). It is
important to note that the study years for these studies reporting the incidence rates
of stroke were more or less during the same time periods except for a more recent
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study in a well-defined population in France which reported relatively stable
incidence rates over the period 1985 - 1994 (Lemesle et al, 1999).
Other possible reasons associated with the changes in stroke incidence include:
• the improved management ofmodifiable risk factors (Wolf, 1993)
• differences in the decline in the incidence of specific stroke subtypes with a high
case-fatality and
• an increased awareness and recognition of transient ischaemic attacks by the
general population as well as by physicians;
• the availability of computed tomography (CT scanning) during the latter half of
the 1970s which appears to have increased the detection of less severe stroke
cases which would have otherwise not have been diagnosed as a stroke event
(Broderick et al, 1989; Wolf et al., 1992).
The end of a decline in the incidence of stroke might be considered artefactual, due to
increased case ascertainment by computed tomography. It could be argued that all
incidence rates before the advent of CT scanning were under estimations; though this
is contentious as the probability of a definite diagnosis of stroke on clinical
examination is high (Broderick et al., 1989; Shahar et al., 1995; Barker and
Mullooly, 1997).
Risk factors for stroke.
There are several well-recognised risk factors for stroke. Increasing age and
increasing blood pressure are the two factors most strongly associated with stroke,
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followed by symptomatic vascular disease (ischaemic heart disease, transient
ischaemic attack and peripheral vascular disease), carotid stenosis and cervical bruit.
Cigarette smoking, diabetes mellitus, valvular heart disease and a high plasma
fibrinogen are all moderately associated with stroke (Hankey et ah, 1994).
Although carotid stenosis of 70% or more in symptomatic patients is associated with
a high relative risk of stroke, as a risk factor it may have very little impact on the
overall incidence of stroke if the prevalence of carotid stenosis in the population is
low.
Patients who have had a TIA are at an increased risk of stroke as well as other serious
vascular events. (Dennis et al., 1990). In addition to the treatment of hypertension the
risk of stroke in TIA patients can also be reduced by about 25% by using aspirin,
(Antiplatelet Trialists' Collaboration, 1988) and by about 12% by performing carotid
endarterectomy for appropriately selected patients. (European Carotid Surgery
Trialists' Collaborative Group, 1991; North American Symptomatic Carotid
Endarterectomy Trial, 1991). While carotid endarterectomy has been shown to
reduce the risk of stroke in the medium term in selected patients, the impact of this
strategy on the overall incidence of stroke is very small representing only a 0.5%
reduction in the incidence of first stroke (Dennis and Warlow, 1991). Although
aspirin and carotid endarterectomy have been found to reduce the risk of stroke
neither is likely to prevent more than 4% of all strokes norwill the reduction of blood
pressure in hypertensive TIA patients prevent many strokes. (Warlow et ah, 1996)
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1.2 Transient ischaemic attack and carotid stenosis.
Only about 15% of strokes are preceded by TIAs and only a small proportion are as
result of severe carotid stenosis (Warlow et al., 1996). Strokes can present so soon
after a TIA not allowing time for the implementation of treatment. Treatment is
furthermore not 100% effective, is also associated with risks and patient compliance
with treatment is not always optimal. The majority of TIA-patients are eligible for
aspirin and/or hypertension control. This is not the case for carotid endarterectomy,
which is only indicated, in recently symptomatic patients with stenosis ofmore than
70% and who are fit for surgery "perhaps only 10% of all hospital referred TIA
cases" (Hankey et al., 1992). Persons who have experienced a carotid territory
transient ischaemic attack (TIA) or minor non-disabling stroke within the previous
six months might be considered suitable candidates for carotid endarterectomy.
Incidence ofTransient Ischaemic Attack. (TIA)
A transient ischaemic attack is an acute disturbance of focal neurological or
mononuclear function with symptoms lasting less than 24 hours and (after adequate
investigation) assumed to be due to vascular disease of an embolic or thrombotic
kind (UK-TIA study group, 1991). The true incidence rate of TIA is difficult to
determine for various reasons. Patients experiencing a TIA do not always present to a
health care professional and even when they do, their symptoms may not be
diagnosed correctly. Patients often present to medical practitioners with only the
history of the event and with very little, if any clinical signs still present. Since the
clinical histories described are often vague and non-specific, an appropriate diagnosis
Chapter One: Introduction
is only possible if the medical practitioners have a high index of suspicion of the
disease.
Transient ischaemic attack incidence studies have been performed in several
countries. A total of 25 studies have been identified over a 30 - year period. The
earliest study was by Acheson and others in the United Kingdom in 1968 (Acheson
et al., 1968) and the most recent study describing the incidence of transient ischaemic
attacks was from Spain in 1996 (Sempere et ah, 1996). Six studies were reported
from the United States ofAmerica from 1969 to 1990 (Friedman et ah, 1969; Karp et
ah, 1973; Whisnant et ah, 1973; Rhoads et ah, 1980; Alter et ah, 1985; Lai et ah,
1990). Three studies each were reported form Sweden (Terent et ah, 1979; Mettinger
et ah, 1984; Terent et ah, 1988) and Italy (Fratiglioni et ah, 1989; Ricci et ah, 1991;
Lauria et ah, 1996). Four countries, each reported two studies. These countries were
the United Kingdom (Acheson et ah, 1968; Dennis et ah, 1989) Denmark
(Liddegaard et ah, 1986; Uggerhoj Anderson et ah, 1988), Australia (Stewart-Wynne
et ah, 1992; Shah et ah, 1995) and Spain, (Matias-Guiu et ah, 1994; Sempere et ah,
1996). The studies form Australia and Spain were also the most recent studies
reported. One study each was reported from the five countries: Estonia (Zupping and
Roose 1976), China (Li et ah, 1985), Norway (Johnson and Skre, 1986), France
(Giroud et ah, 1986) and Japan (Ueda et ah, 1988). Of the 25 studies, 19 were
primarily incidence studies, and six (Karp et ah, 1973; Whisnant et ah, 1973; Li et
ah, 1985; Ueda et ah, 1987; Fratiglioni et ah, 1989; Matias-Guiu et ah, 1994) also
reported on the prevalence of the disease.
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Criteria for "ideal" stroke incidence studies have been previously outlined.
(Malmgren et al., 1987, Sudlow et al., 1996). These criteria, although primary
developed for stroke incidence studies, are also applicable and relevant to all studies
determining disease incidence. Discrepancies in the methodology used in the TIA
incidence studies restrict the potential for comparison in most instances. The main
concerns regarding the TIA incidence studies can be summarised as follows:
1) These studies were not representative of the total population for which an
incidence rate was calculated;
2) The lack of a standard definition used in these studies is regarded as a major main
constraint;
3) Case ascertainment was either by:
a) retrospective review of case notes (Friedman et al., 1969; Alter et al., 1970;
Whisnant et al., 1973; Zupping and Roose, 1976)
b) hospital discharges (Mettinger et al.,1984; Alter et al., 1985; Lai et al., 1990;
Liddegaard et al., 1986; Shah et al., 1995
c) survey techniques (Karp et al., 1973; Rhoads et al., 1980; Li et al., 1985;
Johnson and Skre, 1986; Urakami et al., 1987; Fratiglioni et al., 1989; Matias-
Guiu et al., 1994 and
d) prospective registers (Acheson et al., 1968; Terent et al., 1979; Giroud et al.,
1986; Terent et al., 1988; Uggerhoj Anderson et al., 1988; Dennis et al., 1989;
Ricci et al., 1991; Stewart-Wynne et al., 1992; Shah et al., 1995; Lauria et al.,
1996; Sempere et al.1996;
4) Small populations - less than20 cases (Karp et al., 1973; Johnson and Skre, 1986;
Ueda et al., 1987; (Matias-Guiu et al., 1994);
Chapter One: Introduction
5) Rates were also reported only for selective age groups with different age bands in
the different studies. Crude incidence rates instead of age and sex adjusted rates
were reported in these studies.
The crude annual TIA incidence rate in Western countries derived from these
prospective community studies prior to 1989, is about 5 per 100 000. (Dennis et al.,
1989). A more recent study by Sempere (1992-1994) reported a crude annual
incidence rate of 35 per 100 000 comparable with the rate reported by Dennis and
others. "Amaurosis fugax accounts for about 20% of all TIAs." (Uggerhoj Anderson
et al., 1988; Dennis, 1989) with a crude incidence rate of 6 per 100 000.
Notwithstanding all these inconsistencies, the crude incidence rates reported from the
various countries are very similar. The age-sex adjusted annual incidence rate of TIA
in the UK is estimated at about 42 per 100 000, (Oxfordshire Community Stroke
Project: 1981-1986, Dennis et al., 1989). It should however be mentioned that the
data from the OCSP relate to the 1980's, almost 20 years ago and also to an area
geographically and demographically different to Scotland where the morbidity and
mortality is likely to have been lower than that observed in Scotland. The average
annual risk of stroke during the first year after a TIA is about 11.6% and
approximately 5.9% per annum over the first five years after the TIA (Dennis et al.,
1990;Whisnant and Wiebers, 1987).
Prevalence of Transient ischaemic attack.
The prevalence of a disease is defined as the proportion of individuals in a population
who have the disease at a specific time interval. The prevalence, therefore refers to
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the status of the disease in the community and is usually more appropriate for the
description of chronic stable conditions such as TIA. The estimation of period
prevalence is considered a more suitable measure for acute transient conditions,
which are episodic than the estimation of point prevalence. There is considerable
variation in the prevalence of TIA. It increases with advancing age and differences
exist between whites and blacks and also between males and females.
Twelve community-based surveys (Ostfeld et al., 1973; Karp et ah, 1973; Whisnant
et al., 1973; Boysen et al., 1979; Wilkinson et al., 1979; Li et al., 1985; Urakami et
al., 1987 (Daisen, Japan); Urakami et al., 1987 (Ama, Japan) Ueda et al., 1987;
Fratiglioni et al., 1989; Matias-Guiu et al., 1994; Bots et al 1997) in five countries
have estimated the prevalence of TIA between the years 1965 to 1984. More recent
studies include a study from Spain (Matias-Guiu et al., 1994) and Rotterdam, the
Netherlands (Bots et al, 1997). Four studies (Ostfeld et al., 1973; Karp et al., 1973, Li
et al., 1985, Matias-Guiu et al., 1994) applied door-to-door survey methods in
selected populations and three studies (Wilkinson et al., 1979; Urakami et al., 1987;
Fratiglioni et al., 1989) used questionnaires. The numbers in these study populations
were small and not representative of the general population.
Prevalence ofcarotid stenosis
Carotid stenosis is defined as the narrowing of the carotid artery and is almost always
artherothrombotic in nature. The stenosis is at or near the bifurcation of the common
carotid artery into the external and internal carotid artery. The degree of stenosis is
expressed as the maximum percentage reduction in the diameter of the relevant
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carotid artery. The stenosis may be mild (defined as less than 30%), moderate (30 -
69%) or severe (70 -99%) (European Carotid Surgery Trialists' Collaborative Group,
1991). Although carotid stenosis of 70% or more in symptomatic patients is
associated with a high relative risk of stroke, as a risk factor it may have very little
impact on the overall incidence of stroke if the prevalence of carotid stenosis in the
population is low.
Four studies (Balow et al., 1966; Pessin et al 1977; Thiele et al., 1980;
Bogousslavsky et al., 1986) were identified estimating the prevalence of carotid
stenosis in symptomatic populations. TIAs were the presenting symptom in all four
of the studies, TIA and stroke in one study and TIA, stroke and amaurosis fugax in
another study. These studies were relatively small, ranging from 95 cases to 250
cases in the most recent study (Bogousslavsky et al., 1986). These four studies
display methodological differences, which hamper comparison. The modality used to
determine the percentage stenosis was angiography in all four of the symptomatic
populations. For stenosis of 75% or more the reported prevalence varies from 20%
(Bogousslavsky et al., 1986) to 39% (Pessin et al., 1977). The prevalence of carotid
occlusion is estimated at 5% based on all four studies. (Balow et al., 1966; Pessin et
al., 1977; Thiele et al., 1980; Bogousslavsky et al., 1986). Since these populations
from whom these rates were obtained were not representative of the general
population and were in most instances selected high-risk populations, prevalence rate
of 1% seems reasonable for the general population (Whittey et al., 1998). When
including only individuals 65 years and older a prevalence of 2 - 7% for severe
stenosis seems acceptable based on community studies (Whittey et al., 1998).
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The reported prevalence of carotid stenosis in asymptomatic patients varies from
32.5% (Hennerici et al., 1981) to 3.8% (Pujia et al., 1992). The populations from
whom these rates were obtained were again not representative of the general
population. A more recent study estimated the prevalence of asymptomatic carotid
atherosclerosis in a general population of 25.4% in men and 26.4% in females. (D'
Alessando et al., 1992) All the studies determining the stenosis in asymptomatic
populations are more recent (1981 - 1995) than the studies concerned with
symptomatic populations (1966 - 1986). Doppler ultrasound was used as the
investigating modality for the asymptomatic populations, and this non-invasive
assessment tool became available for assessing the carotid arteries, bifurcation about
20 years ago. (Blackshear et al, 1979)
A value of 20% is usually applied for stenosis greater or equal to 60% for
asymptomatic populations, with a high prevalence. In the case of low prevalence
asymptomatic populations (stenosis 60% or more), 5% is usually regarded as the
reference value (Chamber and Norris, 1985; Alexandrax et al., 1995; Ahn et al.,
1991; Hennerici et al., 1981; Luisiani et al., 1990; Pujia et al., 1992)
Identifyingpatients with extracranial internal carotid artery stenosis
Three methods can be used to detect extracranial internal carotid artery stenosis in
patients presenting with transient ischaemic symptoms. In the first instance it may be
inferred clinically through cervical auscultation for the presence of an arterial bruit
(though this is not an essential, and bruits may be present for reasons other than
internal carotid stenosis). A second method of detecting internal carotid stenosis is by
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means of non-invasive imaging techniques (ultrasonography, computed tomography
angiography, or magnetic resonance angiography.) Thirdly, internal carotid stenosis
may be detected by means of invasive imaging, which includes intra-arterial or
intravenous digital subtraction angiography or conventional cerebral angiography
(Hankey et al., 1990).
Before carotid surgery is considered, the carotid bifurcation must be imaged. The
peri-operative evaluation of potential candidates for carotid endarterectomy includes
duplex ultrasound and conventional carotid angiography or a combination of Duplex
ultrasound and magnetic resonance angiography supplemented by conventional
angiography. The majority of cases presenting with TIAs are assessed by taking a
proper history and doing a clinical examination. Most of the patients are then referred
for duplex examinations and only patients identified having stenosis more than 70%
and who are medically fit for surgery are referred for a conventional angiogram prior
to CEA.
Carotid angiography is currently regarded as the "gold standard" for examining the
carotid arteries and is considered to be 100% sensitive and specific. However, the
investigation is invasive and carries a risk of stroke or death of 1 - 2%. (ACAS,
1995). Duplex ultrasound is largely used as the first "tool" in the evaluation to assess
the degree carotid of stenosis in symptomatic patients. The procedure is overall well
tolerated and inexpensive, it is safe and the sensitivity and specificity range from
approximately 81% to 90% and 82% to 95% (Feussner et al., 1988; Blakeley at al.,
1995). The sensitivity increases to 94 - 99% for detecting stenosis more than 50%,
and in instances of occlusion the sensitivity and specificity of duplex sonography can
be between 91 - 99% and 84 - 96% respectively. The sensitivity and specificity
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however is highly dependent on the skill and experience of the operator and range
from 72 - 97% for sensitivity and from 83 - 95% for specificity. (Khaw, 1997). In
the hands of experienced, trained operators, adhering to validated duplex criteria,
carotid duplex imaging is safe, highly sensitive and specific.
Theproportion ofpatients who have a TIA before their stroke.
Three methods were described of ascertaining the proportion of patients with stroke
who have a TIA before their stroke (Hankey, 1986). The first method is to determine
the annual incidence of TIA and the prognosis of TIA over the average lifetime of a
TIA patient. The second is to describe the prevalence of TIA and the prognosis of
TIA based on the actuarial average annual rate of stroke and the third is to estimate
the proportion of people with a first-ever stroke who recall a previous TIA.
Incidence andprognosis of Transient Ischaemic Attack
The age-and-sex adjusted annual incidence rate of TIA in the UK is estimated at
about 42 per 100 000 (Oxfordshire Community Stroke Project: 1981-1986) (Dennis
et al., 1989). The average annual risk of stroke during the first year after a TIA is
about 12% and approximately 6% per annum over the first five years after the TIA or
30% at five years (Dennis et ah, 1990; Whisnant and Wiebers, 1987). Though
reliable community-based data regarding the long-term prognosis of people with TIA
for stroke are lacking, it is accepted that the probability of surviving ten years after a
TIA is about 55%. Since the long-term mortality rate after TIA is slightly greater
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than the long-term stroke rate, it is expected that 50% of people with TIA would have
suffered a stroke after 10-15 years (Dennis et al., 1990).
Applying these prognostic data to the Scottish population of five million, about 2500
incident TIA cases would be expected and about 300 (12%) would suffer a stroke
within the first year and about 1250 (50%) after 10-15 years. In any one year in
Scotland it is expected that 1250 (12.5%) of the 10 000 first strokes would have
occurred in patients who had a TIA in the preceding 10-15 years.
Prevalence andprognosis of Transient Ischaemic Attack.
It is suggested that a formula should be used to estimate the prevalence of TIA since
surveys conducted to determine the prevalence of TIA are all extremely
unsatisfactory and are unlikely to reflect the actual number of cases in the community
(Hankey, 1986). Prevalence is the product of incidence and survival and since
incidence and survival data are more accurate than prevalence data, it is regarded that
an estimate of the prevalence of TIA using this formula will be more reliable.
Though the long-term (beyond five-years) prognosis of people with TIA for stroke is
not known, the probability of surviving ten years after a TIA is about 55%, and 40%
in surviving 15 years (Goldner et al., 1971). Using this formula it is possible to
estimate the prevalence of TIA in Scotland at about 15 000 or 300 per 100 000. If
these 15 000 people who have previously experienced a TIA are to suffer a stroke at
the actuarial average annual rate of stroke of 6.5% per year over the first five years, it
would be expected that 975 (6.5%) of the 15 000 prevalent people with TIA would
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suffer a stroke each year making up 9.8 % of the 10 000 first strokes in Scotland each
year.
Theproportion ofpeople with a first-ever stroke who recall a previous TIA.
About 10 -15% of people who suffer a stroke recall having a TIA before their stroke,
and only half report these events to a doctor (Dennis et ah, 1989). This suggests that
each year in Scotland 1000 to 1500 people with a first-ever stroke recall having a
prior TIA and 500 - 750 of the 10 000 people with a first-ever stroke each year have
consulted their doctor about it.
Based on the three methods, the proportion of people with a first-ever stroke in
Scotland who had a TIA prior to the stroke is estimated at about 10 - 15% of the
10 000 annual incident strokes. The population attributable risk of transient
ischaemic attacks as a risk factor for stroke appears then to be about 10 - 15%.
Transient ischaemic attack is thus one of the risk factors for stroke that might be
responsible for 1000 -1500 of strokes in the Scottish population.
Applying the annual TIA incidence of 42 per 100 000 population and assuming that
25% of first-ever stroke (incidence of first-ever stroke 400 per 100 000) are non-
disabling strokes (Dennis et al., 1989) to the Scottish population of five million
people, we can expect about 2500 Transient Ischaemic Attacks (TIAs) per annum
and about 2500 (25%) first-ever non-disabling strokes. This will result in about 5000
patients who might be possible candidates for CEA. Of these 5000 Transient
ischaemic attacks and non-disabling strokes, 80% or about 4000 are in the carotid
territory and only 20% (800) have carotid stenosis of 70 to 99% and are eligible for
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carotid endarterectomy. If all of these 800 patients receive a carotid endarterectomy,
80 strokes might be prevented, less than 1% of the 10 000 strokes occurring annually
in Scotland.
It appears then that carotid endarterectomy has a small but significant role to play in
preventing disabling strokes, however this intervention might be quite costly and
certainly will not change the stroke burden. Since stroke is considered to be a
preventable disease the economic assessment of carotid endarterectomy as a stroke
prevention strategy, which might be ofbenefit to some patients, is long overdue.
From within this multifaceted and complex setting, this thesis aims to assess the
costs and benefits of carotid endarterectomy (CEA) in Scotland as a stroke
prevention strategy and the implications for the health care delivery system.
This objective will be achieved firstly by describing carotid endarterectomy in
Scotland with specific reference to the observed changes over time; the geographical
distribution of the procedure; survival of the CEA cohort over time and the influence
of the published randomised controlled trials and the cost implications using generic
cost measures such as bed days as proxy for cost.
Secondly, by performing a systematic review of the economic literature on carotid
endarterectomy, with special emphasis on the cost estimates and the cost-
effectiveness of carotid endarterectomy in Scotland.
Thirdly, by prospectively estimating the cost of carotid endarterectomy in three
hospitals in Scotland. And finally by assessing the transferability of the results from a
randomised controlled trial to a "real-life" population, by assessing the cost-
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effectiveness of carotid endarterectomy based on actual ("real-life") cost estimates
and by describing the lifetime cost associated with this procedure.
1.3 Thesis structure.
A chapter will be dedicated to each of these aspects and the structure of the thesis
will be as follows.
Chapter Two describes the carotid endarterectomy procedure in Scotland from 1981
to 1996. This situation analysis of CEA is the largest historical cohort analysed to
date in the United Kingdom and probably worldwide over the longest time period
and in excess of 12 500 patient-years of observation. The geographical distribution of
CEA, the hospital volume of CEA, the patients' characteristics and survival of the
Scottish CEA patients over time are discussed in relation to the findings of a
published randomised controlled trial. The cost of carotid endarterectomy is
estimated using generic measures such as bed days. The implications of prediction
models on the number of CEA needed to be performed are assessed as well the
recommendations from the randomised controlled trials on preferred centres.
Chapter Three presents the first systematic review of the studies on the costs and
benefits of carotid endarterectomy and pre-operative investigations prior to carotid
surgery as identified in the literature. This review has been conducted using a
standard evaluation protocol recommended to authors, referees and editors for the
review of economic submissions to journals. I have identified inconsistencies in the
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published economic literature and formulated possible explanations for the
discrepancies observed.
Chapter Four reports on the programme cost of carotid endarterectomy where the
"programme " is defined as the "work-up " cost of a cohort of patients who might be
considered for potential carotid endarterectomy and the CEA "procedure" cost in
hospital. This is the first study reporting on the total direct programme cost of CEA
and also the cost in the "work-up" of a cohort of patients for possible carotid
endarterectomy. This is also the first study reporting on the total direct procedure
cost of carotid endarterectomy in Scotland using patient specific cost data in a
prospective study obtained from two Scottish centres. The uncertainties that apply to
the cost estimates are discussed in terms of a sensitivity analysis. The "work-up" of
potential candidates from initial assessment at a neurovascular clinic to carotid
endarterectomy is described as well as implications of associated time delays. Based
on the proportions of patients investigated prior to CEA, a transition ratio from first
consultation to CEA was determined which will provide invaluable information in
estimating need for developing services such as "one-stop" transient ischaemic attack
clinics.
Chapter Five assesses the transferability of results from the randomised controlled
trial, the European Carotid Endarterectomy Trial, to a "real life" Scottish carotid
endarterectomy population. Only modelling studies have been identified
investigating the transferability of the efficacy of trial results to hypothetical
populations. This investigation is unique since the efficacy data from a randomised
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controlled trial and cost data from a study population representing a "real life"
surgical and medical population were investigated. The cost effectiveness of carotid
endarterectomy as it relates to data obtained from "real life" cohorts is evaluated in
terms of stroke prevention. Several null hypotheses related to the transferability of
trial results are tested in this chapter. The uncertainty associated with the cost
effectiveness of this procedure is assessed in a sensitivity analysis. The lifetime cost
of carotid endarterectomy is assessed using an incidence-based approach.
Chapter Six summarises the findings of this thesis and puts forward suggestions to
improve the delivery of health services and subsequently the cost-effectiveness of
carotid endarterectomy. Recommendations for future related research and
conclusions are formulated.
24
Chapter Two: Background - CEA in Scotland
CHAPTER TWO: BACKGROUND
CAROTID ENDARTERECTOMY IN SCOTLAND.
2.1 Introduction
There has been a marked increase in the number of carotid endarterectomies
performed in one centre in Scotland over the eight-year period, 1985 - 1993 (John et
al., 1993). A similar trend in the number of carotid endarterectomies within Great
Britain and Ireland has been documented over the past decade with a sharp rise in the
number of CEA during 1992, twice as many as during 1984 and 1989 respectively
(Murie et ah, 1994). McCollum and others found similar frequencies when
extrapolating audit data (McCollum et ah, 1997). This phenomenon has also been
observed in other countries (Tu et ah, 1998; Gillum, 1995). The onset of this increase
coincided to a large degree with the publication of the results from the two large
randomised controlled clinical trials (RCTs) during the early 1990s (ECST
Collaborative Group, 1991; NASCET Steering Committee, 1991). Guidelines on the
management of patients with carotid stenosis based on these trial results have
subsequently been published (Moore et ah, 1995, Findlay et ah, 1997, Scottish
Intercollegiate Guidelines Network, 1997).
More recently a six-fold increase in the number of carotid endarterectomies being
performed in Scotland has been described for the period 1989 to 1995. The
geographical inequality in the provision of CEA has also been highlighted in this
report, with the CEA rate per 100 000 resident population varying between 0 (two
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regions) and 19 (one region) (Adam et al., 1998). Despite the increase in the number
of carotid endarterectomies and the geographical inequality described, the cost
implications of this procedure, as a stroke prevention strategy has not been assessed
in Scotland, neither have the recommendations from the trials regarding the number
needed to treat to prevent one stroke been assessed.
The cost of carotid endarterectomy in Scotland is not known. Current data sources in
Scotland do not allow for an accurate cost estimation. The length of hospitalisation
for the procedure is a variable routinely collected in the national database of the
National Health Service (NHS) in Scotland, which can be used to estimate the cost of
carotid endarterectomy. Although this database incorporates Healthcare Resource
Groups (HRGs) based on the International Classification of Diseases (ICD) and on
the surgical operations and procedures of the Office of Population Censuses and
Surveys (OPCS) classification, HRG costs for Scotland are not available.
The routinely collected variables for patients who have had a carotid endarterectomy
include demographic variables, the presenting diagnosis according to ICD 9
classification, the operation code, prior admissions for transient ischaemic attacks
(Transient ischaemic attacks) and stroke, length of hospital stay, any admissions
following the procedure and cause of death by ICD 9 code (WHO; Geneva, 1989).
Mortality statistics are linked with the Government Statistical Services from the
General Registrars' Office. It is also possible to describe the frequency of carotid
endarterectomy over time from this database and examine how practice has changed
in relation to the publication of the large randomised controlled clinical trials.
Furthermore, routinely collected variables in this comprehensive database allow for
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the generation of many additional variables, which can be utilised in time to event
analysis, or survival analysis.
The objectives of this study are:
1. to describe the carotid endarterectomy procedure in Scotland from 1981 to 1996;
2. to assess the geographical and hospital variation in utilisation of CEA over time
in Scotland using routinely generated data;
3. to assess the characteristics and survival of the Scottish CEA patients over time
in relation to the findings of a published randomised controlled trial and
4. to estimate the cost of carotid endarterectomy using bed days as a proxy for cost.
At the outset of this chapter the national database, the ISD database, and how the
study population for this investigation was compiled from this database is briefly
discussed. A description of the study population and carotid endarterectomy over the
last sixteen years in Scotland follows. I describe and justify why the data set, the
Scottish ISD-CEA data set, has been divided into three almost equal five-year
periods. I perform time-to-event analyses for these three almost equal five-year
periods and compare the survival curves for different variables. The survival curves
obtained are subsequently compared to the survival reported from the randomised
controlled European Carotid Surgery Trial in Chapter five.
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2.2 Methods
2.2.1 Description of the studypopulation
The study population included a cohort of Scottish patients who had a carotid
endarterectomy procedure during the period 1981 to 1996 and were followed-up till
March 1997 (Scottish ISD-CEA data set). These patients were identified by means
of the Scottish Record Linkage System from the Information and Statistics Division
(ISD) of the Scottish Health Service. ISD was formed when the NHS (Scotland) Act
came into effect on 1 April 1974 and is responsible for the collection, processing and
dissemination of statistical information. A total episode of care is defined as the time
between an admission to a hospital and discharge from the health service, regardless
of intermediate transfers to other institutions. Computerised medical records at
national level in Scotland contain information about episodes of care by consultants.
Heasman described the potential to link these records on a patient specific basis at an
International Symposium in Oxford during 1967 (Heasman, 1968). Procedures have
been developed linking these episodes of care for individual patients, thereby
creating a comprehensive record for each patient containing all episodes of care
received (Heasman and Clarke, 1979).
The study population was thus identified through record linkage with the index event
specified as carotid endarterectomy, coding positions 0.828, L294 and L295
(Kendrick and Clarke, 1993). These codes were from the Tabular List of the
classification of surgical operations and procedures of the Office of Population
Censuses and Surveys 3 (OPCS 3) and the Office of Population Censuses and
Surveys 4 (OPCS 4) codes for the period 1981-1996 and were used to identify
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carotid endarterectomy patients (HMSO, London 1975 and 1990). OPCS 3 codes
were in use during the period 1981 to 1988 and the code 082.8 for operations of
arteries in the neck, NEC (endarterectomy) applies to this period. The OPCS 4
coding system which came into effect in 1989 and is still applicable, includes the
codes L29.4 (Endarterectomy of carotid artery and patch repair of carotid artery) and
L29.5 (Endarterectomy of carotid artery NEC).
Once the index event was identified, additional variables were extracted to inform the
proposed survival analysis. These additional variables were grouped into three
distinct categories. Variables related to the event itself, variables related to
subsequent episodes and variables related to diagnoses in the three months prior to
the carotid endarterectomy. The main events or end points of interest included any
subsequent hospitalised cerebrovascular event (stroke and TIA) and death from any
cause after the carotid endarterectomy.
Not all Scottish patients who were randomised to the European Carotid Surgery Trial
could be successfully identified in the database. Investigation of this led to the
discovery that other 082 codes were also used for the coding of carotid
endarterectomy. These additional codes for Operations ofarteries in the neck, (NEC)
included 082.3 (resection with graft), 082.4 (bypass graft) and 082.5 (implantation
with graft). These codes were therefore added to the specifications of the database to
ensure the identification of "all" or the majority of the patients in Scotland who had
carotid endarterectomy during the study period. It was judged that the additional
OPSC 3 codes (082,3, 082.4, 082.5) with the specific carotid endarterectomy OPCS
3 code (082.8) would identify the majority of carotid endarterectomy procedures
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during the study period. It was assumed that these OPCS 3 codes were similar and
equivalent to the OPSC4 codes (L29.4 and L29 5) used from 1989 onwards.
2.2.2 Defining the data sets
The study population in the main data set, the Scottish ISD-CEA data set, was
divided into three almost equal five-year periods for analysis purposes, because of
the documented change of the procedure over time (John et al., 1993; Murie et al.,
1994; Adam et ah, 1998). This allowed comparisons to be made between the three
different time periods. The first period or the early period of the study included the
five years from January 1981 to December 1985. The second or middle period,
January 1986 to June 1991, referred to the five and a half years prior to the
publication of the two large randomised controlled trials. The third period or most
recentperiod, July 1991 to December 1996, referred to the five and a half years after
the publication of the findings from ECST and NASCET. The survival analysis for
the most recent period also included the first three months of 1997 and follow-up was
for five years and nine months, until 31 March 1997. It is acknowledged that the
follow-up for the cohort for the most recent period was incomplete and that any
differences observed in comparing the final cohort to the earlier cohorts are most
likely due to incomplete follow-up rather than real differences.
An alternative would have been to divide the study population into two periods on
the basis of the OPCS classification, which changed at the beginning of 1989.
Elowever, it was decided that having only two and a half years prior to the
publication of the results of the RCTs might not provide sufficient data to compare
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with a much longer period after publication of trial results. Although it was also felt
that it would not be wise to compare the very early years to the more recent years in
the study, when the procedure has been well established, it was done nevertheless to
emphasise the evolving nature of the procedure over time. Since one of the
objectives of this study was to determine whether results from the randomised
controlled trials (RCTs) could be transferred to "real life" populations, the period
prior to and the period after the publication of RCTs will be highlighted. For the
purpose of this study "real life" referred to everyday practice and clinical situations
encountered in the health care setting.
2.2.3 Estimation ofcarotid endarterectomy cost.
Using the length of stay in hospital (expressed as the number of bed days) for the
carotid endarterectomy procedure, the "cost" of carotid endarterectomy for the three
periods was estimated. The cost of one surgical bed day was estimated at £300. This
cost assigned to a bed day was calculated using the Scottish Health Services Costs
1996/97 as reference. Allocated costs as published in the Scottish Health Services
Costs 1996/1997 include overheads as well as capital charges and was used for all
capital and overhead cost estimations in the study.
2.2.4 Volume ofcarotid endarterectomiesper hospital.
The classification of hospitals where carotid endarterectomies were performed into
low, medium and high volume hospitals was data driven and endorsed by work
previously performed by Edwards and others. Low volume hospitals were defined as
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hospitals performing between one and 12 carotid endarterectomies per year, medium
volume hospitals doing 13 to 49 carotid endarterectomies per year and high volume
hospitals performing more than 50 carotid endarterectomies per year (Edwards et al.,
1991). The number or volume of carotid endarterectomies performed per "vascular"
surgeon per year was not investigated.
2.2.5 Defining the analyses.
Statistical analysis.
The choice of statistical methods was determined by the nature of the variables in the
ISD-CEA data set compiled from the routinely collected data. Most of the variables
are categorical or nominal. Continuous variables include time to event variables and
length of hospital stay. Time-to-event variables have been computed using the date of
carotid endarterectomy procedure as the date of entry into the study.
Normal probability plots were used to assess any departure from normality. The
inter-quartile ranges were defined as Q0 25 . Q0 75 The interquartile range (IQR) is the
difference between the first and third quartiles; this difference indicates the range of
the middle half of the data set (Levin and Rubin, 1991). All categorical variables
were compared by means of chi-square statistics. All p-values reported are two-
sided. Time-to-event variables are analysed using Kaplan-Meier survival curves. The
log-rank statistic and the Breslow tests are used to compare the survival curves
obtained for the groups. All analyses compare survival between patients during the
three time intervals, between men and women and between age categories with
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respect to the length of time to any subsequent stroke event and to death of any
cause.
The log-rank test emphasises the tail of the survival curve and gives equal weight to
each failure time whereas the Breslow test weighs deaths according to the number at
risk at the time of death, placing more weight on early deaths. An alternative test, the
Peto-test, which also places more emphasis on the information at the beginning of the
survival curve where the number at risk is large, could also have been used in the
analysis. According to Kleinbaum (1996) these tests give similar results in practice,
hence the use of the Breslow test.
The main time-to-event outcomes in this cohort were subsequent hospitalised
cerebrovascular events and death from any cause after carotid surgery.
Cerebrovascular events included stroke and transient ischaemic attack and were
defined in this study according to the ICD9 classification, using codes 430 - 438 for
stroke and transient ischaemic attack. All cause mortality was defined as a death
from any cause including a fatal stroke and it is a reflection overall survival. The
cause of death as classified by ISD was used to determine whether a death was stroke
related or not.
Survival analyses were performed for these events occurring from date of operation
up to 1826 days or five years after the procedure, thus determining the risk of having
a "stroke" event or death during the five years after carotid endarterectomy in a
cohort of patients having this operation. "Stroke-free" survival was defined as
surviving for a total period of five years after successful carotid surgery, without
experiencing any hospitalised stroke event.
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Mean survival times with 95% confidence intervals and standard errors are reported.
The mean survival time is not the average of the observed survival times, since it
does not make sense to compute the usual arithmetic average if all of the cases have
not experienced the event. "Special techniques are used to estimate mean survival
time when there are censored observations. If the largest observed survival time is for
a censored observation, the estimate of the mean survival time is said to be restricted
to the largest observed survival time" (Norusis, 1994). The median survival time is
the time point by which half of the cases are expected to experience the event (either
stroke or death) and is not reported. To minimise the effect of confounding of
dissimilar follow-up times for the three periods, a five-year assessment of survival is
investigated for each period instead of survival over the entire period thereby
comparing relative similar periods of survival (i.e. comparing like with like). Using
the entire period will result in different lengths of follow-up. Patients operated on
during the period 1981 -1985 can effectively have 10 to 16 years of follow-up,
patients in the middle period, five to 10 years of follow-up and the most recent group
at the most only five years.
2.3 Results.
Validity ofcarotid endarterectomv coding.
The specific code for carotid endarterectomy procedures in the OPCS 3 classification
in use during the period 1981 to 1988 was 082.8. It was recognised that the codes
082.3, 082.4 and 082.5 were also used for coding of the procedure when patients
from the ECST could not be linked to the specific CEA codes (082.8). Using these
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additional codes in combination with the appropriate CEA codes (082.8, L29.4
L29.5), the CEA extracting procedure form the ISD National database was again
performed. Only 74 (2.6%) cases were identified as being erroneously coded. Forty
of these cases (7.5%) were during the early period and 34 (7.4%) during the middle
period. No carotid endarterectomy coding errors were observed for the most recent
period (Table 2.6). Of the 74 additional CEA identified, 12 more CEA patients who
were randomised to surgery in the ECST could be identified. The five patients who
crossed-over to medical treatment were also subsequently identified in the ISD
database. Fourteen CEA trial patients could not be linked or identified resulting in
92% (172/186) linkage accuracy including the 5 patients who crossed-over to
medical treatment. It is however necessary to mention that the initial linkage without
the additional OPCS 3 codes secured only an 83% linkage (155/186).
2.3.1 Baseline characteristics of the study population.
Number ofpatients, aze and sex distribution.
A total of 2892 carotid endarterectomies were performed over the 16-year study
period from January 1981 to December 1996. When the Scottish ISD-CEA data set
was divided into the three periods a total number of 536 (18.5%) carotid
endarterectomies were performed during the early period, 476 (16.2%) during the
middle period. The majority of operations 1880 (65%), were performed during the
period after the publications of the two large randomised controlled clinical trials
(Table 2.1). The age distribution for this study population exhibits a normal
distribution with the mean age of 64.1 yearsand standard deviation of 8.71 (Table
35
Chapter Two: Background - CEA in Scotland
2.1, Figure 2.1). The mean age of the early and middle period was 61 years and 66
years for the most recent period. Considering the entire data set the majority of
patients 1413 (48.9%) were in the age category 50 to 65 years and 1268 (43.8%) of
patients were between the ages of 66 to 80 years. (Table 2.2).
Of these operations 1719 (59%) were done in men and 1173 (41%) were in women
(Table 2.3, Figure 2.2). The ratio of about 60 men to 40 women was observed over
all the years studied, with the exception of 1988 when the frequency of the operation
(38) was similar in men and women (50%) (Table 2.4). The frequency of the
operation in men for the other years ranged from a low of 55% in 1985 to a high of
68% during 1989
Patient-years ofobservation.
The total years of observation for the 16-year study period was 12547 years with a
mean survival time for the entire study period of 9.9 years (95% C.I. 9.6; 10.2,
Standard Error 0.3). Considering only the five-year follow-up period the mean
survival time was 4.39 years (95% C.I. 4.34; 4.44, Standard error 0.03).
Preceding events.
There were 1295 (45%) documented hospitalised stroke and TIA events in the three
months before carotid endarterectomy in this ISD cohort of 2892 CEA patients. Of
these, 1000 (77%) were hospitalised stroke events, 588 in men and 412 in women.
The difference observed in hospitalised stroke events between men and women was
not significant (p = 0.63). Of the 1000 strokes 468 (46.8%) were between the ages
of 50 - 65 years and 455 (45.5%) in the age group 66 to 80 years. It was not
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possible to distinguish between "minor" and major stroke events in this Scottish
ISD-CEA cohort. The proportion of hospitalised strokes prior the CEA in the
Scottish ISD-CEA cohort was 35% (1000/2892). This was considerably higher than
the proportions of "minor" stroke lasting less than seven days reported in the ESCT
(23% for the surgery group 21% for the medical group) (Table 2.5). This finding
emphasised the difficulty to differentiate between stroke severity in this routinely
collected data source.
In the entire study population 295 patients (10.2%) had a documented (hospitalised)
transient ischaemic event in the three months prior to the carotid endarterectomy.
Of these patients, 186 were males and 109 were females (p = 0.19). Assessing the
frequency of prior transient ischaemic events for the three subgroups, there were
7% (37/536) documented TIAs for the early period, 9% (44/476) for the middle
period and 11% (214/1880) for the third or most recent period (p = 0.01). Only 10%
of cases (295/2892) had a preceding transient ischaemic attack prior to carotid
surgery. This proportion of 10% was considerably less than the proportion of TIAs
(52%) reported in the ECST cohort. It must however be recognised that all these
TIAs in this study population were documented or hospitalised events whereas the
TIAs reported in the ECST were self reported incidents not necessarily requiring
hospital admission. The differences observed between the four age categories
concerning preceding TIAs were non-significant.
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2.3.2 Frequency of the procedure over the 16-year study period.
A total of 98 operations were performed during 1981. A gradual increase was
observed from 1981 till 1985 when 121 patients had a CEA. A gradual decline in the
number of operations was observed from 1986 to 1989, with a minimum of 60
operations during 1989. From 1990 a steep increase in the number of carotid
endarterectomies occurred, with 68 operations in 1990 to a total of 443 procedures
during 1996. This represents more than a six-fold increase (Table 2.4, Figure 2.3).
2.3.3 Geographical distribution ofcarotid endarterectomy and hospital volume.
Over the study period of 16 years, all 2892 carotid procedures could be linked to a
specific health board of residence. The health board resident population for 1995
ranged from a high of 912 500 in Greater Glasgow to a low of 19 870 in Orkney.
Though the health board of residence is not coded on the linked database from 1981-
1985, the health board of residence for the 536 operations performed during the early
period of investigation could be derived through local government district or
postcode of residence. (Table 2.7). The frequency of the procedure according to
health board of residency varies from a minimum of 2 operations in Orkney health
board to a maximum number of 626 operations in the Greater Glasgow health board
(Table 2.7, Figure 2.4).
The CEA rate per 100 000 of the Scottish population has increased steadily from an
all time low of 1.2 per 100 000 (1989) to a maximum of 8.6 per 100 000 (1996). The
CEA rate per 100 000 population per health board of residence varied from zero in
two health boards (Shetland and Orkney) to a maximum of 19 per 100 000 in the
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Tayside health board during 1994. The CEA rate per 100 000 population per health
board has been consistently higher in Tayside compared to the other 14 health
boards, ranging from 6.1/100 000 in 1986 to 17 /100 000 in 1996. Similar increases
were observed in the health board of Argyll and Clyde, Ayrshire and Arran,
Dumfries and Galloway, Grampian and Greater Glasgow. The CEA rate per 100 000
residents in the Lothian health board has remained relatively stable varying between
4.5 /100 000 (1992) and 3.9 (1996) (Table 2.8, Figure 2.5).
Over the 16 years, the operation was performed in 20 hospitals in 11 of the 15 health
boards in Scotland (Table 2.9). Using the hospitals where these early operations were
performed as reference to classify all the procedures with a specific health board of
operation, the maximum number of 1193 (41.2%) operations were also associated
with the Greater Glasgow health board and the minimum of four (0.14%) CEA with
the health board of the Western Isles (Table 2.9). Between 1981 and June 1991
carotid endarterectomy was performed in nine (Greater Glasgow, Tayside, Lothian,
Grampian, Dumfries and Galloway, Lanarkshire, Highland, Forth Valley and
Western Isles) of the 15 health Boards, and since July 1991 also in two additional
health boards, Ayrshire and Arran and Argyll and Clyde. The operation was never
performed in the four Health Boards of the Borders, Fife, Orkney and Shetland
(Table 2.9, Figure 2.6).
Flospital volume.
The number of operations performed per hospital per year for the five years after the
publication of the RCTs is summarised in table 2.10. For the period 1992 to 1996 a
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minimum of three operations were performed in Western Isles Hospital, Stornoway
and a maximum of 368 in the Western Infirmary Glasgow. Nine of the 20 hospitals
performed between 46 and 368 Carotid endarterectomies over the five-year period
assessed. Only three hospitals (Royal Infirmary Edinburgh, Ninewells Dundee, and
Western Infirmary Glasgow) performed more than 45 carotid endarterectomies per
year over three consecutive years (1994 -1996).
Classifying the hospitals into low, medium and high volume hospitals it was found
that 25% of hospitals performing Carotid endarterectomies were considered being
high volume hospitals during 1995 and 1996. The lowest proportion of operations in
high volume hospitals was 8% in 1992 and the highest proportion of 27% in 1996.
More than 50% of hospitals performing carotid endarterectomies between 1992 and
1996 were in hospitals defined as low volume hospitals (1-12 CEA per year) (Table
2.11, Figure 2.7). Of the 15 hospitals performing 443 carotid endarterectomies in
1996, four hospitals were high volume hospitals, doing 294 (66%) of the Carotid
endarterectomies for that year. One hundred (23%) operations were in three medium
volume hospitals and 49 (11%) of the carotid endarterectomies were in eight low
volume hospitals.
2.3.4 Length ofhospital stay.
Examining the distribution of the length of hospital stay for the entire population, a
minimum stay of zero days were observed for five patients, and a maximum stay of
582 days for one patient. The five patients with no recorded hospital stay were from
the Royal Infirmary Edinburgh (1982), Glasgow Royal Infirmary (1995,1996)
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Southern General hospital, Glasgow (1995) and from Ninewells hospital (1994). Two
of these patients subsequently died, one within a week of the procedure and the other
suffered a stroke event one week after the procedure, but the recorded date of death
was during 1993 and coded as a non-stroke related death. Discussions with ISD did
not provide any plausible explanations other than that the patients might have been
transferred to another institution of care and might still be there and hence "not
discharged" from the hospital or National Health Service.
The mean number of days in hospital was 7.98 with a standard deviation of 20.7. The
IQRo 25. o 75 was four to eight days with a median length of stay of five days. It was
not possible to distinguish between type of hospital stay, that is intensive therapy,
high dependency and general ward stay from the routinely collected data. The length
of hospital stay for the three periods shows a reduction in overall length of stay from
the early period to the most recent period, indicating the change in the procedure over
time. The maximum length stay of 582 days appears unacceptably long. This is
likely to be explained by the fact that the total length of hospital stay recorded in this
study population is from admission for the carotid procedure to (eventual) discharge
and thus including transfers to other institutions (hospitals or convalescence centres)
when required by patients who suffered any complications. A truer reflection of the
length of hospital stay for carotid endarterectomy is probably found using the inter¬
quartile range, reflecting the length of hospital stay for 50% of the study population
(Table 2.12, Figure 2.8). A 38.5% decrease in the mean length of hospital stay was
observed from the early period to the most recent period and a 44.8% decrease in
days in hospital from the middle period to the most recent period, again suggesting a
change in the management of these cases.
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2.3.5 Estimation ofCEA cost using bed days as proxyfor cost.
The mean cost for CEA for the period 1981 - 1996 based on the mean number of bed
days was £2396 (median 1500; IQR 1200 - 2400). The mean cost of CEA for the
period 1981 -1985 was £3110 compared to £1926 for the most recent period 1991 -
1996 (Table 2.13).
2.3.6 Outcome events: Subsequent cerebrovascular events and all cause
mortality.
Subsequent cerebrovascular events (stroke and transient ischaemic events).
Subsequent stroke events in this cohort included hospitalised transient ischaemic
attacks and stroke events. It was however not possible to distinguish between ipsi-
and contra lateral stroke as well as major strokes events in this Scottish ISD cohort.
Among the 2892 patients who had surgery over the 16-year study period, there were
128 (4.4%) a strokes or TIAs within 30-days of the carotid surgery and 652 (22.5%)
were reported over the entirel6-year study period (Table 2.14). Of these, 175 were
stroke related deaths, 161 patients suffered a stroke prior to death and 316 patients
who suffered an event after the carotid endarterectomy were either still alive or were
lost to follow-up at the end of the study period. A decrease of 60% in subsequent
stroke events was observed from the early period to the most recent period.
Over a five-year period after CEA, 545 cerebrovascular events were documented
hospitalised events and it appears that the majority (84%; 545/652) of these
subsequent events occurred within five years after the carotid surgery. However,
since the follow-up for the cohort during the most recent period was incomplete,
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inferences can not be drawn on the differences observed between the entire study
period and the five-year period of follow-up. Only crude rates for cerebrovascular
events, which present the actual experiences of the three cohorts, were therefore
reported (Table 2.14).
For the analysis of any fatal or non-fatal stroke event, the overall five-year failure
rate was 19%. The failure rates for the three periods were 27% for the early period,
21% for the middle period and 16% for the most recent period - a percentage
difference of 33% between the early period and the most recent period. However, the
incomplete follow-up of the most recent period should be recognised. These failure
rates were well in excess of those reported in the randomised controlled trials.
NASCET reported an estimated 9% cumulative risk of any ipsilateral stroke at two
years in the surgical group and ESCT reported an overall risk of non-fatal major
stroke or death of 9.6 %.
Cumulative survival to any subsequent stroke event in the five years after carotid
endarterectomy is summarised in table 2.15. Kaplan-Meier estimators for any
subsequent stroke events for patients operated on during the three intervals are shown
in figure 2.9. The log-rank tests for differences in the survival form any subsequent
stroke event between these three time intervals, were significant (p = 0.005). The
Breslow-test, which places more weight on the early events, was highly significant
(p<0.001). No significant difference in the five-year risk of any subsequent
cerebrovascular event between men and women was observed (Log-rank: p = 0.14
and Breslow: p = 0.11) (Figure 2.10). Differences in five-year risk of any subsequent
stroke for the four age categories were also significant with a p-value of 0.001 for
both the Log-rank and Breslow tests (Figure 2.11). Over the 16-year period a total of
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259 (9%) subsequent carotid endarterectomies were documented in this study
population (Scottish ISD-CEA cohort) (Table 2.14).
All cause mortality.
A total of 783 deaths were reported over the 16-year study period. Of these deaths,
175 (22%) were reported to be stroke related and 608 were reported as non-stroke
deaths. Of the 608 deaths due to other causes, 161 (26.5%) patients suffered a
subsequent stroke after the carotid endarterectomy and prior to death, resulting in 447
(57%) reported deaths assumed not to be associated with stroke. Sixty-six patients
(2.3%) died within 30 days after carotid surgery. A total of 484 deaths were reported
during the five years of follow-up after CEA, 135 (27.9%) for the early period, 118
(24.4%) during the middle period and 231 (47.7%) deaths in the most recent period
(Table 2.16). The 5-year crude mortality rate for the entire CEA cohort was 167 per
1000. The five-year crude mortality rates for the three periods were 252 per 1000 for
the early period, 248 per 1000 for the middle period and 123 per 1000 for the most
recent period. Although the differences observed between the number of deaths
during the three periods were statistically highly significant (p < 0.001) for both the
entire period and the five-year follow-up period it should be borne in mind that the
follow-up for the final cohort was incomplete influencing any inferences drawn. The
difference observed in overall survival for the three periods was not significant (Log
rank p = 0.67; Breslow p = 0.1\)(Table 2.19, Figure 2.12). Of the 783 reported
deaths for the entire period, 489 were in men and 294 in women. Considering only
the five-year period of follow-up, 312 deaths occurred in males and 172 in females.
The difference observed between men and women was statistically significant (p =
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0.05) for the entire period as well as for the five year follow-up (p = 0.015) (Table
2.17, Figure 2.13). Data about the outcome events were available in all patients for
the early and middle periods and were assumed to be "complete" since no censoring
was observed during the five year period investigated The five-year risk of all cause
mortality was assessed for the three time periods. For the primary analysis of all
cause mortality the overall five-year failure rate was 16.7%. The failure rates for the
three periods were 25% for the early and middle period and 12% for the most recent
period - a percentage difference of 52% between the two periods before publication
of the randomised trials and the most recent period. Comparing the five year overall
survival between men and women in this study population, a statistical significant
difference was observed (p = 0.016) using the log-rank test statistic (Figure 2.13).
Statistical significance between males and females was not reached (p= 0.07) with
the Breslow test, which places more weight on the early deaths. The mean survival
time for women (4.5 years; 95% C.I. 4.37, 4.54) was slightly longer than for the men
(4.3 years; 95% C.I. 4.27, 4.41). A similar trend was observed when men and women
were compared during the different time periods using the Log-rank statistic (Table
2.17). Comparing the five-year overall survival for the four age categories, highly
significant differences with both the log-rank and Breslow tests were obtained (p <
0.001). The mean survival time for patients less than 50 years of age was 4.8 years
(95% C.I. 4.65 - 4. 92) compared with 3.2 years (95% C.I. 2.56 - 3.93) in the age
category older than 80 years (Table 2.18, Figure 2.14).
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2.4 Discussion.
The CEA rate per 100 000 population in Scotland has increased steadily over the
years 1985 to 1993 from 1.2 per 100 000 to 8.6 per 100 000 in 1996. The CEA rate in
Scotland in 1993 of 5.9/100 000 was also higher than the CEA rate of 3.5 per 100
000 for England and Wales and considerably higher than the CEA of 0.7/100 000
observed in Northern Ireland (Irvine et al., 1996). Despite the higher CEA rates in
Scotland, significant regional variation in the provision of CEA per health board of
residence has again been highlighted in this report with the CEA per 100 000
residence per health board varying between zero to 19 per 100 000 population for one
specific year. Though extensive variation in the CEA rates was seen during the years
investigated in three of the fifteen health boards, these three health boards are notably
the smaller health boards with a different population composition. The population
rates for carotid endarterectomy reported were crude rates only, which represent the
actual experiences of the population and provide data for the allocation of health care
resources. Although these crude rates are easy to calculate and are widely used for
comparisons, the values may be confounded by the underlying population structure.
Age and sex standardised rates might therefore provide more precise rates for
comparison, however standardisation of rates was not performed in this study.
The majority of hospitals performing carotid endarterectomies after the publication
of the randomised controlled trials were considered to be low-volume hospitals.
However most of the carotid endarterectomies performed after the publication of the
trial results were in a small number (3.3%) ofhigh-volume hospitals. In 1996 11% of
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carotid endarterectomies were performed in eight low-volume hospitals, 23% in three
medium-volume hospitals and 66% of operations in four high-volume hospitals.
The assessment of this routinely collected data on CEA over a 16-year period in
Scotland illustrated the influence of the publication of the results of the two large
randomised controlled trials during the early 1990s on the practice of carotid
endarterectomy. The years preceding the publication of the trial results saw a
decrease in the number of carotid endarterectomies in Scotland. A marked and
sustained increase was found from 1992 onwards. This study provides confirmation
that the frequency with which this operation is performed has changed as result of
published clinical evidence from the two large randomised clinical trials
demonstrating the efficacy of CEA but that practice might not have been altered.
The limitations of this data set, obtained from a routinely collected data source,
should be recognised before drawing definite conclusions from the results obtained in
this study. The absence of clinical variables in this data set, the selected nature of the
population studied and the incomplete follow up for the final cohort compounded the
inferences drawn from this study.
The study showed that the "stroke-free" survival of patients not associated with the
trial was not comparable with the "stroke-free" survival of patients in the ECST. The
"stroke-free" survival of the surgical patients in the ECST at three years was
estimated at about 88% (the percentage without any stroke that lasted more than
seven days or surgical death) (ECST, 1991). The corresponding estimates for the ISD
cohort were 82%, 83% and 76% for the most recent, middle and early period
respectively (Table 2.14). These results also suggested that clinical practice might
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have changed from the early period to the later periods. This investigation further
demonstrated the reduction in the use of health care resources based solely on length
of hospital stay. The use of bed days as a proxy for cost appears to be an extremely
crude measure of the cost of CEA when compared to the cost estimates from
Newcastle and the Wessex study (Radestock, 1992; Smithies et al., 1997).
In the context of the Scottish population the maximum number of carotid
endarterectomies performed during 1995 continues to be within the limits (450 -
700) of the number of CEA we would expect, based on suggestions from the
Association of British Neurologists (Brown et al., 1992) and estimates, using the
incidence rates of TIA and of minor non-disabling strokes (Hankey et al., 1996,
Smithies et al., 1997). Based on these estimates the number of patients eligible for
CEA in Scotland is expected to be somewhere between 450 and 700 per year. The
increase observed in the number of carotid endarterectomies in Scotland over the last
couple of years from 68 (1990) to 443 (1996) can be considered as still within the
expected volume of CEA for Scotland. What is however alarming is the huge
variation observed in the volume of operations performed between the hospitals.
Three operations were performed in one hospital (Western Isles) and a total of 368
operations in another (Ninewells) for the five year period after the publication of the
trials results. It is evident from the results presented in tables 2.10 and 2.11, that the
50% of hospitals in Scotland where carotid endarterectomies were performed were in
low-volume hospitals performing one to 12 carotid procedures per year. This
demonstrates a very low carotid endarterectomy activity in the majority of hospitals.
Although carotid endarterectomies were performed mainly in low and medium
48
Chapter Two: Background - CEA in Scotland
volume hospitals, just over half (51%) of all carotid endarterectomies over the period
1992 to 1996 was in high volume hospitals. It also suggests that the
recommendations from the trials and subsequent guidelines of about 50 CEA per
surgeon per year are not implemented or alternatively might not be appropriate for
Scotland. If the delivery of carotid endarterectomies and the benefits from the
procedure are to be optimised, these findings need to be further investigated
(NASCET Collaborators, 1991; SIGN guidelines, 1994; Moore et al., 1995).
Reliability and validity of routine collected data with special reference to ISP .
The data used for this analysis were obtained from a routinely collected data set.
Routinely collected hospital discharge statistics or administrative data sets have
become widely used for epidemiological studies, quality assessment and medical
effectiveness research, mainly because these data sets provide large samples at low
cost. The use of these sets however remains controversial based on concerns that
such data is inaccurate and lacks especially physiological variables. The findings of
this study should therefore be interpreted against the background of all the limitations
of data collected in this manner.
Prerequisites for data quality include completeness, validity, accuracy, availability as
well as timeliness (Wyatt, 1995). The analysis of routinely collected data have
always been open to criticism, since these data sources are usually dependent on
hospital and district returns. Variation of data collection between institutions is not
unexpected considering the multiple steps involved to submit a "return". Data should
be reliable and valid for analysis to allow inferences to be drawn from the results
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obtained. Reliability addresses the issues of accuracy, consistency and completeness
and whether it provides consistent results. Validity of the data set relates to the
degree to which the analysis performed on collected data will measure what it
intended to measure. Aspects to consider here include the role of chance, the effect of
bias and confounding. Data validity, in the case of ISD data is restricted mainly to
data feasibility, e.g. checking age and sex against a particular diagnosis.
Accuracy ofSMR1 and OPCS coding.
The Scottish Morbidity Record 1 (SMR1) is an episode-based record capturing all
inpatients and day cases discharged from Scottish hospitals, excluding psychiatric
and obstetric wards. The main reason for admission is entered onto the SMR1, which
is essential for statistical analysis, audit and contracting. Discharge summaries are
generally used by coding personnel to determine ICD or OPCS codes. When these
summaries are not available, case notes are examined or the doctor in charge of the
case is contacted to obtain relevant information. If the information available is still
insufficient, the National Health Service Centre for Coding and Classification
(NHSCCC) at Loughborough is contacted. This process is known as terming and also
defines Read codes, which contains a range of variables other than diagnoses and
procedures. Only once sufficient information is obtained, are ICD or OPCS codes
established by referring to the appropriate code books. Codes are then entered into
Patient Administration Database (SMR1) from which contract allocations, Healthcare
Resource Groups (HRGs) and pricing are carried out on a monthly basis. The data
are submitted quarterly to the Department of Health or Scottish Office. Considering
Chapter Two: Background - CEA in Scotland
all the different steps involved in the data collection, it is not surprising that errors
occur, especially taking into account the variation in recording practice and coding
policy between different hospitals. However, the accuracy of hospital discharge data
depend to a large degree on the willingness and conscientiousness ofmedical staff to
supply the information (Galland et al., 1998; McKee and James, 1997; Harley and
Jones, 1996; Davenport et ah, 1996).
The accuracy of ICD and OPCS codes produced by Hospital Activity analysis were
assessed as far back as 1980 and reported to be 20% inaccurate. Although the time
period studied, pertained to general surgery only, it was also observed that the
situation in subspecialties is no better. The disagreement was more pronounced when
a patient had more than one diagnosis or operative procedure (Gough et al., 1980;
Romano and Mark, 1994). More recently Galland and others reported on the
accuracy of OPCS coding with specific reference to vascular surgery in the United
Kingdom and found that OPCS codes considerably underestimate (31%) the actual
amount of vascular activity, with endovascular procedures less well documented than
surgical reconstructions (Galland et al., 1998). Though error rates of between 20 -
40% have been described using different criteria, (Mukherjee et al., 1991; Smith et
al., 1991) it is suggested that these reports of data inaccuracy may be an
overestimation due to publication bias (Sellar et al., 1990). The Quality Assessment
and Accreditation Unit (QAA) of the Information and Statistics Division (ISD) is
responsible for monitoring the quality of SMR data against national standards.
According to Harley and Jones an improvement of 5.4% in the accuracy of main
operation coding has been observed between 1992 (85.3%) and 1994 (90.7%)
(Harley and Jones, 1996). This study however found that the accuracy of main
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operation and second operation coding for carotid endarterectomy was only 83%
with the first identification process using the patients who were in the ECST data set
as the "gold" standard. It was assumed that it would be possible to identify all
patients who were randomised to the surgical arm of the ECST in the CEA cohort
from ISD for the period 1981 to 1996. This was clearly not the case since only 83%
(155/186) of the Scottish patients in the surgical arm of the ECST could be
identified. Re-examining the ECST data it was discovered that ten patients who were
in the ECST were incorrectly coded using codes 082.3 and 082.5, and a further two
were identified when the link numbers were consolidated. The identification of the
additional 12 CEA patients and five patients who crossed over to medical care
increased the accuracy of identifying patients who were known to be randomised to
CEA in the ECST and should have been coded as such by 9% to 92% (172/186).
This increase in accuracy of identifying a surgical procedure was only possible since
data from the surgical arm of the Scottish cohort of the ECST data set was available.
The identification of incorrect OPCS codes resulted in a "re-run" of the computer
programme with the additional codes on the ISD data base, to ensure that "all" the
CEA in Scotland over the period 1981 to 1996 would be accounted for.
Left and right censoring in survival analysis.
Though information was collected on documented TIAs and non fatal strokes during
the three months prior to CEA, time to event analysis, i.e. time from presenting
stroke or TIA to carotid endarterectomy was not performed since the issue of left
censoring could not be satisfactorily addressed. Furthermore, information of events
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prior to CEA was incomplete. Only documented hospitalised TIAs/stroke events are
known and no record exists of transient events patients had, but did not report to their
doctor. The information on preceding events leading to carotid surgery is thus
incomplete and even when reported, the onset of the event recorded may or may not
have been the first transient ischaemic episode. The exact survival time on the left
was thus in most instances unknown. The measures of survival analysis however
have been primarily developed to deal with data that are right censored (Figure 2.15).
Results and the implications of the randomised controlled trials.
The ECST and NASCET reported an absolute risk reduction of major stroke and/or
death 9.6 % and 16.5% respectively in-patients with severe stenosis. Based on the
findings from these trials the number needed to treat (NNT) with a CEA to prevent
one stroke is between six and 10 over a 3- and 2-year period respectively. If all the
patients eligible for a CEA in Scotland were to receive a CEA about 800 patients will
have a carotid endarterectomy and 80 strokes might be prevented, less than 1% of the
10 000 strokes occurring annually in Scotland.
CEA lowers the overall risk of ischaemic stroke by about 50% over the next three
years in patients with 70 - 99% stenosis. Only about 20% of such patients have a
major stroke on medical treatment alone. Whether an operation will be beneficial for
an individual depends on the risk of stroke and death with surgery and the risk of
stroke without surgery. Prognostic models have been developed to assist clinicians
to identify those patients who will benefit the most form surgery.
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The risk-factor modelling suggested that the NNT might be as low as three carotid
endarterectomies to prevent one stroke or as many as a 100 carotid endarterectomies
to prevent one stroke when the risk profile of patients is taken into consideration
(Rothwell et ah, 1999). To reduce the NNT to as low as three, suggests that only
patients in the high risk category might be considered for the procedure, and might
at the same time deprive patients who might be considered having a lower risk from
the operation and the associated benefit. Identifying the three patients who would
benefit most from carotid endarterectomy, and result in the prevention of one stroke,
might be very costly and might have far-reaching implications for carotid
endarterectomy in Scotland.
2.5 Summary
This was the largest historical cohort analysed to date over the longest time period
and in excess of 12500 of patient-years of observation for the entire study period of
16 years. This study showed that CEA rates in Scotland have increased over time
and that the variation seen by health board might indicate over or under utilisation
of the procedure. The accuracy of routinely collected data for CEA was found to be
between 83% and 92%. The study further showed that the cost of CEA decreased
over time, mainly because of the reduction in hospitals stay during the letter years.
It was clear from this investigation that the use of routinely collected data for
epidemiological studies and quality assessment of health care delivery remains an
area of concern and that determining needs and provision of health services based
on routinely collected data might result in an underestimation of services required
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both with regards to human resource need, physical facilities and financial
resources.
The influence of the publication of the results of the two larger randomised trials
was evident in this study with a marked increase of CEA from 1992 onwards. The
study demonstrated that the majority of hospitals in Scotland performing carotid
endarterectomies after the publication of the trials are defined as low-volume
hospitals, suggesting that current recommendations regarding hospitals where these
operations should be performed are inappropriate for Scotland. The study showed
that the stroke-free survival of CEA patients in Scotland not in a trial was not
comparable with the stroke-free survival of Scottish patients randomised to surgery
in the ECST.
The use of routinely collected data for epidemiological studies and quality
assessment of health care delivery remains an area of concern. Results from
randomised controlled trials might have influenced some aspects of practice, but
recommendations based on trial results appeared not to be fully implemented.
This investigation representing the largest historical CEA population being studied to
date provided the unique opportunity of linking the study population to patients in a
randomised controlled trial conducted almost over the identical time period. Results
obtained also questions the transferability of trial results to other settings. Definitive
conclusions will however only be possible once more comparable cohorts are
assessed.
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Table 2.1: Baseline characteristics for Scottish ISD-CEA patients: 1981 -1996.
Males Females
The entire period: 1981 - 1996 (n = 2892)
Number 1719(59%) 1173
Mean age (SD) 64.1 (8.68) 64.0(8.75)
Preceding events 588 412
Subsequent "stroke" events* 309 236
Deaths 312 172
The early period: 1981 - 1985 (n = 536)
Number 324 (60%) 212
Mean age 60.6 61.3
Preceding events 97 63
Subsequent "stroke" events* 89 55
Deaths 93 42
The middle period: 1986- June 1991 (n = 476)
Number 283(59%) 192
Mean age 61.4 60.7
Preceding events 84 48
Subsequent "stroke" events* 60 40
Deaths 81 37
The most recent period: July 1991 - 1996 (n = 1880)
Number 1112(59%) 768
Mean age 65.7 65.5
Preceding events 407 301
Subsequent "stroke" events* 160 141
Deaths 138 93
* Strokes and TIA during five-year follow-up period
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Table 2.2: Age distribution for the Scottish ISD-CEA patients for the three five-year
periods investigated: 1981 -1996.
Three five-yearperiods
Age 1981 -1985 86 -Jun 1991 Jul 91-1996 1981-1996
category
<50 years 54(10%) 40 (8.4%) 65 (3.5%) 159(5.5%)
50 - 65 years 322 (60.1%) 293 (62.7%) 798 (42.4%) 1413 (48.9%)
66 - 80 years 157(29.3%) 142 (30.5%) 969 (51.5%) 1268 (43.8%)
>80 years 3 (0.6%) 1 (0.2%) 48 (2.5%) 52(1.8%)
Total 536 (18.5%) 476 (16.5%) 1880(65%) 2892
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Table 2.3: Age and sex distribution for the three five-year study periods and for the
Scottish ISD-CEA cohort: 1981 -1996.
Age categories in years
<50 50-65 66-80 >80 All ages
1981 - 1985
Males 35(11%) 197(61%) 89 (27%) 3(1%) 324(60.4%)
Females 19(9%) 125 (59%) 68 (32%) 0 212(39.6%)
1986 - June 1991
Males 16(5.7%) 184(65%) 83(29.3%) 0 283 (59.5%)
Females 24(12%) 109(56%) 59(31%) 1(0.5%) 193(40.5%)
July 91 - 1996
Males 34(3%) 483 (43%) 567 (51%) 28(3%) 1112(59%)
Females 31(4%) 315(41%) 402(52%) 20(3%) 768 (41%)
1981 - 1996
Males 85(5%) 864(50%) 739 (43%) 31(2%) 1719(59.4%)
Females 74(6%) 549 (47%) 529(45%) 21(2%) 1173(40.6%)
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Table 2.4: Number of carotid endarterectomies per year for males and females and
the crude CEA rate per 100 000 population in Scotland: 1981 -1996.
Year Males (%) Females Total CEA rate/ 100 000
1981 58 (58%) 40 98 2.0
1982 59 (63%) 34 93 1.9
1983 67 (63%) 40 107 2.1
1984 73 (62%) 44 117 2.3
1985 67 (55%) 54 121 2.4
1986 67 (57%) 47 114 2.3
1987 58 (59%) 41 99 2.0
1988 38 (50%) 38 76 1.5
1989 41 (68%) 19 60 1.2
1990 44 (65%) 24 68 1.4
1991 77 (59%) 54 131 2.6
1992 168 (63%) 98 266 5.3
1993 178 (59%) 123 301 6.0
1994 220 (56%) 176 396 7.9
1995 243 (60%) 159 402 8.0
1996 261 (59%) 182 443 8.9
Total 1719(59%) 1173 2892 3.6*
* Cumulative rate
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Table 2.5: Preceding cerebrovascular events (strokes and transient ischaemic






















All events 197 (37%) 176 (37%) 922 (49%) 1295(45%)
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Table 2.6: Carotid endarterectomy coding according to OPCS 3 and OPCS 4
classification for the three study periods for the Scottish ISD-CEA cohort.
CEA code correct
Period Yes No Total
January 1981 - December 1985 496 (92.5%) 40 (7.5%) 536
January 1986 - June 1991 441 (92.6%) 34 (7.4%) 476
July 1991 - December 1997 1880(100%) 0 1880
January 1981 - December 1997 2818 (97.4%) 74 (2.6) 2892
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Table 2.7: Health Board of residence for males and females for the Scottish ISD-
CEA cohort: 1981 -1996.
Health Board of
Residence
Males Females Number Percent
Argyll and Clyde 144 110 254 8.8
Ayrshire and Arran 154 117 271 9.4
Borders 21 9 30 1.0
Dumfries and Galloway 59 37 96 3.3
Fife 105 52 157 5.4
Forth Valley 53 37 90 3.1
Grampian 120 71 191 6.6
Greater Glasgow 362 264 626 21.6
Highland 28 9 37 1.3
Lanarkshire 137 106 243 8.4
Lothian 187 120 307 10.6
Orkney 1 1 2 0.1
Shetland 2 2 4 0.1
Tayside 344 234 578 20.0
Western Isle 2 4 6 0.2
Total 1719 1173 2892 100
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Table 2.8: CEA rate per 100 000 in Scotland per health board of residence for the
period 1986 -1996.
Years 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996
SCOTLAND 2.2 1.9 1.5 1.2 1.3 2.6 5.2 5.9 7.7 7.8 8.6
Argyll and 1.8 2.0 0.7 0.2 0.9 2.1 6.7 5.3 9.2 10.6 9.3
Clyde
Ayrshire and 1.6 0.8 1.9 0.5 0 1.3 5.6 10.6 13.8 12.2 9.8
Arran
Borders 4.9 2.0 0 1.0 0 1.0 3.8 4.7 1.9 1.9 2.8
Dumfries and 2.8 0.7 0.7 2.7 1.4 2 8.8 10.1 8.1 6.8 8.8
Galloway
Fife 3.2 1.7 1.2 0.6 1.1 2.9 3.4 2.8 4.8 6.8 7.7
Forth Valley 0.7 0.7 1.1 0.7 1.5 1.5 2.2 3.7 5.1 3.7 5.5
Grampian 1.2 1.0 1 0.6 0.8 2.7 2.1 2.5 5.3 5.3 8.1
Greater 2.3 2.2 1.5 1.6 1.4 2.9 6.5 7.8 9.6 8.8 12.4
Glasgow
Highland 1.0 0.5 0 0 0.5 0.5 1.0 1.4 3.9 2.9 3.8
Lanarkshire 1.6 2.1 1.2 0.7 0.7 2.1 2.7 5.2 5.2 6.2 8.0
Lothian 2.0 1.3 1.3 1.6 1.9 2.8 4.5 4.2 3.8 5.5 3.9
Orkney 0 0 0 0 0 0 0 5.1 0 0 5.1
Shetland 0 4.5 0 0 0 8.9 0 0 0 0 4.3
Tayside 6.1 6.7 5.4 3.6 4.6 5.6 14.7 12.4 19.0 18.5 17.0
Western Isles 0 0 3.3 0 0 0 3.4 0 6.8 0 0
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Table 2.9: Health Board of operation and hospital for the Scottish ISD-CEA cohort:
1981 -1996.
Health board of Hospital of operation Frequency (%) Total (%) per
operation per hospital health board
Western Isles Western Isles, Stornoway 4(0.1) 4(0.1)
Argyll and Clyde Inverclyde, Royal, Greenock 6 (0.2) 6 (0.2)
Highlands Raigmore 25 (0.9) 25 (0.9)
Lanarkshire Monklands 26 (0.9) 26 (0.9)
Forth Stirling Royal 9 (0.3) 33 (1.2)
Falkirk and District 24 (0.8)
Dumfries and Dumfries and Galloway 66(2.2) 66 (2.2)
Galloway
Ayrshire and Arran Isle of Arran Memorial 1 (0.03) 171(5.9)
Ayr Hospital 170 (5.9)
Grampian Aberdeen Royal Infirmary 195 (6.8) 195 (6.7)
"Lothian" Western General, Edinburgh 4(0.1) 4(0.1)
Royal Northern Infirmary 4(0.1) 4(0.1)
Royal Infirmary, Edinburgh 456(15.7) 464(16)
Tayside Dundee Royal Infirmary 116(4.0) 709 (24.7)
Ninewells 593 (20.5)
Greater Glasgow Southern General, Glasgow 37(1.3) 1193(41.2)
Stobhill 54(1.9)
Gartnaval, Glasgow 284 (9.8)
Western, Infirmary 369 (12.8)
Glasgow Royal Infirmary 449 (15.5)
Total 2892 (100) 2892
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Table 2.10: Health Board of operation and hospital for the period 1981 - 1996 prior
to and after publication of the randomised controlled trials.
Hospital of operation 1981
1991
1992 1993 1994 1995 1996 1992
1996
Total
Western Isles, 1 3 3 4
Stornoway
Inverclyde, Royal, - - - - - 6 6 6
Greenock
Raigmore 4 2 3 4 5 7 21 25
Monklands 8 2 2 3 9 2 18 26
Stirling Royal 2 3 4 9 9
Falkirk and District 17 1 2 1 3 7 24
Dumfries and 13 9 11 12 9 12 53 66
Galloway
Isle ofArran 1 _ _ _ _ _ 0 1
Memorial
Ayr Hospital 1 19 38 46 43 23 169 170
Aberdeen Royal 70 12 12 30 27 44 125 195
Infirmary
Western General, 4 - - - - _ 0 4
Edinburgh
Royal Northern 4 - - - - - 0 4
Infirmary
Royal Infirmary, 203 48 44 46 59 56 253 456
Edinburgh
Dundee Royal 70 16 12 5 8 5 46 116
Infirmary
Ninewells 273 47 45 78 78 72 320 593
Southern General, 4 _ _ _ 33 33 37
Glasgow
Stobhill 28 2 3 4 7 10 26 54
Gartnaval, Glasgow 161 67 56 - _ _ 123 284
Western, Infirmary 1 20 126 116 106 368 369
Glasgow Royal 221 40 55 36 37 60 228 449
Infirmary
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Table 2.11: The number of carotid endarterectomies in Scotland over the period
1992 - 1996 classified according to hospital volume
Years
Number of CEA in: 1992 1993 1994 1995 1996 Total CEA (n)
Low volume hospitals: 28 43 35 42 49 197(11%)
Medium volume hospitals: 170 147 158 107 100 682(38%)
High volume hospitals: 67 111 204 253 294 929 (51%)
Total CEA (n) 265 301 397 402 443 1808
* low volume: 1-12 operations; medium volume:13 -49 operations; high volume > 50 operations
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Table 2.12: Length of hospital stay of ISD-CEA cohort: 1981 -1996.
(Minimum, maximum, mean, standard deviation, and interquartile range.)
Length of
hospital stay
1981-1985 1986-June '91 July '91 - 96 1981-1996
Minimum 0 1 0 0
Maximum 533 582 357 582
Mean 10.4 11.6 6.4 7.98
IQR 5 - 10 5-9 3-7 4-8
Median 7 7 5 5
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Table 2.13: Estimated cost (£) of carotid endarterectomy for the ISD-CEA cohort
(1981 - 1996) based on the number of days hospitalised for carotid surgery.
1981-1985 1986-June '91 July '91 - Dec 96 1981 -1996
Mean (£) 3U0 3448 1926 2396
Median (£) 2100 2100 1500 1500
IQR (£) 1500-3000 1500-2700 900-2100 1200-2400
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Table 2.14: Subsequent cerebrovascular events (stroke and TIA) within 30 days of
carotid surgery, all subsequent cerebrovascular events from date of surgery for the












0 days - 30 days 28(5.2%) 16(3.4%) 84(4.5%) 128(4.4%)
0 days -16 years 215(40%) 132 (28%) 305(16%) 652(22.5%)
0 days - 5 years 144 (27%) 100 (21%) 301(16%) 545 (18.8%)
Subsequent CEA 97(18%) 45 (9.5%) 117(6%) 259 (9%)
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Table 2.15: Survival tables for subsequent stroke events in the five years after
carotid endarterectomy for the Scottish ISD-CEA cohort: 1981 - 1996.
Time 1981 - 1985 1986-June 1991 July 1991 -1997
Time Cumulative Number Cumulative Number Cumulative Number
months survival remain survival remain survival remain
0 .9981 535 .9979 475 .9910 1863
6 .8489 455 .9076 432 .9133 1621
12 .8209 440 .8824 420 .8874 1379
18 .7948 426 .8592 409 .8702 1152
24 .7780 417 .8508 405 .8524 993
30 .76491 410 .8382 399 .8354 811
36 .75752 406 .8256 393 .8175 626
42 .7481 401 .8214 391 .8082 481
48 .7407 397 .8067 384 .8019 331
54 .73883 396 .8025 382 .7869 200
60 .7313 392 .7899 375 .78194 156
'25 months;2 38 months;3 56 months; 457 months
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Table 2.16: Mean survival time with 95 % confidence intervals and standard error
for the ISD-CEA cohort over the 16-year study period and for a five-year follow-up
period.
0 -16.3 years 0-5 years
1981 - 1985 n= 536 n= 536
Deaths (d) d = 345 d = 135
Mean (95% C.I.) 9.78 (9.31-10.25) 4.35 (4.23 , 4.47)
Standard error 0.24 0.06
1986 - June 1996 n = 476 n = 476
Deaths (d) d = 198 d = 118
Mean (95% C.I.) 9.92 (9.39 - 10.46) 4.39 (4.27, 4.51)
Standard error 0.27 0.06
July 91 -March 97 n = 1880 n = 1880
Deaths (d) d = 240 d = 231
Mean (95% C.I.) 7.85 (7.41 - 8.30) 4.41 (4.34, 4.48)
Standard error 0.23 0.04
1985 -March 97 n= 2982 n = 2982
Deaths (d) d=783 d= 484
Mean (95% C.I.) 9.9(9.6-10.2) 4.39(4.34.4.44)
Standard error 0.3 0.03
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Table 2.17: Mean survival time (years), 95 % confidence intervals and standard
error for men and women in the ISD-CEA cohort: 1981 - 1996.
Years of follow-up
0-16.3 years 0 - 5 years
All deaths (d)* £II-S3 d = 484
Males d= 489 d = 310
Mean (95% C.I.) 9.6(9.2, 10.0) 4.34(4.27, 4.41)
Standard Error 0.2 0.04
Females d = 294 D = 172
Mean (95% C.I.) 10.3 (9.8, 10.8) 4.45 (4.37, 4,53)
Standard Error 0.2 0.04
*d = deaths
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Table 2.18: Mean survival time in years by age category for the Scottish ISD-CEA
cohort over a five-year follow-up period.
Age category Patients (n) Deaths (d) Mean survival (95% C.I.)
(years)
<50 years 159 14 4.8 (4.65 - 4.92)
50 - 65 years 1413 208 4.5 (4.44 - 4.58)
66 -80 years 1268 245 4.2 (4.12-4.3)
>80 years 52 17 3.2 (2.56 - 3.93)
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Table 2.19: Survival tables for all cause mortality for the Scottish ISD-CEA cohort
for the three periods: 1981 - 1996.
1981 -1985 1986-June 1991 July 1991 -
1997
March
Time Cumulative Number Cumulative Number Cumulative Number
months survival remain survival remain survival remain
0 0.9981 531 0.9979 466 .9979 1889
6 0.9474 504 0.9679 452 .9602 1727
12 0.9229 491 0.9465 442 .9428 1477
18 0.9117 485 0.9208 430 .9243 1226
24 0.8891 473 0.9015 421 .9034 1049
30 0.8722 464 0.8887 415 .8806 858
36 0.8477 451 0.8528 402 .8654 658
42 0.8289 441 0.8330 389 .8388 492
48 0.8083 430 0.8030 375 .8209 355
54 0.7838 417 0.7772 363 .7971 222
60 0.7462 397 0.7537 352 .7728 131
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Figure 2.1: Age distribution in five-year intervals for the Scottish ISD-CEA study
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Figure 2.2: Number of carotid endarterectomies by gender in Scotland for the three
study periods, 1981 -1996.
1200
Jan 81-Dec 85 Jan 86-June 91 July 91-Dec 96
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Figure 2.3: Number of carotid endarterectomies by year in Scotland: 1981 - 1996.
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Figure 2.6: Carotid endarterectomies in Scotland by hospital: 1981-1996.
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Figure 2.7: Carotid endarterectomy hospital volume (%) in Scotland for the 5 years
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Figure 2.8: Hospital stay for the Scottish ISD-CEA study population over the 16-
year period: 1981 -1996.
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Figure 2.9: Kaplan-Meier five-year survival estimates for any subsequent stroke for
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Figure 2.10: Kaplan-Meier five-year survival estimates fin* any subsequent stroke
for males and females in the Scottish ISD-CEA cohort: 1981 -1996.
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Figure 2.11: Kaplan-Meier five-year survival estimates for any subsequent stroke by
age category for the Scottish ISD-CEA cohort: 1981 -1996.
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Figure 2.12: Kaplan-Meier five-year survival estimates of death from any cause for
the three time periods for the Scottish ISD-CEA cohort: 1981 -1996.
2 3 4
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No deaths: 8 169
1943 1511 1161
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Figure 2.13: Kaplan-Meier five-year survival estimates for death from any cause for














No at risk: 1171
No deaths: 2
Males:
No at risk: 1798 1432 1150


















Chapter Two: Background - CEA in Scotland
Figure 2.14: Kaplan-Meier five-year survival estimates of death from any cause by




















Chapter Two: Background - CEA in Scotland
Figure 2.15: Schematic presentation of the effect of left and right censoring in the
time-to-event analysis for carotid endarterectomy.
Left censoring:
time of event unknown
Right censoring:




Chapter Three: Systematic review
CHAPTER THREE: A SYSTEMATIC REVIEW OF THE
LITERATURE EXAMINING THE COSTS AND BENEFITS OF
CAROTID ENDARTERECTOMY AND THE ASSOCIATED PRE¬
OPERATIVE INVESTIGATIONS.
3.1 Introduction.
The systematic review of available literature on the proposed topic of investigation is
regarded by some as secondary research and not a very exciting activity. This
however constitutes an important and necessary element of any research project and
may not be neglected (Greenhalgh, 1997). A systematic review constitutes an
overview of primary studies that used explicit and reproducible methods. A meta-
analyis on the other hand is a mathematical synthesis of the result of two or more
primary studies addressing the same hypothesis (Greenhalgh, 1997). As this review
is a systematic review and not a meta-analysis no attempt will be made to weight the
different studies or synthesise the results mathematically. In order to present this
review in a more interesting manner I assessed and discussed the studies identified in
the literature on the resource implications of carotid endarterectomy and the pre¬
operative investigations prior to carotid endarterectomy using a set of recommended
guidelines for the review of economic submissions to journals.
Costs and consequences are the essential components of any economic evaluation,
irrespective of the activities of interest. These two components each need to be
addressed when studies on economic evaluations are assessed and two key questions
need to be answered: Is there a comparison between two or more alternatives? and
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are both the costs (inputs) and consequences (outputs) of the alternatives examined?
The consequences of carotid endarterectomy have been assessed in two large
randomised controlled trials (European Carotid Surgery Trialists' Collaborative
Group, (ECST) 1991; North American Symptomatic Carotid Endarterectomy Trial
(NASCET) Steering Committee, 1991). There is conclusive evidence that carotid
endarterectomy reduces the risk of stroke in symptomatic patients with more than
70% stenosis of the internal carotid artery. The cost implications of this procedure
however, have not yet been satisfactorily addressed. Since the health care
environment has become much more cost conscious in the last decades and is
moving more and more into settings with limited resources, there is an increasing
interest in the application of economics to this intervention.
The essential elements of economic evaluations were listed as far back as 1974 by
Williams. More recently Drummond et al created a structure which captures all the
important and relevant methodological criteria for assessing economic studies
(1997). Drummond and Jefferson on behalf of the British Medical Journal Economic
Evaluation Working party also produced a set of guidelines for the evaluation of
"economic submissions", a "checklist" for use by referees, authors and editors
(Drummond and Jefferson, 1996; Drummond, 1985).
Eastcott and colleagues in London introduced carotid endarterectomy, or rather
carotid reconstruction for symptomatic cerebrovascular disease in 1953 (Eastcott et
al., 1954). Since then, five randomised controlled trials (RCTs) of carotid
endarterectomy for patients with symptomatic carotid stenosis have been conducted.
Two of these trials (Fields et al., 1970; Shaw et al., 1984) were launched in the
1960s, but neither demonstrated any benefit for this procedure. The number of
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carotid endarterectomies nevertheless escalated, and many inappropriate
endarterectomies were performed generating concerns both in Europe and North
America, resulting in three larger RCTs being set up: The European Carotid Surgery
Trial (ECST) in 1981, the Veterans Affairs Co-operative Studies program (VACS) in
1986 and the North American Symptomatic Carotid Endarterectomy Trial
(NASCET) in 1987. Patients in these trials were randomised to carotid surgery in
addition to best medical treatment versus best medical treatment alone. Medical
treatment included the control of modifiable vascular risk factors such as
hypertension, (Collins et al., 1990) and advice to stop smoking (Shinton and Beevers
1989). The risk of stroke in patients with symptomatic carotid stenosis can also be
reduced by long term antiplatelet therapy such as aspirin or ticlopidine (UK-TIA
study group, 1991; Hass et ah, 1989).
The ECST and NASCET trials demonstrated carotid endarterectomy to have a
definite and statistically significant benefit in terms of stroke risk reduction to
individuals with transient ischaemic events and mild ischaemic stroke originating
from the carotid artery territory. The VACS Study was terminated prematurely when
the results from ECST and NASCET became available (Hobson et ah, 1993).
The cost-effectiveness of carotid endarterectomy (CEA), however, has not been
critically and extensively assessed. A recent systematic review of the cost-
effectiveness research of stroke evaluation and treatment identified only modelling
studies assessing cost-effectiveness and expressed concern about the divergent
conclusions drawn from studies addressing similar questions (Holloway et ah,
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1999). Holloway et al suggested that it might be premature to use results from
current cost-effectiveness research in policy and practice guidelines.
In order to perform cost-effectiveness analysis the cost of the procedure must be
compared with the cost ofmedical treatment and related to the effectiveness gains of
the respective alternatives. Many studies have been performed to determine the cost
of carotid endarterectomy. Comprehensive assessment of the cost of medical care as
an alternative to carotid endarterectomy has not been undertaken. Most studies refer
only to the cost of antiplatelet therapy and do not consider the cost of regular visits or
the cost of managing adverse effects such as gastrointestinal haemorrhage (Oster et
al., 1994). Though a number of studies were identified in the literature, addressing
the costs and cost-effectiveness of the CEA and the associated pre-operative
investigations, the requirements for a proper economic evaluation of the procedure or
associated investigations are not satisfied by any of them.
3.2 Methodology.
3.2.1 Objective
The objective of this systematic review was:
• to critically appraise the studies identified in the literature addressing the
economic implications of carotid endarterectomy and the pre-operative
investigations in symptomatic and asymptomatic persons with carotid stenosis
prior to carotid endarterectomy and
• to discuss any implications for future research.
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3.2.2 Inclusion and exclusion criteria
I sought to identify all published studies assessing the cost implications of carotid
endarterectomy and studies assessing the cost implications of preoperative
investigation modalities for carotid stenosis in both symptomatic and asymptomatic
patients. I excluded all carotid endarterectomy studies and preoperative imaging
investigation studies for carotid stenosis not concerned with cost or economic
evaluation. I excluded all studies not in the English language.
3.2.3 Search strategy
A systematic search strategy was developed to identify research papers specifically
related to the evaluation of the costs and benefits of carotid endarterectomy and of
the preoperative investigations associated with carotid surgery (Appendix 1). In
developing a search strategy, the Cochrane Stroke Group MEDLINE search strategy
was examined for possible use to identify studies related to the costs and benefits of
carotid endarterectomy. This search strategy has as its main objective the
identification of stroke related studies and although used in one of the preliminary
searches, was found to generate many inappropriate studies to the proposed review.
A novel search strategy was developed to detect possible studies for the review.
The following databases were searched: 1) electronic searches ofMEDLINE, (1966 -
1997) EMBASE (1974 - 1997) and BIOSIS (1982 - 1997); 2) reference lists from
relevant studies and reviews; 3) personal communications with experts in this field.
A total of 381 papers concerned with cost issues were identified in Medline using the
electronic search strategy for the period 1966 to 1997 Of the 381 potential papers
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only 37 were considered relevant to the research question. To identify the 37 most
appropriate papers the titles, abstracts and keywords of the 381 potential papers were
searched for specific words. The following words were used in truncated form: cost;
cost-effectiveness; economic; carotid surgery; carotid endarterectomy; carotid
stenosis. Of the 37 papers identified for further evaluation 30 out of 213 possible
studies were published during the period 1993 to 1997 and seven of 90 possible
studies during 1984 to 1992. For the period 1966 to 1986, a total of 78 possible
studies were identified, but none of them were considered relevant for purpose of this
review. (For the years 1981 -1986: 65 studies, for 1976 - 1980: 11 studies and for
1966 - 1975 only two studies).
Searching EMBASE yielded 432 possible studies for the period 1980 to 1998 with a
total of 27 papers relevant to the systematic review. The search of EMBASE did not
identify additional studies not already identified using the MEDLINE database.
A hand search of journals was not undertaken, hence sensitivity and specificity of the
electronic searching was not performed.
3.2.4 Methodological quality
Published studies were identified and assessed, and a decision made whether to
include or exclude a specific study. The characteristics of each study collected,
included: 1) type of study (randomised controlled trial, observational or modelling);
2) study design (prospective or retrospective); 3) study method; (partial or full
economic evaluation); 4) study objective 5) study population (size, age and gender);
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6) cost elements (costs or charges); 7) study centre (United Kingdom, Europe, or
USA)
The methods used to critically appraise these studies followed the guidelines for an
economic evaluation proposed by Drummond and Jefferson. These guidelines
address ten distinct aspects which were discussed under three separate headings: 1)
study design including the study question, the selection of alternatives and the form
of evaluation applied, 2) data collection incorporating effectiveness data, benefit
measurement and valuation, costing and modelling, and 3) analysis and
interpretation of results which encompass the adjustments for timing of costs and
benefits, allowing for uncertainty and the presentation of results. 1 applied this
"check-list" by Drummond and Jefferson to the studies concerned with the resource
implications for diagnostic modalities in selecting patients for carotid surgery
patients as identified in the literature (Appendix 2).
3.2.5 Outcome measures:
1 defined the following outcomes I would consider relevant for the purpose of
this review:
i. For carotid endarterectomv
1) Cost per life-year gained, 2) incremental cost-effectiveness ratios and 3) cost per
carotid endarterectomy.
ii. For pre-operative investigationsprior to carotid endarterectomv
1) Number of cases with internal carotid stenosis of > 70% detected, and
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2) The cost of the imaging procedure to identify these cases suitable for carotid
endarterectomy.
3.3 Results
For the purpose of this review a brief description of the characteristics of the
published studies will be given. This is followed by a brief description of the
requirements of each of the ten criteria, against which these studies were assessed,
before discussing the results of the individual studies.
3.3.1 Studies assessing the cost consequences ofcarotid endarterectomy.
3.3.1.1 Study characteristics
A total of twenty-three reports, addressing the economic implications of carotid
endarterectomy, were identified in the literature over a 30-year search period (Figure
3.1). Twenty of these were published studies of which three were miscellaneous
publications, (a cost management algorithm (Ricotta et ah, 1998), a short report
(Baird, 1995), and one letter (Mead, 1995)) (Table 3.1). Eighteen of these studies
were published studies and were identified using MEDLINE, EMBASE and BIOSIS
databases. The remaining two studies were unpublished reports. All the studies
identified were however conducted and reported on during the last 10 years. These
studies were divided into full and partial economic evaluations. The full economic
evaluation being studies assessing the cost and benefits of CEA and the partial
economic evaluation referred to studies assessing only the cost of CEA.
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Of the twenty studies, (18 published and 2 unpublished), three (Cronenwett et al.,
1997; Kuntz et al., 1996; Nussbaum et al., 1996) were full economic evaluations,
which used modelling techniques based on published RCT data and one (Lavender et
al., 1998) applied cost data to their model to assess the effectiveness of CEA. The
remaining sixteen studies (Smurawska et al., 1998; Back et al., 1997; Mellisano et
al., 1997; Garrard et al., 1997; Dardik et al., 1997; Ballard et al., 1997; Pollard et al.,
1997; Smithies et al., 1996 (unpublished ); Hirko et al., 1996; Ammar, 1996; Kriass
et al., 1995; Luna et al., 1995; Patel et al., 1995; Radestock 1992 (unpublished);
Maini et al., 1990; Green et al., 1987) were partial economic evaluations using
retrospective observational data for their research. Three of the studies (Back et al.,
1997; Mellisano et al., 1997; Ammar, 1996) used a combination of retro-and
prospective observational data. None of these studies were randomised controlled
trials.
a) Type ofstudy.
Cost-effectiveness analysis: modelling studies:
Three of the studies (Cronenwett et al., 1997; Kuntz et al., 1996; Nussbaum et al.,
1996) applied Markov modelling techniques based on published randomised
controlled trial data to perform cost-effectiveness analyses. The modelling study by
Lavender used SIMULA simulation language to perform an effectiveness analysis.
The study by Kuntz considered symptomatic and asymptomatic populations, two
studies (Lavender et al., 1998; Nussbaum et al., 1996) considered symptomatic
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populations, and one (Cronenwett et al., 1997) considered an asymptomatic
population only.
Retrospective cost analysis and cost description studies.
Eight studies (Back et al., 1997; Mellisano et al., 1997; Garrard et al., 1997; Dardik
et al., 1997; Ballard et al., 1997; Pollard et al., 1997; Ammar, 1996; Kraiss et al.,
1995) were retrospective studies, using observational data to compare alternatives in
their cost analyses. Eight (six published and 2 unpublished) of the studies
(Smurawska et al., 1998; Smithies et al., 1997; Hirko et al., 1996; Luna et al., 1995;
Patel et al., 1996; Radestock 1992; Maini et al., 1990; Green et al., 1987) were cost
description studies. In the majority of the retrospective studies, symptomatic as well
as asymptomatic patients were considered. The published studies by Patel, Pollard,
Kraiss, the unpublished reports by Smithies and Radestock and the short report
(Baird) did not describe their study populations in terms of being symptomatic and/or
asymptomatic. The smallest percentage of asymptomatic patients assessed was 14%
in one study (Maini et al., 1990) and 53% was the largest proportion of asymptomatic
patients (Back et al., 1997) in studies with both symptomatic and asymptomatic
patients. The average proportion of asymptomatic patients assessed in all these
studies was 32%.
One study (Ricotta et al., 1998) investigated global pricing and capitation models as
cost management strategies for carotid endarterectomy. Although the authors referred
to the unit costs of the CEA procedure as well as charges associated with the pre¬
operative diagnostic testing, this study was not critically assessed and is not
discussed in this review.
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b) Study length.
The shortest study period was 12 months in three (Garrard et ah, 1997; Ammar,
1996; Green et al., 1987) of the sixteen CEA cost studies. One of these three studies
(Ammar, 1996) being a prospective study. The study of Maini (1990) having the
longest study period was a retrospective review of case notes over a 10-year period.
The mean length of the study period for all the studies was 39.2 months.
c) Size ofstudies.
The maximum number of patients was 343 reported from Italy in a prospective study
(Melissano et al., 1997). The minimum number was 49 cases in a retrospective
review of patient notes from the Department ofVascular Surgery, Royal North Shore
Hospital Sydney, Australia (Patel et al., 1995). The mean number of cases in these
studies was 168. Only one study (Nussbaum et al., 1996), applying modelling
techniques, described the number of patients used in the modelling; three groups with
100 patients in each of the hypothetical groups.
d) Age and sex distribution.
The mean age of the patients in these studies was 68 years with the youngest study
population having a mean age of 64.5 (Nussbaum et al., 1996) and the study
population with the oldest mean age being 76 years (Ammar, 1996). The study
populations were predominantly male, (70%), with only one study (Ballard et al.,
1997), a retrospective review of case notes of symptomatic and asymptomatic
patients, having almost equal numbers of male (53.1%) and female patients. All but
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three of the published studies were reported from the United States of America. The
three exceptions included one study from the United Kingdom (Lavender 1998), one
from Northern Italy (Melissano et ah, 1997), and one from Australia (Patel et al.,
1995). The two unpublished reports (Smithies et al., 1997; Radestock 1992) were
both from the United Kingdom.
3.3.1.2 Study design
The study design includes the (a) study question, (b) the selection of alternatives and
(c) the form of evaluation applied.
a) Study question
The question should be economically important in terms of its resource implications
and should be phrased in such a way that considers both the costs and consequences
of the alternative treatment(s), service(s) or programme(s). The question should
clearly state and justify the viewpoint for the evaluation.
Cost-effectiveness analysis: modelling studies:
Only two papers (Cronenwett et al., 1997; Kuntz et al., 1996) formulated satisfactory
research questions addressing the three elements needed for economic studies
described by Drummond and Jefferson. Their research questions assessed both the
costs and consequences of two alternatives, medical therapy versus carotid
endarterectomy. Though the economic importance in terms of the resource
implications of the relevant choices was not explicit in their questions this was
discussed in the introduction sections of the papers. Their questions were framed
101
Chapter Three: Systematic review
against the background of NASCET and ACAS (Executive Committee of the
Asymptomatic Carotid Atherosclerosis Study, 1995), which showed significant risk
reductions for carotid endarterectomy, but did not consider the cost-effectiveness of
carotid endarterectomy.
The study question by Nussbaum and others (1996) was considered reasonable,
though not clearly formulated and the research objective was not immediately
apparent. In assessing the paper the research objective was forthcoming in the phrase:
"we evaluated the long term, societal cost-benefit ratio of carotid endarterectomy
using a decision analysis model". These three modelling studies assessed the
lifetime cost of patients treated with CEA or best medical care. The primary
objective of the study by Lavender and others was not to evaluate the cost-
effectiveness of CEA and the research question in terms of an economic assessment
was not relevant.
Retrospective cost analysis studies. (Comparing cost ofalternatives)
Eight studies (Back et al., 1997; Pollard et al., 1997; Melissano et al., 1997; Garrard
et al., 1997; Dardik et al., 1997; Ballard et al., 1997; Ammar, 1996; Kraiss et al.,
1995) were primarily concerned with methods or alternatives to reduce the cost of
carotid endarterectomy. Only the research question by Kraiss in these eight studies
was regarded as satisfactory. The research questions in remaining seven studies
(Back et al., 1997; Pollard et al., 1997; Melissano et al., 1997; Garrard et al., 1997;
Dardik et al., 1997; Ballard et al., 1997; Ammar, 1996) were considered reasonable
in terms of economic evaluation since two of the elements required for a well
formulated question were considered.
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Retrospective cost description studies (Describing only the cost ofthe procedure).
Published studies.
Six studies (Smurawska et al., 1998; Hirko et al., 1996; Luna et al., 1995; Patel et al.,
1995; Maini et ak, 1990; Green et ak, 1987) described the cost of the procedure.
Three studies (Smurawska et ak, 1998; Hirko et ak, 1996; Maini et ak, 1990)
described the cost of carotid endarterectomy over time and how it has changed due to
changes in management. Of the six cost description studies (Smurawska et ak, 1998;
Hirko et ak, 1996; Luna et ak, 1995; Patel et ak, 1995; Maini et ak, 1990; Green et
ak, 1987) only two (Maini et ak, 1990; Green et ak, 1987) formulated satisfactory
questions. The research questions in the other four studies were reasonable. Two
studies compared the cost of carotid endarterectomy between institutions (Luna et ak,
1995; Green et ak, 1987).
Unpublished studies.
The research questions in the unpublished reports (Smithies et ak, 1997; Radestock
1992) were considered reasonable since two of the three elements for a proper
question were addressed.
b) The selection ofcompeting alternatives.
The rationale for the choice of the alternatives should be given and also whether a
"do-nothing" alternative was considered. The alternative interventions should be
properly described, i. e. Who did what, to whom, where and how often?
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Cost-effectiveness analysis: modelling studies:
The alternatives in the modelling studies (Lavender et ah, 1998; Cronenwett et al.,
1997; Kuntz et al., 1996; Nussbaum et al., 1996) were carotid surgery versus medical
treatment. Nussbaum also considered a do-nothing alternative.
Cost analysis studies.
The alternatives were sufficiently described in all eight studies concerned with
methods to reduce costs by comparing conventional protocols with alternative
protocols (Back et al., 1997; Pollard et al., 1997; Melissano et al., 1997; Garrard et
al., 1997; Dardik et al., 1997; Ballard et al., 1997; Ammar, 1996; Kraiss et al., 1995).
The alternative protocol allows only duplex investigation preoperatively,
preoperative work-up on an outpatient basis, same day admission, regional
anaesthesia, and selective admission to intensive care units and early hospital
discharge. Angiography was only to be performed selectively in cases where duplex
results were inconclusive. The rationale for the choices was explained and
justification given for their inclusion in the relevant studies.
Cost description studies.
Alternatives were not discussed in the six cost description studies (Smurawska et al.,
1998; Hirko et al., 1996; Luna et al., 1995; Patel et al., 1995; Maini et al., 1990;
Green et al., 1987). The elements responsible for the change in practice over time and
their associated influence on the costs were referred to in these studies.
Both the unpublished studies (Smithies et al., 1997; Radestock, 1992) did not refer to
the alternatives that would be investigated. These studies, although having the word
cost-effectiveness in the title, were not considered to be cost-effectiveness analyses
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but were more in line with cost-outcome description studies. Though the
investigators set out to produce cost-effectiveness analyses, the essential principles
were ignored. No reference to a cost-effectiveness ratio was made in either of these
studies. These reports did not discuss alternatives to be compared and did not
mention alternatives in terms of their observational data though used the
effectiveness data from the RCT published studies in their analyses. The Newcastle
study (Radestock, 1992) referred to alternative stroke prevention strategies by
discussing the cost of hypertension treatment and the cost of screening for
hypertension. The study from Wessex (Smithies et ah, 1997), in addition to the cost
per stroke prevented by treating hypertension, also referred to the cost per stroke
prevented with aspirin treatment, treatment of hypercholesterolaemia and the number
ofpersons who need to stop smoking, based on the literature.
c) Form ofEvaluation
The forms of evaluation should be stated i.e. cost minimisation, cost effectiveness,
cost benefit and cost utility analysis. "Is it worth achieving this goal?" for cost
benefit analyses and "What is the most efficient way of spending a given budget?"
when assessing cost minimisation and cost effectiveness studies. Cost-effectiveness
analysis can for all practical purposes be one of two types. In the first instance, the
health effects of the alternatives are known to be equal and therefore only the costs
need to be analysed. The least costly alternative is the most efficient and this is often
referred to as cost-minimisation analysis. When the alternatives may differ in both
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cost and effect, a cost-effectiveness ratio (cost per unit of health effect) needs to be
calculated for each.
The three modelling studies (Cronenwett et ah, 1997; Kuntz et ah, 1996; Nussbaum
et al., 1996) applied cost-effectiveness analyses and estimated the "lifetime cost" of
CEA. Cost analysis and cost description analysis were used in all the other studies.
The unpublished studies (Smithies et al., 1997; Radestock, 1992) were cost-outcome
description studies. The cost description studies (Smurawska et al., 1998; Hirko et
al., 1996; Luna et al., 1995; Patel et al., 1995; Maini et al., 1990; Green et al., 1987)
described the use of resources for carotid endarterectomy. These studies were
mainly concerned with the direct costs of the procedure. The group of studies (Back
et al., 1997; Dardik et al., 1997; Melissano et al., 1997; Garrard et al., 1997; Ballard
et al., 1997; Pollard et al., 1997; Ammar, 1996; Kraiss et al., 1995) concerned with
methods or alternatives to reduce the cost of carotid endarterectomy can be classified
as cost analysis studies and not cost minimisation studies. Since the outcome of the
procedure using different clinical pathways has not been established yet.
Of the eighteen studies concerned with the cost of carotid endarterectomy, eleven had
the word cost-effectiveness in the title or in the abstract, but only in four were the
basic principles of a cost-effectiveness analysis applied. However, as pointed out by
Drummond et al, the distinction between cost-effectiveness, cost-benefit and cost-
utility analyses are often made purely for instructional or academic reasons, and the
distinctions in real life are often blurred.
The "modelling" study by Lavender et al can not be regarded as a "true" cost-
effectiveness analysis, since the computer simulation techniques were applied to
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estimate the effectiveness of CEA in the first place and not the cost implications.
The investigators however acknowledged the importance to include costs in the
development of a model assessing the effectiveness of CEA and "investigated" the
cost-effectiveness of CEA in their discussion (Lavender et al., 1998).
Six of these eighteen studies (Mellisano et ah, 1997; Back et ah, 1997; Ballard et ah,
1997; Ammar, 1996; Luna et ah, 1995; Kraiss et ah, 1995) with cost-effectiveness in
the title or abstract could not be regarded as either cost-effectiveness, cost-benefit or
cost-utility analyses. Eight studies (Mellisano et ah, 1997; Back et ah, 1997; Ballard
et ah, 1997; Garrard et ah, 1997; Pollard et ah, 1997; Dardik et ah, 1997; Ammar,
1996; Kraiss et ah, 1995) are considered cost analysis studies. Eight studies
(Smurawska et ah, 1998; Smithies et ah, 1997; Hirko et ah, 1996; Luna et ah, 1995;
Patel et ah, 1995; Radestock, 1992; Maini et ah, 1990; Green et ah, 1987) were
retrospective and concerned primarily with the description of just the costs of carotid
endarterectomy. The study by Pollard et al requires some clarification since this is a
study not primarily concerned with carotid endarterectomy but with the cost-savings
resulting from same-day admissions for two "comparable" procedures i.e. lower
extremity revascularisation and carotid endarterectomy. This study is thus different
from all the other studies where carotid endarterectomy was the procedure of main
interest.
3.3.1.3 Data collection
The data collection incorporates the elements: 1) Effectiveness data; 2) Benefit
measurement and validation; 3) Costing and 4) Modelling.
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a) Effectiveness data
Details of the design and the results of the study from where the effectiveness data
were obtained and which are to be used in the economic evaluation should be given.
It should state clearly whether the effectiveness data were from the results of a single
study or from a meta-analysis. The gold standard for assessing the efficacy of
interventions is the randomised double blind controlled trial, which has the highest
internal validity and is most free from bias. Failing the gold standard an overview of
clinical studies for establishing effectiveness or observational data or modelling
techniques can be used. Generalisability of the study population is important in
assessing the results, as is the transferability of the findings.
Cost-effectiveness analysis: modelling studies:
The results from the randomised controlled trials, the NASCET (North American
Symptomatic Carotid Endarterectomy Trial Steering Committee, 1991) and ACAS
(Executive Committee of the Asymptomatic Carotid Atherosclerosis Study, 1995)
were applied as the effectiveness data in the three studies (Cronenwett et al., 1997;
Kuntz et al., 1996; Nussbaum et al., 1996) using modelling techniques to assess the
cost-effectiveness of carotid endarterectomy. Since the cost-effectiveness of CEA
was not formally assessed by Lavender, this study will not be assessed with the other
modelling studies.
The effectiveness measure applied in these studies is defined as "stroke-free" life
years after CEA. A "stroke-free" life year is defined as surviving "stroke-free" for a
total period of two years (NASCET), three years (ECST) and five years (ACAS) after
successful carotid surgery.
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Kuntz evaluated symptomatic and asymptomatic populations, Cronenwett evaluated
an asymptomatic population and Nussbaum evaluated a symptomatic population.
Nussbaum et al also used observational data in addition to published data in their
modelling study. Kuntz and Cronenwett did not specify the sizes of their
hypothetical cohorts. Nussbaum reviewed the results of 150 carotid endarterectomies
performed at an academic centre and applied a Markov model comparing three
cohorts of patients, each with 100 subjects, who had experienced transient ischaemic
attack. One cohort was observed, one cohort received aspirin therapy and the third
cohort had carotid surgery.
Cost analysis and cost description studies.
The remaining sixteen studies were observational cost analysis and cost description
studies (.Published: Smurawska et al., 1998; Back et al., 1997; Dardik et al., 1997;
Melissano et al., 1997; Garrard et al., 1997; Pollard et al., 1997; Ballard et al., 1997;
Ammar, 1996; Hirko et al., 1996; Patel et al., 1995; Luna et al., 1995; Kriass et al.,
1995; Maini et al., 1990; Green et al., 1987; Unpublished: Smithies et al., 1997;
Radestock, 1992).
b) Benefit measurement and valuation
Primary outcome measures for the economic evaluation should be clearly stated,
i.e. cases detected, life-years gained or cost-effectiveness ratios in the case of carotid
endarterectomy. Details should be given of the methods used to value health benefits.
These methods include time-trade off and standard gamble. It is also important that
the subjects from whom valuations were obtained should be stated, for example
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patients, members of the general public, or health professionals. Since measuring
preferences for health outcomes as described above is a very time consuming and
complex task, pre-scored multi-attribute health-status classification systems are
preferred. Benefits are measured in natural units such as life-years gained, mmHg
reduction in hypertension control in cost-effectiveness analysis, in monetary units in
cost-benefit analysis and in healthy years or quality adjusted health years in cost-
utility analysis. The use of an overall ratio or index e.g. cost-effectiveness ratio (i.e.
the difference in costs divided by the difference in life-years) is the preferred and
accepted manner to report cost-effectiveness analysis.
Cost-effectiveness analysis: modelling studies.
Only the modelling studies by Kent, Nussbaum and Cronenwett referred to benefit
measurements. Kent et al and Cronenwett calculated cost-effectiveness as the
"incremental cost of surgery per quality adjusted life year gained" when compared
with medical treatment. Nussbaum and Kent expressed the lifetime cost in terms of
"quality adjusted life expectancy". The outcome measures in the unpublished reports
were the estimated cost per stroke prevented.
c) Costing.
Costing involves the estimation of resources used. Unit costs of the resources should
be reported separately from the quantities of the resources used. Estimation methods
for both quantities and unit costs should be explained, as well as recording the
currency and price date.
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Cost-effectiveness analysis: modelling studies.
Kuntz, Nussbaum and Cronenwett described the cost estimates used in the
construction of their decision analytic models. These estimates were based on the
average allowable reimbursements for professional fees and hospital charges for
diagnostic related groups (Table!.2). Estimates of all cost variables were given in
the three modelling studies. The costs in the modelling studies were expressed in
US$, the reference years were 1993 (Kuntz et ah, 1996) and 1996 (Cronenwett et ah,
1997). Nussbaum failed to mention the year to which the cost in his study referred.
Cronenwett also reported the undiscounted rate, allowing the reader to recalculate
results using different discount rates.
Cost analysis and cost description studies.
The retrospective studies all used charges with the exception of Smurawska, Garrard
and Patel who used costs in their calculations. The study by Patel was a cost
description study with itemised costing on all investigations before and during
hospitalisation. Only one (Ammar, 1996) of these retrospective studies mentioned the
reference year for which calculations were done. Two retrospective/prospective
studies (Back et ah, 1997; Ammar, 1996) reported costs in US$ and one study
reported costs in ECUs (European Currency Unit) (Melissano et ah, 1997).
The cost of CEA in four similar cost analysis studies (Back et ah, 1997; Dardik et ah,
1997; Ballard et ah, 1997; Kraiss et ah, 1995) varied from a minimum of US$ 7608
(Ballard et ah, 1997) to a maximum of US$ 11 546 (Back et ah, 1997) for the
conventional protocol. The cost of CEA over time reported by Smurawska (1998)
demonstrated a decrease from US$ 10 394 ± 7821 during 1994 to US$ 6857 ± 3014
in 1996.
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The unpublished studies (Smithies et al., 1997; Radestock, 1992) were reported in
pound sterling but a reference financial year was not specified. Radestock reported a
cost of £3300 per CEA based on retrospective data and Smithies et al estimated the
cost of CEA based on HRG cost between £1890 and £4670. The study from Wessex
(Smithies et al., 1997) used a standardised approved approach as outlined in "The
Costing for Contracting Manual" (NHSE Leeds 1995). Applying a consultation
process with health care professionals an aggregate Healthcare Resource Group
(HRG) cost for Routine Vascular Surgery which included CEA was produced. The
CEA "costs" estimates for the individual studies are summarised in Table 3.2.
d) Modelling
In assessing economic evaluations, details of any modelling used should be given
e.g. decision tree model, regression modelling, epidemiology model as well as
justification of the type of model and key parameters applied. Different types of
decision modelling methods can be applied, for example: 1) decision tree modelling,
2) Markov modelling, 3) Monte Carlo simulation models and 4) Standard life tables.
Modelling may be applied to: a) extrapolate the progression of clinical outcomes, b)
transform final outcomes from intermediate measures, c) examine the relation
between inputs and outputs in production function models, d) use data from a variety
of sources to undertake a decision analysis and e) use evidence from trials or
systematic reviews to "predict" what might happen in different clinical settings or
populations.
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Cost-effectiveness analysis: Modelling studies in symptomatic patients.
Kuntz et al constructed decision analytic models to calculate the lifetime costs and
quality adjusted life expectancy for two separate hypothetical cohorts treated either
with carotid endarterectomy or with medical treatment. They based their analysis
primarily on the results from the NASCET and the ACAS. Nussbaum also
constructed a Markov model comparing three cohorts of 100 patients each who
experienced a transient ischaemic attack and were managed by observation, aspirin or
carotid endarterectomy to calculate the lifetime cost of CEA to society. Separate
outcomes for carotid endarterectomy were determined on operative results from their
own institution as well as from the NASCET.
Cost-effectiveness analysis: Modelling studies in asymptomatic patients.
Cronenwett et al performed a cost-effectiveness analysis using a Markov decision
model in which the probabilities for the base case analysis were based on data from
ACAS and used NASCET data for patients who crossed over, i.e. became
symptomatic and calculated the incremental lifetime cost.
3.3.1.4 Analysis and interpretation of results
The analysis and interpretation of result section summarises (a) adjustments for
timing of costs and benefits, (b) allowance for uncertainty and (c) the presentation of
results.
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a) Adjustmentsfor timing ofcosts and benefits
It is important that the time horizon over which costs and benefits are considered is
given. The time horizon should preferably extend over the entire anticipated life of
the treated individuals to capture all the effects of the alternatives. Discount rates
should be given and if not considered, an explanation should be given as to why not.
Discounting means that the money we spend now is worth more at present than it
would be in the distant future. Discounting can be defined as follows: costs that are
incurred at different points in time need to be "weighted" or discounted to reflect the
fact that those costs which occur in the immediate future are ofmore importance than
those costs which accrue in the distant future.
Cost-effectiveness analysis: Modelling studies. (Table 3.2)
The three modelling studies in asymptomatic patients addressed adjustments for
timing of costs and benefits by applying a discount rate of 3% (Kuntz et al.,
1995) and 5% (Cronenwett et ah, 1997; Nussbaum et ah, 1996).
b) Allowance for uncertainty.
Sensitivity analysis should be applied when there is uncertainty about the costs and
effectiveness of different procedures. This investigates the extent to which results are
sensitive to alternative assumptions about key variables.
Uncertainty can be related to the observed data inputs, the extrapolation of the data
and to the analytical methods. Details should be given of the statistical tests used and
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the confidence intervals when stochastic data are reported. Details should be given of
the approach used when a sensitivity analysis is performed.
Sensitivity analyses were done in the modelling studies; one-way analysis in all three
studies and a three-way analysis in one study (Kuntz et al., 1996). Kuntz and others
reported that the cost-effectiveness of CEA in symptomatic patients were not very
sensitive to wide variations in baseline assumptions. In asymptomatic patients,
however, the cost-effectiveness of CEA were sensitive to a number of variables, most
importantly the operative risk associated with carotid endarterectomy and the cost of
the procedure. Cronenwett and others found that age was the variable that most
significantly influenced cost-effectiveness of CEA and the second most important
variable was stroke rate during medial management. This translated to carotid
endarterectomy being cost-effective when the patient was younger (< 70 years) and
the stroke rate was high. This finding is in keeping with clinical expectations.
Sensitivity analyses were applied in both the unpublished studies. A one-way
sensitivity analysis was applied in the study from Newcastle, this was however not a
modelling study where this technique to address uncertainty is best used. The
analyses performed in the Newcastle and Wessex studies were more appropriate as a
scenario analyses. (Best case, worst case scenario)
Uncertainty was accounted for with standard statistical tests in the retrospective and
prospective studies with two exceptions, Patel and Melissano.
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d) Presentation of results.
Presentation of results should ideally refer to incremental analysis, major outcome
measures, comparisons with other health care interventions and should of course
answer the original study question.
The modelling studies presented their results as cost-effectiveness ratios or as quality
adjusted life expectancy expressed as the average lifetime cost to society. The two
unpublished studies reported on the cost per stroke prevented. The results of the cost
description and cost analysis studies were presented as the cost of CEA in monetary
units.
Cost-effectiveness analysis: Modelling studies
The modelling studies (Cronenwett et al., 1997; Kuntz et al., 1996) presented their
results as cost-effectiveness ratios. Nussbaum presented his results as quality
adjusted life expectancy expressed as the average lifetime cost to society of either
observation or aspirin therapy or CEA after TIA.
Kuntz et al found that for a typical symptomatic NASCET patient carotid
endarterectomy provides a benefit of 0.35 discounted QALYs compared with
medical treatment at an incremental cost per QALY gained of $4100. For a typical
asymptomatic ACAS patient carotid endarterectomy provides a benefit of 0.15
discounted QALYs compared with medical treatment at an incremental cost of
$52700 per QALY gained.
Nussbaum estimated the average life expectancy among TIA patients with no
intervention to be 7.18 years, 7.26 years with aspirin treatment, 7.63 years based on
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the NASCET results and 7.69 years when results from his own centre was used.
QALYs were estimated to be 6.03 without treatment, 6.25 years with aspirin, 7.18
years with carotid endarterectomy based on NASCET data and 7.35 years when data
from their own centre was used. This translated to a gain of 1.15 QALYs (7.18 -
6.03) in favour of surgery where no treatment was given or 0.93 QALYs, or 11.2
months in favour of surgery in the group where aspirin was given (7.18 - 6.25).
Cronenwett reported for the base case an undiscounted quality adjusted life
expectancy in the medical group of 11.1 years versus 11.6 years in the surgical
group. Discounting at 5% yielded 7.87 QALYs in the medical group and 8.12
QALYs in the surgical group, resulting in a difference of 0.25 QALYs (three months)
in favour of the surgical group. Cronenwett concluded that the incremental cost-
effectiveness ratio of $8004 calculated, compared favourably with other commonly
accepted medical practices.
Unpublished studies reporting on cost-effectiveness ofCEA.
Rctdestock used the number needed to treat (NNT) from the NASCET and the ECST
results to prevent one stroke and multiply the cost estimate from the observational
data with the NNT to calculate the cost to prevent one stoke. Using these reference
values, a cost of £37 570 was estimated to prevent one stroke, based on NASCET
data. The cost of stroke as obtained in the literature was briefly discussed in the
report, but it was not related to the cost of carotid endarterectomy.
Smithies and others used the cost estimated from the 203 carotid endarterectomies in
their retrospective data set and applied the NASCET and ECST data to it. They
calculated the number of disabling or fatal strokes that could be avoided at 2 -3 years
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for the 203 carotid endarterectomies. The calculated cost of carotid endarterectomy
was then multiplied with the estimated number of strokes avoided.
Though comparisons with other health care interventions in terms of relative cost
effectiveness were made in these modelling studies it is a prerequisite that this
should be done only "when close similarity in study methods and settings can be
demonstrated". Neither of the studies refer to methods and settings; references are
given which can be follow to verify whether methods and settings were
comparable. This was however considered outside the scope of this study was not
pursued.
3.3.2. Studies assessing the cost consequences of carotid imaging - Pre-operative
investigations prior to carotid endarterectomy.
3.3.2.1 Study characteristics
Seven studies and an Editorial were identified in the literature addressing the
resource implications of imaging strategies for carotid endarterectomy in both
symptomatic patients and asymptomatic populations using the search strategy
described. Four of the studies (Lavenson et al., 1996; Vanninen et al., 1995;
Kent et al., 1995; Hankey et al., 1990) considered symptomatic populations.
The remaining three studies (Yin et al., 1998; Lee et al., 1997; Derdeyn et al.,
1996) assessed the cost implications of screening for carotid stenosis in
asymptomatic persons.
The Editorial "Cost-effective investigation of patients with suspected transient
ischaemic attacks" should be regarded as a protocol or a set of recommended
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guidelines on how to manage a particular group of patients with a description of
costs attached to the proposed investigations. Since this paper was an Editorial
it was not considered appropriate to evaluate it using the suggested criteria for
economic evaluations, and was therefore not considered in this review.
The baseline characteristics of these studies are summarised in table 3.3.
Symptomatic populations.
Only two (Kent at ah, 1995; Vanninen et al., 1995) of the four studies in
symptomatic populations reported the mean age of their study populations and
the percentage males in the study population. The mean number of patients in
these four studies (Lavenson et ah, 1996; Kent et ah, 1995; Vanninen et ah,
1995; Hankey et ah, 1990) were 132 with 45 the smallest number of patients
(Vanninen et ah, 1995) and 296 patients the largest study population (Hankey et
ah, 1990). One study (Kent et ah, 1995) used Markov modelling, two
(Vanninen et ah, 1995; Hankey et ah, 1990) described various scenarios and
one study (Lavenson et ah, 1996) described the cost effect of duplex
examination on strokes avoided.
Asymptomatic populations.
The three studies (Yin et ah, 1998; Lee et ah, 1997; Derdeyn et ah, 1996)
investigating the cost-effectiveness of screening asymptomatic populations for
CEA all applied Markov modelling techniques. The mean age of these three
study populations was 62.5 years. Two (Lee et ah, 1997; Derdeyn et ah, 1996)
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of the three studies investigated all-male populations and only one (Derdeyn et
ah, 1996) referred to the number of patients investigated.
3.3.2.2 Study design
Seven studies (Yin et ah, 1998; Lee et ah, 1997; Lavenson et ah, 1996; Derdeyn et
ah, 1995; Kent et ah, 1995; Vanninen et ah, 1995; Hankey et ah, 1990) were
identified reporting on the "cost" of pre-operative investigations. When evaluating
these studies against the requirements for an "ideal" research question, five (Yin et
ah, 1998; Lee et ah, 1997; Derdeyn et ah, 1995; Kent et ah, 1995; Vanninen et ah,
1995) satisfied the criteria outlined by Drummond and Jefferson, but only two
studies (Kent et ah, 1995, Vanninen et ah, 1995) were in symptomatic patients.
Though neither of the studies, both in symptomatic and asymptomatic populations,
formulated the outcomes of interest in the research question per se, the outcome
measurements were described and referred to in six of the studies, the exception
being the study by Lavenson et ah
a) Research question
Symptomatic patients.
Two (Kent et ah, 1995; Vanninen et ah, 1995) of the four studies investigating
symptomatic patients formulated their research questions in such a manner which
addressed the economic importance in terms of resource implications and the
relevant choices or alternatives. Kent and co-workers considered both the costs of the
screening modalities as well as the outcome objective in their study question. Both
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these studies discussed and justified their viewpoint for the analysis In the case of
Vanninen the outcome measure of interest became only apparent in the results
section of their paper.
Two studies (Lavenson et ah, 1996; Hankey et ah, 1990) did not address the aspects
considered necessary elements in a research question for the economic evaluation of
health care interventions. The study by Lavenson failed to satisfy the requirements
needed for an adequately formulated research question. Duplex ultrasound was the
only alternative considered and the outcome of interest was not incorporated in the
study design section, but became apparent only in the result section.
The economic implications in terms of resource implications concerning the
alternative choices were not clearly formulated in the paper by Hankey and co¬
worker. The viewpoint of the economic evaluation was also not implicitly stated,
though the perspective of provider organisation became apparent. This study is
regarded as methodologically unsound to be assessed in terms of the requirements for
an economic evaluation.
Asymptomatic patients
All three studies (Yin et ah, 1998; Lee et ah, 1997; Derdeyn et ah, 1995)
investigating screening of asymptomatic populations satisfied the requirements for a
well formulated question.
b) The selection ofcompeting alternatives.
Two studies (Kent et ah, 1995; Vanninen et ah, 1995) in symptomatic patients
compared three alternatives duplex sonography, magnetic resonance angiography and
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contrast angiography and in one study (Kent et al., 1995) a combination strategy of
these three imaging modalities was also assessed. One study in symptomatic patients
(Hankey et ah, 1990) compared clinical methods against duplex ultrasound. The
three studies assessing "cost-effectiveness" in asymptomatic populations (Yin et ah,
1998; Lee et ah, 1997; Derdeyn et ah, 1996) compared duplex sonography against a
"do-nothing" alternative. They also described the rationale for the selection of the
alternatives with justification for their choices and evaluated the cost-effectiveness of
screening in terms of resource implications.
The alternative interventions (imaging modalities) as well as the rationale for their
selection were described in sufficient detail by Kent and Vanninen. Hankey
investigated the "safest, most cost-effective way of selecting patients for
angiography" by comparing clinical examination methods and duplex ultrasound to
identify patients for angiography. The alternatives considered by Hankey and co¬
worker, clinical methods versus duplex ultrasound, were only discussed towards the
latter part of their paper. The study design is described as a prospective cohort study,
but that is only true with respect to the evaluation of the 485 consecutive patients
with TIA who were referred and evaluated for a possible conventional carotid
angiogram and not regarding the proposed cost-effectiveness evaluation. During the
prospective study period, duplex ultrasound was also not available as an imaging
modality in the settings where these patients were assessed. This study design is
more in keeping with a type of modelling where "modelling techniques enable an
evaluation to be extended beyond what has been observed in a single set of direct
observations". This study could more appropriately be considered as an example of
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"retrospective" modelling or a scenario analysis. The study by Lavenson et al did not
compare alternatives and was classified as cost-description study.
c) Form ofEvaluation
Seven of the eight studies refer to cost-effectiveness in the title, but in only four (Yin
et al., 1998; Lee et al., 1997; Kent et al., 1996; Derdeyn et al., 1995) was a cost-
effectiveness analysis performed. Vanninen and others refer to cost effectiveness of
the imaging procedures, but fail to do an appropriate analysis to determine cost
effectiveness. Drummond and Jefferson emphasise that the methodology used in a
given study should be examined to determine whether it suits the problem under
review. In assessing the methodologies used in the studies, only the four studies
referred to already qualify as cost effectiveness analyses.
Hankey used the term cost-effectiveness inappropriately in terms of economic
evaluations and did not perform a cost-effectiveness analysis. They analysed "cost-
effectiveness" by using estimated costs of several imaging strategies that might be
used to investigate a hypothetical sample of patients with symptomatic stenosis. This
study, though comparing two alternatives, is more in keeping with a cost-outcome
description study. The study by Lavenson et al referred to cost savings in the title and
in the methodology discussed the cost implications or cost effect of duplex
examination.
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3.3.2.3 Data collection
a) Effectiveness data
None of the identified studies in symptomatic patients were randomised controlled
trials. Three studies (Kent et al., 1995; Vanninen et al., 1995; Hankey et al., 1990)
evaluating symptomatic patients were observational studies. Sensitivities and
specificities for the imaging techniques were based on the observational data and
used as baseline results for the models in symptomatic patients in two (Kent et al.,
1995; Vanninen et al., 1995). Hankey et al assumed the sensitivity for Duplex
ultrasound to be 100% in their "model". In asymptomatic patients, one study
(Derdeyn et al., 1996) generated Doppler sensitivities and specificities locally by
reviewing carotid bifurcation examinations over a two-year period at their institute.
Two studies (Yin et al., 1998; Lee et al., 1997) performed a meta-analysis to obtain
estimates of sensitivity and specificity of duplex ultrasound.
The prevalence of carotid stenosis in two studies (Vanninen et al., 1995; Hankey et
al., 1990) in symptomatic patients was obtained from their observational data. Kent
and others referred to a prevalence used in their sensitivity analysis, but did not
describe its source.
In the asymptomatic populations (Yin et al., 1998; Lee et al., 1997; Derdeyn et al.,
1996) estimates of carotid stenosis prevalence were obtained through a literature
review. The angiographic complication rate, surgical risk, stroke risk and mortality
rate, and benefit of CEA reported in ACAS (1995), were the rates used for the
asymptomatic populations. For symptomatic populations corresponding rates
reported from NASCET were used in the modelling. The 30-day to two-year
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probabilities of stroke among symptomatic patients were estimated from NASCET
and used in the subsequent modelling by Kent et al. The three studies (Yin et ah,
1998; Lee et al., 1997; Derdeyn et al., 1996) assessing asymptomatic populations
developed decision models to evaluate the effect of screening or no screening on
QALY and cost. Yin, Lee and Derdeyn applied the results from the NASCET and the
ACAS in the modelling studies.
b) Benefit measurement and valuation
Four studies, only one (Kent et al., 1995) being in symptomatic patients, assessed the
outcome measures in economic terms e.g. "incremental cost per quality-adjusted life
year gained" (Derdeyn et al., 1996; Kent et al., 1995), "quality-adjusted-life-years",
and "costs and marginal cost effectiveness ratios" (Yin et al., 1998; Lee et al., 1997).
Cases detected and the cost effect of carotid surgery in terms of strokes prevented
were the main outcome measures in the studies by Vanninen, Hankey and Lavenson.
Kent used time-trade-off and assumed that the quality weight for one year of life after
a major stroke was 0.4 and a disutility of 0.25 years for a minor stroke. Only Lee,
Derdeyn and Yin valued health benefits. Both Lee and Derdeyn used time-trade-off
methods to measure preferences of patients at risk for stroke. Yin derived quality of
life adjustments from earlier studies. The degree to which minor and major stroke
decreases quality of life was adjusted with a factor that ranged from zero for death
and one for complete health. Kent referred to health-related weights in a similar
fashion than Yin, and assumed a disutility following a major stroke of 0.4 and after a
minor stroke of 0.25 years (utility meaning preference). Similar to the studies
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assessing the cost consequences of carotid endarterectomy, no reference to standard
accepted methods to measure benefits was made. No details were given on how the
benefits were measured, and I assumed that these benefits were obtained from the
literature.
c) Costing.
Quantities of resources, estimated unit costs and costing details were reported
adequately in all the studies evaluating cost-effectiveness in symptomatic patients. In
the asymptomatic population studies, unit costs were reported for all the cost
variables. All these studies on cost-effectiveness of screening for carotid surgery
used estimated costs rather than charges with the exception of Lee who used charges
as a proxy for cost. Six studies reported costs in US dollars (1994 -1995), five of
these studies (Yin et ah, 1998; Lee et ah, 1997; Derdeyn et ah, 1996; Lavenson et ah,
1996; Kent et ah, 1995) were from the United States and one from Finland
(Vanninen et ah, 1995). The cost in the study by Hankey et al was reported in pounds
sterling.
All the studies reported in US dollars refer to the year on which the costs were based.
In the study by Kent et al all costs were converted to 1993 dollars. Kent and co¬
workers did not include the cost of duplex ultrasound investigations because it was
assumed that all patients were initially screened with Doppler and that it would
therefore be a constant. By not incorporating this cost, the overall cost of the
preoperative investigations would have been reduced, resulting in a more favourable
cost-effectiveness ratio. Considering, however the unit cost of preoperative
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investigations, Duplex ultrasound is the least costly. It can thus be argued that since
an ultrasound investigation is needed anyway to decide whether a patient will be
further investigated, this cost should not be included in the cost to estimate a cost-
effectiveness ratio.
The study reported in pounds sterling from the UK (Hankey et al., 1990) reflected
probably 1989 - 1990 prices, although it was not apparent. The financial year, on
which all the cost calculations to the NHS were based, was not specified in the paper.
Private consultant fees were based on the recommendations of the British Medical
Association's fees working party in 1989.
d) Modelling
Four (Yin et al., 1998; Lee et al., 1997; Derdeyn et al., 1996; Kent et al., 1995) of the
seven papers applied modelling according to acceptable economic simulation
techniques using Markov modelling. Two of these studies (Derdeyn et al., 1996;
Kent et al., 1995) used results from observational data in subsequent modelling. Two
other studies (Vanninen et al., 1995; Hankey et al., 1990) used a "type" ofmodelling,
but not a proven recognised modelling approach. Markov models were developed in
the case of all three studies (Yin et al., 1998; Lee et al., 1997; Derdeyn et al., 1996)
evaluating the cost-effectiveness of screening versus no screening in asymptomatic
populations based on evidence from clinical trails (ACAS, 1995; NASCET, 1991;
and ECST, 1991).
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Symptomatic populations.
The three studies (Kent et al., 1995; Vanninen et al., 1995; Hankey et al., 1990)
assessing symptomatic patients were observational studies that applied modelling
techniques to extend their evaluation beyond the set of observations. Data from their
observational studies were used to describe the baseline characteristics of the
hypothetical cohorts for the subsequent modelling. Kent and others used the results
from their observational data in subsequent Markov modelling. Vanninen and co¬
workers also used observational data and constructed several hypothetical models
based on theoretical population of 1000 patients, but did not use a recognised
modelling technique. Hankev did not specify a specific model either or referred to
the term modelling in their paper. In the study conventional angiography and duplex
ultrasound were extrapolated to a 1000 patients in different scenario settings, which
can for all practical purposes be considered as a form of modelling. The assumptions
by Hankey et al are unrealistic regarding Duplex sensitivity as 100% and
angiographic complication rate the same for all degrees of stenosis. That only
patients with carotid ischaemic symptoms who were likely to proceed to carotid
angiography would be referred is however reasonable. Bearing these assumptions in
mind these findings are not generalisable to other populations and create a potential
for bias. Since Duplex ultrasound was not available at the time at the centre where
Hankey conducted the prospective study, the study can be considered as a "form of
retrospective modelling". No reference is however made to any of the economic
modelling techniques considered appropriate in economic evaluations of this nature.
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Asymptomatic populations
In the asymptomatic populations, the two studies (Lee et al., 1997; Derdeyn et al.,
1996) assumed the two cohorts to be men older than 65 years and 60 years, whereas
one study (Yin et al., 1998) modelled a population of people 60 years and older.
Derdeyn developed a computer model to simulate the cost-effectiveness of screening
an asymptomatic cohort of 1000 men during a 20-year period. Two populations were
evaluated: a population with a low prevalence (4%) of > 60% stenosis, representative
of the general population and a population with a high prevalence (20%) of > 60%
stenosis and associated vascular risk factors.
Restricting the hypothetical population to men 65 years and older (Lee et al., 1997;
Derdeyn et al., 1996) seems appropriate, since the stroke rate and carotid disease in
men are higher than in women (about two thirds of participants in ACAS were male)
and the risk of stroke increases rapidly between the age of 60 and 70 years (Barnett et
al., 1992). It was therefore assumed that screening would have the greatest benefit
when done in 65-year old men, and if screening were not cost-effective for this group
it would be unlikely to have any benefit in other groups. These models, which
combined published data of the accuracy and cost of duplex ultrasound and carotid
angiography and of the risks, benefits and costs for hypothetical cohorts, could create
further bias.
Lee and Yin explicitly defined Markov states. In the case of Yin seven well-defined
Markov states were described, whereas Lee described only three Markov states.
Although it must be recognised that Lee described these three possible states only
with regards to major complications of angiography, Yin described seven Markov
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states for screening. The three Markov states, minor stroke, major stroke and death
due to angiography used by Lee are the major outcome events of interest and are the
same as those described by Yin for angiography. Yin, by using more Markov states
ensured that "all" possibilities were accounted for from the point of screening, but
then these additional Markov states as defined by Yin could be regarded as transition
probabilities.
Kent and Derdeyn did not provided a schematic presentation for their decision
analysis and although not considered essential a diagram on the decision tree helps to
describe the various probabilities. Lee and Yin provided suitable diagrams. Derdeyn
and Lee used transition probabilities of one-year, and Yin used one-month
probabilities. Though one-year periods as time points are chosen usually for
pragmatic reasons and to simplify decision analytic models, one-month periods are
more appropriate for Markov modelling.
3.3.2.1 Analysis and interpretation of results (Table 3.4).
a) Adjustments
Of the studies concerned with symptomatic patients, only one (Kent et al 1995)
referred to a time horizon and allowed for discounting both with regards to costs and
benefits. The studies assessing asymptomatic populations all discussed a time
horizon and discounting. In three studies (Yin et al., 1998; Lee et al., 1997; Kent et
al., 1995) the lifetime cost and quality-adjusted life expectancy of patients were
estimated and one study considered a period of 20 years (Derdeyn et al., 1996).
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Kent et al (symptomatic patients) and Yin (asymptomatic patients) used discount
rates for both costs and utilities (QALYs) of 5% and Derdeyn and Lee (asymptomatic
populations) used a rate of 3%. It was not explicit in the paper by Derdeyn whether
the discount rate of 3% also applied to utilities. Yin also provided a sensitivity
analysis within a range of 0 - 10%, which is a sensible approach since the choice of a
discount rate is arbitrary.
b) Allowancefor uncertainty.
Standard statistical analyses were performed in two studies (Kent et al., 1996;
Vanninen et al., 1996) investigating symptomatic patients and then only with regards
to the stochastic data.
The uncertainty inherent to extrapolation has been reasonably handled by the
application of Markov decision analysis modelling in the studies by Kent, Derdeyn,
Lee and Yin. Base case variables with appropriate ranges were tested in three studies
(Yin et al., 1998; Derdeyn et al., 1996; Kent et al., 1995). Lee and Yin applied
sensitivity analysis to their models to address aspects of uncertainty intrinsic in
hypothetical cohort populations. The effect on marginal cost-effectiveness was
examined by Kent et al by changing the prevalence of carotid stenosis, the cost of
screening and surgery, the complication rates as a result of the procedures and the
stroke risk reduction from carotid endarterectomy. A sensitivity analysis was
performed to determine the robustness of the baseline results to variations in the
model parameters with good effect since this allowed for the data to be interpreted
not only as point estimates. The model by Yin assessed similar parameters compared
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with the other studies, but included also the starting age of screening and thereby
accounted for the effects of ageing and the progression of the disease. This was
considered a sensible approach, since the risk of stroke increases with increasing age.
The prevalence of carotid stenosis used in these modelling studies range from 2 -
20%. Derdeyn who modelled a high risk of stenosis as well as a low risk population
with suitable prevalence rates made this distinction between populations with
different carotid stenosis prevalence rates. Kent et al did not refer to a prevalence rate
of carotid stenosis, but since they studied symptomatic patients and applied
modelling to their observational data, reference to a prevalence rate of carotid
stenosis was considered unnecessary. Kent and Derdeyn assessed the effect of change
for each variable over a wide range in a one-way analysis. Kent also performed a
three-way sensitivity analysis of the effect of the sensitivity and specificity of duplex
ultrasound and the acceptable cost-effectiveness threshold on the choice of contrast
angiography versus duplex ultrasound as a preoperative test. Though Yin did not
specify the form of sensitivity analysis used, it is assumed that he also performed a
one-way sensitivity analysis, since one-way sensitivity analysis is the simplest and
most common form of this type of analysis. Sensitivity analysis, however, has three
major limitations: 1) since the researcher has discretion as to which variables and
what values are included, this can create selection bias; 2) as no guidelines exist on
what degree of variation in results is acceptable proof that the analysis is robust,
interpretation of a sensitivity analysis is considered arbitrary and 3) the interactions
between parameters may not be reflected when uncertain parameters are varied one at
a time. These limitations are therefore extremely relevant and applicable to the
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sensitivity analyses performed in these four studies (Yin et al., 1998; Lee et ah, 1997;
Derdeyn et ah, 1996; Hankey et ah, 1990).
c) Presentation ofresults.
Symptomatic populations.
Most of the studies comply with the requirement in reporting on the main
components of cost and benefit, direct cost, indirect costs, life years gained and
improvements in quality of life in a disaggregated form.
Kent et al reported on the incremental cost per quality adjusted life year gained in
evaluating symptomatic patients. Kent found that the combination strategy of duplex
ultrasound and MRA followed by conventional angiography (CA) for dissimilar
findings resulted in the greatest quality adjusted life expectancy. Taking the cost of
CA and MRA as well as the cost of carotid endarterectomy into consideration,
neither of these strategies was cost-effective. The combination strategy was found to
be more effective than Duplex, but also more expensive at $22 400 per QALY gained
compared with Duplex at $9000 per QALY gained. The use of duplex ultrasound
was found to be less expensive than CA, but was associated with a greater lifetime
morbidity and mortality. If conventional angiography is preferred to duplex
ultrasound, Kent et al estimated an additional cost of $99 200 for each QALY gained
which is higher than many of the cost effectiveness ratios reported for other medical
interventions.
Vanninen reported on the imaging cost per patient and on the cost per stroke
prevented. Lavenson reported only on the cost per stroke prevented. Hankey found
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that to detect stenosis of 75% or more it is "most cost effective" to screen with
Duplex irrespective of the presence of a carotid bruit. The word "most" is not defined
and quantified by an acceptable cost-effectiveness ratio neither expressed in units to
allow comparison for example cost per QALY gained. Cost consequences were
expressed in terms of the cost per number of disabling strokes, addressing the
outcome measure of interest, but not satisfying a cost-effectiveness analysis.
Asymptomatic populations.
The three studies assessing the cost-effectiveness of screening asymptomatic
populations reported on the incremental cost per quality adjusted life year gained and
also compared the options available.
Lee et al evaluated the cost-effectiveness of screening under the assumption that
surgery has prolonged benefits over a lifetime, and found that screening resulted in
an additional cost of $1553 per person. It generated 0.013 QALY or 4.75 days more
than no screening at a cost of $120 000 per QALY. When the complication rate of
angiography reached 2%, the non-screening strategy however, generated more
QALYs and was less expensive than screening. Lee et al found that the marginal
cost-effectiveness was receptive to the disease prevalence in the screening
population. Lee used the recommendations of Laupacis and others to assess cost-
effectiveness (Laupacis et al., 1992).
Derdevn et al found a one time screening programme of a population with a high
prevalence (20%) of > 60% cost $35 130 per incremental QALY gained. One time
screening in a low prevalence population of >60% stenosis produced an incremental
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discounted cost of $52 588 per incremental QALY. Derdeyn concluded that a one¬
time screening programme for an asymptomatic population with a high prevalence of
carotid stenosis might be cost-effective, but that annual screening of populations with
a low prevalence of carotid stenosis is detrimental since more QALYS were lost in
the screened population than by natural progression of carotid stenosis using limits of
cost-effectiveness ratios as published in the literature. These limits are however
controversial. Derdeyn followed the limits as proposed by Goldman and Kupersmith
and co-workers (Goldman et al., 1992; Kupersmith et ah, 1995).
Yin et al concluded that for 60-year old patients with asymptomatic stenosis of 60 -
99% and a prevalence of 5%, duplex screening increased the quality adjusted life
years gained, decrease the lifetime cost of care under baseline assumptions. The
incremental cost per QALY gained or the cost effectiveness ratio was $39 495. Yin et
al derived their screening strategies from duplex ultrasound with and without
angiography and did not study MRA as a supplement to ultrasound. Referring to the
characteristics of a screening modality, which should be non-invasive having a low
procedural risk, considering angiography in the context of screening is regarded as
inappropriate. Yin used the recommendations by Laupacis et al. and concluded that
one time screening is more cost effective than screening every five years provided a
4.5% or more carotid stenosis prevalence is present in the population to be screened
and that the specificity of Duplex of at least 91%.
From these published limits it is obvious that there is little consensus regarding what
is considered very cost-effective or borderline, with the exception of the expensive
category where agreement exists.
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3.4 Critique of published studies.
The methods and economic data upon which these studies assessing the economic
implications of carotid endarterectomy and the pre-operative investigations prior to
the procedure are based, need to be improved if robust conclusions regarding the
cost-effectiveness of carotid endarterectomy are to be formulated. Although the
essential elements for structured economic evaluations have been described first in
the early 1970s by Williams and again more recently by Drummond, only reasonable
adherence to these recommendations were noted in these studies evaluated. It is
important that the conduct and reporting of studies assessing economic implications
of interventions should be standardised "to ensure that those performing such studies
are held accountable for their study methods and interpretation" (Holloway et al.,
1999). The more recent studies however suggest a better adherence to the
recommended guidelines and recommendations for economic publications, though
this could still be improved upon.
The use of a checklist for critically appraising the studies assessing the cost and
benefits of carotid endarterectomy provided a structure for evaluation, which protect
against sources of bias (Drummond et al., 1996; Oxman 1994).
The basic requirements for sound cost-effectiveness analyses were not adhered to in
any of these studies. It is evident in reviewing these studies examining the costs and
benefits of carotid endarterectomy and pre-operative imaging investigations that the
term "cost-effectiveness" is used indiscriminately by investigators, authors and also
by editors who published the manuscripts. The distinction between cost-effectiveness
analyses and cost-utility analyses, which often becomes blurred, was not evident in
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these studies (Drummond et al., 1997). Reported outcome measures were used
inappropriately to the type of analysis performed. Outcomes were reported in
measurements associated with cost utility analyses in studies where the investigators
set out to perform cost-effectiveness analyses. Though the form of economic
evaluation was alluded to in the title of all these studies, Drummond and Stoddart
pointed out that "the titles of studies are notoriously bad guides to their contents"
(Drummond and Stoddart, 1985). This was reaffirmed in the assessment of these. I
acknowledged however that cost-utility analysis is a special form of cost-
effectiveness analysis where the effectiveness is measured in the number of life-years
gained adjusted for quality of life or similar measures of utility. Although it might be
argued that much of my criticisms are levelled at terminology and semantics,
inappropriate use of terminology leads to confusion when evaluating the literature. It
is however debatable whether studies should be invalidated purely because of the
inappropriate use of terminology, which was clearly the case in most of these studies.
On the other hand if terminology is used out of the acceptable context in scientific
literature, comparison between studies will prove to be more difficult.
The majority of the studies identified that investigating the cost implications of
carotid endarterectomy are studies from the United States from America. The studies
can be classified into two broad categories: studies assessing the cost implications of
carotid endarterectomy and studies assessing the cost-implications of the pre¬
operative investigations for CEA. The studies investigating the cost implications of
CEA can be divided into studies assessing the cost-effectiveness of carotid
endarterectomy or modelling studies (full economic evaluation) and studies
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evaluating cost minimisation strategies or CEA cost description studies (partial
economic evaluation).
All the studies investigating cost-effectiveness of CEA or pre-operative
investigations were modelling studies, applying the same effectiveness data from the
NASCET and ACAS. The heterogeneity in study methods and results reported
however makes it difficult to compare the cost-effectiveness of these studies. All the
modelling studies applied an incidence-based approach estimating the lifetime cost of
patients treated either surgically with carotid endarterectomy or medically with
aspirin. Only one study (Nussbaum et al., 1996) reported on the average lifetime cost
to society using different treatment strategies. These modelling studies estimating the
lifetime cost of CEA included the cost of stroke, but did not include the cost of the
"work-up" of a patient population who might be considered for carotid surgery.
Ignoring the cost of identifying the CEA patients from a cohort of potential carotid
surgery candidates might underestimate the total cost of carotid surgery resulting in
cost-effectiveness ratios favouring carotid surgery.
Effectiveness measure or "stroke-free " life years sained.
It is disturbing that the results of the base-case cost-effectiveness ratios reported from
the different studies, assessing the same interventions are so divergent, considering
the similarities in the models. Not only was the same effectiveness measure, "stroke-
free" life expectancy used in the modelling studies, but in assessing the outcome of
patients after CEA or medical treatment, similar 30-day probabilities of stroke and
death and annual stroke rates were also applied in the these studies. Nevertheless
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different results were obtained. While this discordance might be mainly due to the
variation in the CEA cost estimates, some of it might be attributable to the
effectiveness measures expressed differently in the individual studies. The life
expectancy gained was either reported in terms of undiscounted or discounted
QALYs. However, different discount rates were used, and life-years gained were not
always quality adjusted, which obviously impede on meaningful comparisons. Since
the same efficacy data from the published RCTs, the NASCET and ACAS were used
one would expect the effectiveness data to be of the same magnitude. The reported
life expectancy gains, applied in these studies, for a typical NASCET patient or
ACAS patient were 4.2, 4.4 and 3 months respectively regardless of the qualification
of the effectiveness measure used. This finding might however indicate that the
methods used to discount life expectancy could be inappropriate.
Cost measures ofCEA. medical treatment and stroke.
The estimated cost of CEA was derived from Medicare reimbursements for
professional fees and hospital charges for the relevant diagnosis-related group in all
these studies. The differences in the cost of carotid endarterectomy might be because
Medicare reimbursements from different geographical areas were used to determine
the cost of the procedure resulting in different estimates.
To assess the lifetime cost of these patients, the cost of stroke had to be considered.
The cost estimations used in these three studies for the acute care of stroke, annual
care of stroke and the cost for the first year of stroke were also very different
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(Table3.2). The cost estimates for stroke in these studies were obtained from the
literature in all instances.
Comparing the "cost" estimates for CEA between the various observational studies
were difficult, since cost or charges were used in the individual studies. "Charges
represent the highest level mix of local and distant institutionalised cost, transferred
among sites that generated revenues and losses" (Back et al., 1997). Using charges
can thus overinflate the costs incurred, making the procedure more costly and
seemingly less cost-effective, but probably giving a more accurate estimate. None of
the authors however indicated to what extent the use of charges might have biased
their estimates.
The cost description studies all identified hospitalisation costs as one of the major
contributors to escalating health care cost. Reducing the length of hospital stay seems
a sensible way to decrease the cost of the procedure. The use of duplex ultrasound as
a "reliable" imaging modality to determine carotid stenosis is gaining support and
routine use of conventional angiography might therefore soon be unnecessary
contributing to the overall cost reduction of CEA. It was generally found that
selective use of angiography, avoiding routine ITU admission and discharging the
patient from hospital on the first postoperative day could reduce the cost of carotid
endarterectomy by almost 50%.
Benefit measurements.
It is important to value health benefits and this can be done either through time-trade¬
off or standard gamble methods. Since cost-effectiveness analysis deals with effects
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measured in natural units, valuing these effects in terms of their monetary benefit or
utility is not applicable. However, the majority of the studies concerned with carotid
endarterectomy and preoperative investigations applied utility measurements from
the literature to their findings, which might be responsible for the differences,
observed in the reported outcome measures. They failed to describe how these
benefit measurements were determined and used preference scores from the literature
in their calculations. They did not apply or refer to any of the existing pre-scored
multi-attribute health status classification systems: Quality of Well-Being (QWB),
Health-Utility Index (HUI) and EuroQol neither were the Short Form (SF) 36, the
Nottingham Health Profile and the Sickness Impact Profile which are comprehensive
measures of health-related quality of life (Drummond et ah, 1996). As an extensive
discussion of utility measures was considered outside the scope of this investigation,
valuing health benefits and associated problems were not pursued.
Discounting.
The different discount rates as well as the application of discounting in these studies
might explain some of the variation in the reported outcome measures. Controversy
still exists in health care on discounting. It is generally agreed that costs should be
discounted in any study if the time horizon is longer than one year and current
recommendations vary between 3 - 6%. Discounting was only applied in the three
modelling studies. The rates of 3 and 5% used are considered within the acceptable
proposed range. It is suggested that a single discount rate should apply to both costs
and health benefits, even when health benefits are expressed in non-monetary units
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such as life years gained. In discounting only costs and not health benefits as well,
the health gain over time can appear more favourable than what it really is.
Discounting costs and utilities at the same rate appears methodologically sound since
it provides consistency between cost-effectiveness and cost-benefit analysis.
Discounting costs and utilities at the same rate however underwrites the notion that it
is possible to transform resources into health at any time, which might be unrealistic.
Study population.
The reported outcome measures might also be biased. All-male populations or
predominantly male populations were used in the modelling studies, but the
effectiveness result measures from the NACSET and the ACAS that were applied
were derived from both males and females in the trials. Since the modelling was
predominantly based on the results from the NASCET and ACAS trials, the gender
mix from those studies should ideally have been used in the modelling. Modelling
based on a 100% male population might be unrealistic and not representative of the
gender mix encountered in normal everyday practice. Although the justification
given by the authors for including only men in their modelling studies was
reasonable, it remains possible that substantial bias was introduced since an all-male
study population does not represent the general population.
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Modelling.
The application of modelling techniques using published data from clinical trials in
hypothetical cohorts is also a matter of concern. Hypothetical cohorts are not actual
or verifiable study populations. Many assumptions are required in subsequent
modelling, thus creating a huge potential for bias. As mentioned, predominantly male
populations were used in these modelling studies, but the effectiveness measure was
from a mixed population and was not adjusted to be gender specific.
Limitations of Markov modelling can be summarised as follows: 1) strict
assumptions are required about "zero memory" meaning that the transition
probabilities only depend on the health state patients are in now, and not how long
they had been in that state or how they got there; 2) comorbidity is only indirectly
assessed and 3) estimates of costs and event probabilities are used.
The primary concern about these modelling studies relates to the patient cohorts
used. It is important that a study cohort simulates an identifiable patient population
before the conclusions of the analysis can be applied clinically.
Models must be interpreted with caution and these results are usually not
generalisable to genuine populations for whom disease progression might be very
different from what is expected. Markov modelling has distinct advantages to
decision tree models, since decision tree models do not specify when events occur in
contrast with the Markov modelling which assumes that the patient is always in one
of a finite number of states of health referred to as Markov states. The structure of the
decision tree model also implies that an event may occur only once. In the case of
Markov modelling all events are modelled as transitions from one state to another
and each state is assigned a utility. The time horizon of the analysis is divided into
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equal increments of time, referred to as Markov cycles. Markov modelling also
makes provision for events occurring more than once which is obviously true in the
case of transient ischaemic attacks (Sonnenberg and Beck, 1993). Since the
progression of arteriosclerosis in the carotid arteries might be rapid in some
individuals, one-year periods for modelling transitions are regarded as inappropriate,
thus the one-month period used by Yin is considered more realistic. Nevertheless
modelling remains a prediction of possible events based on probabilities in
hypothetical cohorts, which might explain the variation seen between these studies.
Modelling studies can thus only be regarded as the " best alternative" in the absence
of "real" life populations.
3.5 Summary
From the limited published evidence available, the cost-effectiveness of carotid
endarterectomy remains unclear for several reasons. Considerable variation was
observed between the studies. An incremental cost of $4100 per quality
adjusted life year gained for symptomatic patients was reported. The cost-
effectiveness of carotid endarterectomy in asymptomatic patients varied from
$8000 to $52 700 per quality adjusted life year gained. The cost effectiveness of
the pre-operative investigations varied from $35 100 per QALY in symptomatic
patients to $120 000 in asymptomatic patients. The cost of carotid
endarterectomy varied from $7608 to $11 546 and from £1800 to almost £5000.
The lack of agreement among studies addressing the same intervention reduces
confidence that these analyses are reliably estimating the cost-effectiveness they
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purport to measure. The main reason for these inconsistencies is probably
related to the study design used in the different studies. Although the variation
in cost estimates used was not considered to be enormous, it contributed to the
inconsistencies observed. After critically appraising these studies it is apparent
that a study other than a modelling study, is needed to assess the economic
consequences of carotid endarterectomy and of the imaging procedures prior to
carotid endarterectomy. The differences in the model structure as well as
differences in the input variables may explain the divergent conclusions. The
variation in input variables, which was identified as the major contributing
factor resulting in different conclusions, needs to be reduced if the results from
cost-effectiveness analysis are to be used by health care policy makers. The
quality of the studies assessing the cost and benefits of carotid endarterectomy
and the associated pre-operative investigations need to be improved if robust
conclusions regarding the cost-effectiveness of carotid endarterectomy are to be
formulated.
An accurate estimate of the cost of CEA, the cost of medical treatment for TIA
patients not having surgery and of the lifetime cost of stroke for Scotland is needed, if
the cost-effectiveness ofCEA as stroke prevention is to be critically assessed.
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Table 3.1: Study characteristics of the studies assessing the costs and benefits of
carotid endarterectomy:
MARKOV MODELLING STUDIES - COST-EFFECTIVENESS ANALYSIS.
Author(s)
Kuntz et al. Nussbaum et al. Cronenwett et al. Lavender et al.
Year and 1996, USA 1996 USA 1997, USA 1998, UK
Country
Original Cost in 1994 US$ Cost in ? US$ Costs in 1996 US$ Costs in 1992 £
currency sterling
Patient Symptomatic & Symptomatic & Asymptomatic Symptomatic
population asymptomatic asymptomatic > 60-99% stenosis > 70% stenosis
Number
Age (mean) 65 65 67 65
years




Alternatives CEA vs. medical CEA vs. aspirin CEA vs. medical CEA vs. medical
considered treatment vs. observation treatment treatment
Evaluation Cost-effectiveness Cost- Cost-effectiveness Effectiveness of




Effectiveness NASCET; ACAS NASCET and ACAS , NASCET ECST; NASCET
data sources own data
Outcome Incremental cost- Life expectancy Incremental cost- Marginal 1 cost
measures effectiveness ratio Cost-benefit effectiveness ratio per QALY
for CEA, QALYs ratio for CEA
of CEA
Cost data 1993 Medicare Medicare Medicare CEA cost
sources Reimbursement Reimbursement Reimbursement reported in
and DRGs and DRGs Newcastle study
ANALYSIS AND INTERPREATION OF RESULTS:
Time horizon "Life-time" "Life-time" to Costs & life QALM
& discount Costs & life age 99. Costs & expectancies at 5% discounted at 6%
rate expectancies at life expectancies
3% at 5%
Sensitivity Peri-operative Cost ofCEA on Age, stroke rate Age, stroke rate
analysis risk, stroke risk, overall life-time during medical with and without
CEA risk cost, cost of care, peri-op event CEA, CEA costs
reduction, Cost of peri-operative rate, costs
CEA, Cost of complications,
stroke. stroke rate
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Table 3.1: Study characteristics of the studies assessing the costs and benefits
of carotid endarterectomy: (Continue)
RETROSPECTIVE STUDIES, OBSERVATIONAL DATA, COST
ANALYSIS.
Author(s) Back et al Dardik et al. Mellissano Kraiss et al
Year &
Country
1997, USA 1997, USA 1997, Italy 1995, USA
Original
currency



























































Outcome Cost ofCEA Reduce LOHS,
measures Outcome after Outcome
CEA
Cost data Office of clinical Hospital
sources resource charges
management









* % asymptomatic patients in study population.
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Table 3.1: Study characteristics of the studies assessing the costs and benefits
of carotid endarterectomy: (Continue)
RETROSPECTIVE STUDIES: OBSERVATIONAL DATA, COST ANALYSIS.
Author(s) Garrard et al Pollard et al. Ballard et al. Ammar.
Year & Country 1997, USA 1997, USA 1997, USA 1996 USA
Original currency US$; 1995 US$; 199? US$; 199? US$; 199?
Patient population Symptomatic CEA, (83) Symptomatic Symptomatic
asympt LER, (39) asympt. (45%) * asympt (38%)*
(51%)* CABG (177)
Number 97 83 194 237
Age (mean) years 68 70 74 76
Males 53% 66%
Study period 12 months 24 months 30 months 12 months
STUDY DESIGN:
Alternatives • CEA ± Pre¬ • CEA ± Various variables
considered angiogram operative angiogram assessed to reduce cost
+duplex evaluation: +duplex ofCEA; preoperatively
hospital vs. in theatre and
outpatient postoperatively
clinic




Outcome Cost of CEA Reduce Surgical Cost reduction
measures based on LOHS, outcome, Outcome of CEA
duplex only resource cost
Cost data sources Medicare Medicare 1995 Charges
1995; Own institution
CPT1, DRG2





* % asymptomatic patients in study population.
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Table 3.1: Study characteristics of the studies assessing the costs and benefits of
carotid endarterectomy: (Continue■)
RETROSPECTIVE STUDIES: OBSERVATIONAL DATA, COST DESCRIPTION.
Author(s) Smurawska et al Hirko et al. Luna et al. Patel et al


















































_ _ Charges Hospital charges
own institution
and state billing #




% asymptomatic patients in study population.
#Medical Consumer Price Index
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Table 3.1: Study characteristics of the studies assessing the costs and benefits of
carotid endarterectomy: (Continue)
RETROSPECTIVE STUDIES: OBSERVATIONAL DATA, COST DESCRIPTION.
Author(s) Maini et al Green et al Smithies et al Radestock.




* % asymptomatic patients in study population.
#Medical Consumer Price Index
1987, USA 1997 UK 1992, UK
(Wessex) (Newcastle)




























Describing CEA University vs. Describing CEA
over two 5-year Community cost in different
periods hospital NHS trusts
Comparing CEA









Outcome & cost Cost of CEA
over time
Cost ofCEA
Hospital charges Hospital HRG costs




ANALYSIS AND INTERPREATION OF RESULTS
One-way
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Table 3.2: Results and conclusions of the studies assessing the costs and benefits of
carotid endarterectomy:
MARKOV MODELLING STUDIES - COST-EFFECTIVENESS ANALYSIS.
Author(s) Kuntz et al. Nussbaum et al Cronenwett et al Lavenson et al.
Year & 1996, USA 1996 USA 1997, USA 1998, UK
Country
CEA cost 11 390 12 495 8 500 3 300
Stroke cost:
acute 8 550 7 026 9 000
Annual 24 820 21 233 18 000
Baseline Lor typical Life expectancy 7.18 Average life Costs in £ sterling
results NASCET patient years for observation; expectancy in
CEA provides 7.26 for aspirin; 7,63 medical 11.6 vs.
benefit of 0.35 for NASCET; 7.69 11.9 in surgical
discounted QALYs UMHC. Lifetime cost: group. QALYs
at incremental cost with aspirin = 24 070 of 7.87 for
of $4100 per CEA NASCET: medical and
QALY gained. 23 538 8.12 for surgical
treatment.
Sensitivity In symptomatic Model relatively Most sensitive to
analyses patients: not very insensitive to small age changes and
sensitive to wide variations in individual stroke risk.
variations in parameters
baseline variables.
Best Incremental CER1 Observe & aspirin Younger patient 45 year old ; low 1-
of CE vs. medical treated groups: highest with lower month stroke risk
therapy: $400/ % of strokes, lifetime stroke rate post-op; high stroke
QALY2 gained for a costs of observation during medical risk without CEA.
50-year man and and aspirin most care resulted in CEA cost £3224,
$33 800 for an sensitive to changes in best outcome. gave 10.3 QALM3
asymptomatic 50- cost. Very high stroke Cost of
year male patient. rate CEA more cost-
effective.
£3800/QALY
Worst Incremental CER If peri-operative Age variable 85 year old; high 1-
for CEA= $ 11 300/ stroke rate influenced cost- month stroke risk
QALY gained in 75 exceeds 12% the effectiveness the post-op; low stroke
year old male with benefit of CEA most. Stroke rate risk with no CEA.
symptoms. becomes very during medical care CEA cost £4993;
$89 500/ QALY in small second. Generated 0.6





expensive than > 60-99% stenosis
efficient use of either observation
resources. No or aspirin and also
symptom patients: results in
CE not efficient. increased QALYs
1 CER = Cost-effectiveness ratio 2 QALY = Quality Adjusted Life Year 3 QALM = Quality Adjusted
Life Months
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Table 3.2: Results and conclusions of the studies assessing the costs and benefits
of carotid endarterectomy: (Continue)
RETROSPECTIVE STUDIES: OBSERVATIONAL DATA, COST ANALYSIS.
Author(s) Back et al Dardik et al. Mellissano et al. Kraiss et al
Year &
Country





- - - -
CEA cost Mean cost Mean cost Mean cost Charges
Conventional 11 456 ± 4072 9508 ±724 6 764 ECU 11 140 ±729













can reduce CEA cost





















'GA = General anaesthesia
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Table 3.2: Results and conclusions of the studies assessing the costs and benefits of
carotid endarterectomy: {Continue)
RETROSPECTIVE STUDIES: OBSERVATIONAL DATA, COST ANALYSIS.
Author(s) Garrard et al Ballard et al. Pollard et al. Ammar.




CEA cost Total charges Mean cost Cost p.a. Charges over
time
Conventional 20 203 7 608 74 000 p.a. 23 000
Alternative 14 174 5 534 15 000 p.a. 13 000
Results & Angiograms 43% Agreement between Outpatient Cost containment
Conclusions of total costs of duplex and preoperative strategies to
CEA. angiogram in evaluation & same reduce CEA
Non-routine use detecting stenosis > day admission charges.
of angiogram 45% associated with a Reported on %
does not increase No difference decrease in length of use of
post-op risk of between stroke & hospital stay which angiogram,
stroke or LOHS.2 death rate for CEA led to cost savings ECGs, blood
based solely on tests, X-rays,
duplex. carotid shunts,
CEA performed on ICU stay. Cost-
duplex results is cutting strategies




'GA = General anaesthesia
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Table 3.2: Results and conclusions of the studies assessing the costs and benefits
of carotid endarterectomy: (Continue)
RETROSPECTIVE STUDIES: OBSERVATIONAL DATA; COST DESCRIPTION
















































































care, but increase cost of
CEA. These areas
include prolonged pro-




would reduce cost of
CEA.
ICU = Intensive Care Unit;2 LOHS = Length of hospital stay *Medical Consumer Price Index
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Table 3.2: Results and conclusions of the studies assessing the costs and benefits
of carotid endarterectomy: (Continue)
RETROSPECTIVE STUDIES: OBSERVATIONAL DATA, COST DESCRIPTION.
Author(s) Maini et al Green et al. Smithies et al Radestock.
Year &
Country




























Results obtained at a
community hospital
are comparable to
results at a university
hospital.
"Estimation" of CEA Mean cost
cost based on HRGs
from health
professionals.
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Table 3.3: Study characteristics of pre-operative investigations for carotid
endarterectomy in symptomatic populations and asymptomatic populations:
SYMPTOMATICPOPULATIONS: COST-EFFECTIVENESS ANALYSIS.
Author(s) Kent et al. Vanninen et al. Lavenson et al. Hankey et al.
Year & 1995, USA 1996 USA 1996, USA 1990, UK
Country
Original Cost in 1993 US$ Cost in ? US$ Costs in 1996 US$ Costs in 1992
currency sterling
Number 88 45 (1000)3 100 296 (1000)3
(48 symptomatic;
52 asymptomatic)




Study period 19 months 12 months — 10 years
STUDY
DESIGN:
Alternatives Duplex, MRA1, Duplex, MRA1, Duplex Clinical evaluation
considered CA2, CA2, vs. Duplex
Combination Combination
Evaluation Cost Cost Cost savings/duplex
form effectiveness effectiveness performed
analysis analysis Cost of stroke
avoided/duplex
performed.
Modelling Markov Scenario setting - Scenario setting
DATA COLLECTION:
Effectiveness NASCET;ECST Own centre NASCET;ACAS Published data
data sources
Outcome Incremental cost- Number of Cost effect of Costs & number of
measures effectiveness strokes prevented duplex examination disabling strokes
ratio for CEA, on strokes avoided after CA
QALYs
Cost data 1993 Medicare Local hospital, NHS cost
sources Reimbursement Kuopio University estimates;
Hospital. Finland BMA fees;
BUPA
ANALYSIS AND INTERPREATION OF RESULTS:
Time horizon Cost & life
& discount expectancy at 5%
rate
Sensitivity Multi-way Scenario setting
analysis
1 magnetic resonance angiography;2 conventional angiography;3 number in modelling
156
Chapter Three: Systematic review
Table 3.3: Study characteristics of pre-operative investigations for carotid
endarterectomy in symptomatic populations and asymptomatic populations:
(Continue)
SCREENING ASYMPTOMATIC POPULATIONS FOR CAROTID STENOSIS;
MARKOV MODELLING STUDIES; COST-EFFECTIVENESS ANALYSIS.






























Duplex screening vs. no Duplex screening vs. no
screening. screening.
Effectiveness Published data;

















Time horizon 20 years. 30 years; Costs & QALYs
& discount 3% costs & utilities. discounted at 5%.
rate
Sensitivity Probabilistic; multi - Probabilistic; multi - Probabilistic; multi -
analysis way. way. way.
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Table 3.4: Results and conclusions of pre-operative investigations for carotid
endarterectomy in symptomatic and asymptomatic populations.
SYMPTOMATIC POPULATIONS: COST-EFFECTIVENESS ANALYSIS
Author(s) Kent et al. Vanninen et al. Lavenson et al. Hankey et al.




Best For pre-op detection of Duplex & MRA with
70 -99% stenosis sensitivity of 100%
combination of duplex resulted in 27.9
& MRA supplemented strokes prevented
by CA is associated
with greater morbidity
& mortality.
Worst Using Duplex alone CA only,
less expensive, but complication rate of
performing CA alone angiography of
resulted in 0.5%; sensitivity of
unacceptable high 100% resulted in
costs 23.3 strokes
prevented
Conclusions Combination strategy Both models, which Cost savings Patient
of duplex & MRA included duplex from the use of selection prior
reserving CA for before CA, were duplex to CEA should
disparate results more cheaper than when examinations to consist of
cost effective than CA CA is routinely identify carotid clinical
alone. performed on all artery lesions evaluation and
patients. for CEA and Duplex.
Combination of thus prevent Performing
Duplex & "costly" strokes Duplex on all
confirmatory clinically




1 CER = Cost-effectiveness ratio 2 QALY = Quality Adjusted Life Year 3 QALM = Quality Adjusted
Life Months
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Table 3.4: Results and conclusions of pre-operative investigations for carotid
endarterectomy in symptomatic and asymptomaticpopulations: (Continue)
SCREENING ASYMPTOMATIC POPULATIONS FOR CAROTID STENOSIS;
MARKOV MODELLING STUDIES; COST-EFFECTIVENESS ANALYSIS.
Author(s) Derdeyn et al. Lee et al. Yin et al.
Year &
Country






Annual screening of a




cost of £35 130 and $52








surgery if indicated is
cost-effective.
Over a lifetime,
screening resulted in an
additional cost of $1553
per person and generated
0.013 QALY (4.75days)
more than no screening











Screening of a hypothetical
population increased average
QALYs and lifetime cost.
Incremental cost /QALY
gained was $39 495.
Linking age & prevalence
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Figure 3.2: Schematic presentation of studies examining the cost and benefits of the
peri-operative investigations associated with carotid endarterectomy.
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CHAPTER FOUR: THE PROGRAMME COST OF IDENTIFYING
PATIENTS FOR CAROTID ENDARTERECTOMY.
4.1 Introduction
The cost of carotid endarterectomy (CEA) reported in the literature has considered
only the cost of the pre-operative investigations (Lavenson et ah, 1996; Kent et al.,
1995; Vanninen et ah, 1995; Hankey et al., 1990) and the cost of the surgical
procedure for the individual patient (Smurawska et al., 1998; Back et al., 1997;
Mellisano et al., 1997; Garrard et al., 1997; Ballard et al., 1997; Pollard et al., 1997;
Hirko et al., 1996; Smithies et al., 1996; Ammar, 1996; Kriass et al., 1995; Luna et
al., 1995; Patel et al., 1995; Radestock, 1992; Maini, 1990; Green et al., 1987). The
cost incurred in selecting patients from the potential "pool" of referred patients has
been largely ignored in these studies. In order to estimate the total direct cost of this
procedure, it is necessary to include the cost incurred at the different levels of
investigation prior to carotid endarterectomy, since the cost of investigating a large
"pool" ofpotential patients is not inconsequential and can not be ignored.
The "pool" of potential patients is those experiencing symptoms suggestive of a
transient ischaemic attack (TIA) and minor non-disabling stroke associated with the
distribution of the carotid artery. These patients are usually assessed clinically by a
neurologist, geriatrician, stroke physician or vascular surgeon. If the patient is
considered clinically to have a transient ischaemic attack originating in the carotid
territory and is fit for surgery, the patient is referred for a duplex investigation to
determine the degree of internal carotid stenosis. Patients with stenosis ofmore than
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about 70%, who are deemed medically fit for probable carotid surgery are then
usually referred for carotid angiography to obtain a more precise estimate of the
degree of stenosis. Once stenosis of 70% or more is confirmed the patient is prepared
for a carotid endarterectomy. This investigation pathway or "work-up" for patients
suffering a TIA is only applied to patients who have suffered a recent ischaemic
event to ensure that carotid surgery is performed within a maximum time period of
six months from most recent symptoms (Humphrey, 1994; Brown et al., 1992;
ECST, 1991; Brown et al., 1994).
The aim of this study was to estimate the "total direct" programme cost of carotid
endarterectomy to the National Health Service (NHS) as applied to a cohort of
patients with transient ischaemic attack and non-disabling stroke referred to a
teaching hospital for CEA assessment, investigation and carotid endarterectomy. The
"total direct" programme cost of carotid endarterectomy incorporates the cost
incurred during the "work-up" of a potential "pool" of carotid endarterectomy
patients as well as the cost of the carotid endarterectomy "procedure". Only the
"direct" cost as estimated in two independent study populations is reported.
The cost of identifying patients from a cohort of potential candidates who might be
suitable candidates for a carotid endarterectomy was described as the "work-up" cost.
The "work-up" for CEA was defined as the assessment at the neurovascular clinics,
the duplex examination and the carotid angiogram. The cost associated with the
"work-up" was estimated as a deterministic value, (Barber and Thompson, 1998) or
alternatively described as a top-down approach estimating the unit cost for a
neurovascular attendance, a duplex investigation and a carotid angiogram.
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The CEA "procedure" is defined as the episode of care in hospital and includes the
bed days and the theatre component. The cost of carotid endarterectomy, the
"procedure" cost, was estimated using "patient specific" cost data which were
prospectively collected in consecutive patients. The use of patient specific cost data
to estimate cost is also known as a bottom-up approach (Barber and Thompson,
1998; Whynes and Walker, 1995). Applying the "procedure" cost to the number of
patients identified for carotid endarterectomy in the "work-up" of the "pool" of
patients a total direct "programme" cost was estimated. Costs are estimated by
measuring the quantities of resources utilised and by assigning a unit cost or price to
the resources used (Drummond, 1996).
Since economic evaluations of health care procedures are costly and can not always
be performed when necessary and in all settings, a sensitivity analysis was
performed. The cost estimates obtained in this study were used to address the
uncertainty encountered with economic evaluations associated with these
programmes. A sensitivity analysis involves three steps. Firstly, the identification of
the uncertain parameters for which a sensitivity analysis is required, secondly the
specification of the plausible ranges over which uncertain factors are thought to vary,
and thirdly the calculation of study results based on combinations of the best guess.
164
Chapter Four: CEA cost
4.2 Methods
4.2.1 Setting
The cost description study estimating the total "programme" cost of CEA was
performed in three hospitals in Scotland. Two of the three hospitals are large general
major teaching hospitals (Royal Infirmary, Edinburgh and the Western General
Hospital, Edinburgh) covering a full range of services and one a general hospital
(Southern General Hospital, Glasgow) with some teaching units.
Data were collected at the Western General Hospital to estimate the "work-up" cost
of CEA. Itemised cost data were prospectively collected on a consecutive number of
carotid endarterectomy patients operated on at the specialised vascular surgery unit at
the Royal Infirmary, Edinburgh and at the vascular unit at the Southern General
Hospital, Glasgow, to estimate the procedure cost ofCEA.
4.2.2 Description ofthe two study populations.
To estimate the "work-up" cost of carotid endarterectomy a cohort consisted of
patients identified from the Neurovascular clinic attendance book (July 1997 to June
1998) and the Lothian Stroke Register (July 1996 to June 1997) at the Western
General Hospital, Edinburgh was studied over a one-year period. The Lothian Stroke
Register (Appendix 3 and 4) is a hospital-based stroke register with the aim to collect
information on stroke, transient ischaemic attack and retinal artery occlusion in
patients presenting at the Western General Hospital whether admitted or not. Both
the neurovascular clinic attendance book and LSR were used, since these two data
sources complement each other. The LSR provided detailed information on the
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number of patients with carotid territory transient ischaemic attack, the number of
duplex investigations and number of angiograms performed on the cohort, whereas
the neurovascular clinic attendance book provided essential information on the
number ofpatients who might be considered for possible CEA.
The cohort of patients studied to determine the "procedure" cost, comprised of
consecutive patients operated on at the Royal Infirmary in Edinburgh and
Southern General hospital in Glasgow for whom patient specific cost data were
collected during the period 15 December 1997 to 15 July 1998 at the Royal
Infirmary, Edinburgh and during the period 1 January 1998 to 17 July 1998 at the
Southern General hospital in Glasgow.
4.2.3 Defining theprogramme.
The programme is defined as the "work-up" to CEA and the CEA "procedure" itself
(Figure 4.1). Using the selection criteria described in Section 4.2.4, the "pool" of
patients who might be potential candidates in the work-up to CEA was identified.
Patients referred to the neurovascular clinics at the Western General Hospital with
transient ischaemic attack (TIA)-like symptoms and clinically assessed as having
carotid territory ischaemic events were considered suitable candidates for further
investigation. The degree of stenosis in the internal carotid artery was then
determined using the non-invasive duplex imaging technique. Based on a duplex
finding of stenosis in the internal carotid artery of 70% or more, probable candidates
for carotid endarterectomy were identified. These candidates were then evaluated
using conventional carotid angiography, the current "gold standard" to determine the
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degree of stenosis more accurately. Only patients who displayed internal carotid
artery stenosis of 70% or more, not having an occluded vessel or any complications
associated with the angiography were regarded suitable candidates for carotid
endarterectomy and were referred for surgery.
4.2.4 Selection criteria at each level of investigation to estimate the "work-up"
cost ofCEA.
Inclusion and exclusion criteria (Figure 4.2).
Neurovascular clinic: (NVC)
Inclusion criteria.
• Patients with symptoms suggestive of transient ischaemic attacks, minor and
major non-disabling stroke, Amaurosis Fugax, retinal artery occlusion as well
as other non-specific "neurological" symptoms.
• Appointments of longer than 30 minutes, since 30-minute or longer
appointments are allocated to all "new patients" to allow sufficient time for a
thorough clinical assessment.
Exclusion criteria.
• Appointments of less than 30 minutes duration ("follow-up visits").
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Lothian Stroke Register: (LSR)
The modified Rankin Scale (Oxford Handicap Scale) of clinical prediction of
outcome at one year was used to select patients with a diagnosis of TIA or stroke.
The values, 0 to 5, in the Modified Rankin Scale are defined as follows:
• 0 indicates no symptoms;
• 1 refers to minor symptoms which do not interfere with lifestyle;
• 2 means some restriction to lifestyle, but patients can look after themselves;
• 3 is defined as significant restriction to lifestyle, which prevent total
independence;
• 4 refers to a severe handicap preventing independent existence, though not
requiring constant attention and
• 5 means patients are severely handicapped, totally dependent and requiring
full-time attention (Bamford et al., 1989).
Inclusion criteria.
• All patients with probable and definite anterior territory carotid ischaemic
attacks and retinal artery occlusion were included provided:
i. The Rankin Scale of clinical prediction of outcome at one year was 0, 1 or
2, and
ii. That the Oxford Handicap Scale before the stroke was not 3, 4, or 5.
• These patients were regarded as a minor stroke patients and were included in
the group of "possible patients" suitable for further investigation for CEA.
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Exclusion criteria.
• Patients with a disabling stroke and a previous stroke were excluded if the
Oxford Handicap Scale of clinical prediction of outcome at one year were 3, 4
or 5 regardless of the Oxford Handicap Scale before the event.
• Patients with posterior circulation transient ischaemic attacks were also
excluded since the benefit of carotid endarterectomy is specifically for the
anterior circulation ischaemic events, i.e. carotid arteries.
• Patients with epilepsy, migraine, tumours, syncope, dizziness, hypoglycaemic,
hyperventilation and other non-specific symptoms seen at the clinics.
• Patients with atrial fibrillation.
Duplex investigation
Inclusion criteria.
Patients with internal carotid artery stenosis of 70% or more detected with duplex
ultrasound examination were included for further investigation since the benefit
of CEA in reducing the risk of stroke in patients with stenosis of 70% or more
has been shown in two large randomised controlled clinical trials (ECST
Collaborative Group, 1991; NASCET Steering Committee, 1991).
Exclusion criteria.
Patients with internal carotid artery stenosis of less than 70% detected with
duplex ultrasound examination were excluded from this cohort.
169
Chapter Four: CEA cost
Conventional carotid angiography.
Inclusion criteria.
• Internal carotid artery stenosis of 70% or more.
Exclusion criteria.
• Internal carotid artery stenosis of less than 70%.
• Any complications during and immediately after angiography.
• Internal carotid artery occlusion of the symptomatic artery.
• Medically "unfit" for surgery due to other comorbidities.
4.2.5 Measurement of the resource quantities in theprogramme.
4.2.5.1 Resource quantities to selectpatients for carotid endarterectomyfrom a
"potential cohort" ofcandidates, the "work-up" cost.
The resource quantities at each level in the work-up for a typical uncomplicated
patient who proceeded to carotid endarterectomy included one attendance as a
"new" patient at the neurovascular clinic, one carotid duplex ultrasound
investigation, one follow-up consultation after the duplex investigation to inform
the patient of the findings of the duplex and one conventional carotid
angiography before the carotid endarterectomy.
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4.2.5.2 Resource quantities used in performing carotid endarterectomy, the
"procedure" cost.
Resource quantities used in performing carotid endarterectomy included the
resources used for one episode of care in hospital for the CEA from admission to
discharge. An episode of care included the peri-operative period, the time in
theatre and the hospital stay after the procedure in theatre. The episode of care in
hospital included peri-operative and post-operative bed days and resources used
in theatre. Data collected on the resources used for these patients having CEA
during the pre-operative stage, prior to the hospital admission, were deterministic
in nature, whereas data collected during the episode of care were patient specific
cost data.
4.2.5.3 Resource quantities usedfor the carotid endarterectomy after discharge
from hospital, the post-operative cost.
The resources used during the post-operative period included one follow-up visit
at the vascular surgery outpatients department with the vascular surgeon
approximately six weeks after the procedure and one post-CEA duplex
investigation performed at that time.
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4.2.6 Assignment ofprices or unit costs.
4.2.6.1 Neurovascular clinic consultation unit cost.
The average unit cost per "new" neurovascular attendance was based on costs
published in the Scottish Health Service Costs (SHSC) 1996/1997. These costs
are produced by the Scottish Office of the Department of Health and include
direct and allocated costs associated with an attendance at an outpatient
department. The direct cost per attendance includes medical and nursing staff,
and laboratory cost. The allocated costs incorporate all other costs not included as
direct costs.
The arithmetic mean of the cost per neurovascular outpatient attendance at the
Western General Hospital, the Southern General hospital and the Royal Infirmary
Edinburgh was estimated at £99 per outpatient attendance (Neurology outpatient
departments: Western General Hospital (£63), Southern General Glasgow (£113)
and Royal Infirmary Edinburgh (£120)). Though patients with symptoms
suggestive of transient ischaemic events are routinely assessed at neurovascular
outpatients clinics, divisions of the neurology departments, these patients are not
routinely seen at the Department of Neurology at the Royal Infirmary but at the
Vascular Surgery Outpatient Department at the Royal Infirmary, Edinburgh. This
outpatient department at the Royal Infirmary, Edinburgh however is not
separately accounted for in the Scottish Health Services Costs Book.
All vascular outpatients' consultations are incorporated with general surgery
outpatient consultations, which consist of a completely different case-mix than
those patients assessed at a neurovascular clinic. The vascular surgery outpatient
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department attendances are assumed to be incorporated in the attendance figures
of general surgery outpatients at a cost per attendance of £46. This cost of £46 is
considered an underestimation of a neurovascular clinic consultation when
compared to the cost estimates from the Neurology departments at the Western
General hospital and the Southern General hospital. The calculation of an
arithmetic mean for an outpatient attendance at the two hospitals with
neurovascular clinics was considered as the most appropriate alternative in
estimating the cost for a "new" patient's visit at an outpatient department. The
average unit cost per "new" neurovascular attendance at an outpatient department
was therefore estimated at £88 and a follow-up consultation at the clinic was
estimated at half the cost of a "new" neurovascular attendance at £44. The
follow-up visits are usually of shorter time duration than a "new" neurovascular
clinic attendance and the cost for such a visit was therefore adjusted to £44 per
follow-up visit.
In determining the cost of haematological and biochemistry investigations for the
CEA cost description cohort prior to carotid endarterectomy, the unit cost
estimates were based on the Pricing Index of Investigations from the National
Health Service. All radiological examinations and other radiological
investigations were determined using assigned costs form the Department of
Radiology at the Royal Infirmary, Edinburgh which include allocated costs and
human resource costs.
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4.2.6.2 Unit costs assignedfor duplex ultrasound.
The total cost of one duplex investigation was estimated at about £70. The cost
of the duplex ultrasound equipment and consumables was calculated using the
capital cost of the room, the depreciated current value of the machine, the annual
maintenance and consumables, totalling a cost £26.60 per duplex investigation.
The human resource cost was estimated at £38.67 per examination and includes
the salary of a full-time Superintendent III radiographer and 30% of a consultant
radiologist's annual remuneration. The estimated overhead cost inclusive of
electricity, heating and administration was estimated at £5.17 (Appendix 5).
4.2.6.3 Unit costper carotid angiography.
The direct cost of equipment and consumables used for a carotid angiography
was calculated from existing sources at the Department ofRadiology at the Royal
Infirmary, Edinburgh. Hourly remuneration for human resources was calculated
using published pay scales for the medical staff involved and includes
superannuation and National Insurance. Hospitalisation or bed day cost was
calculated using the Health Service Cost 1996/1997 of the Information and
Statistics Division of the NHS in Scotland. The equipment and consumable cost
for both the selective and non-selective (arch) intra-arterial digital subtraction
angiogram was estimated at £280 per investigation. The total human resource
cost of a radiologist, two radiographers and an auxiliary nurse performing a
carotid endarterectomy was estimated at about £74. The total direct procedure
cost was thus estimated at £354 not including the overnight hospitalisation.
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Overnight accommodation is usually required when performing a carotid
angiogram. The length of hospital stay is usually regarded as two bed days
resulting in an additional cost of £596 for hospitalisation using the mean
estimated bed day cost of £298. The total direct and allocated cost of a carotid
angiogram was estimated at £950 per angiogram.
A unit cost estimate of any other radiological procedures carotid endarterectomy
patients might have had, was based on cost estimates from the Departments of
Radiology and Directorate of imaging at the Western General Hospital and the
Royal Infirmary, Edinburgh. A chest X-ray was estimated at £20 and a computed
tomography (CT) scan at £121.
4.2.6.4 Unit costs for the resources used during carotid endarterectomyprocedure.
The Scottish Health Service Costs (SHSC) 1996/1997 was used to describe all
costs associated with the hospitalisation of a patient for the carotid surgery. Cost
is analysed between direct and allocated costs. Direct cost includes medical,
dental and nursing staff, and the cost of professions allied to medicine. Direct
cost, as published in the SHSC, was used for the hospitalisation of each
individual in the prospective CEA costing study with the exception of the direct
theatre costs, which were collected during the study (Appendix 6). The theatre
cost and the laboratory cost components of the direct cost per surgical case were
adjusted using the cost estimations from the itemised data collection (Appendix
6). The costs for all anaesthetic equipment and medications as well as all surgical
materials and equipment were obtained from the Purchase Order Details from the
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Procurement Department for the Royal Infirmary Edinburgh, National Health
Trust, published April 1998. The cost assigned to bed days was calculated using
the Scottish Health Services Costs 1996/97 as reference. Allocated costs as
published in the Scottish Health Services Costs 1996/1997 include overheads as
well as capital charges and was used for all capital and overhead cost estimations
in the study.
4.2.7 Sensitivity analysis: Deterministic/probabilistic.
Sensitivity analyses were performed for the programme cost of a cohort of
potential patients investigated for possible carotid endarterectomy and for the
procedure cost of carotid endarterectomy.
4.2.7.1 Programme cost sensitivity analysis: deterministic analysis.
In the case of the programme cost, point estimates for the parameters in the work-up
to carotid endarterectomy were applied to determine the cost (a top down approach).
The sensitivity analysis performed on these point estimates is considered to be
deterministic in nature. A base transition ratio model was constructed using the
proportions in the transition progression from a consultation as a "new" patient to
duplex investigation, to a subsequent follow-up consultation, to a carotid angiogram
and to the carotid surgery. The point estimates used in the study were applied to the
observed transition ratio observed in the work-up to CEA in this study to estimate the
cost incurred at each transition level.
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Sensitivity analyses for the programme cost were thus performed from two
perspectives by:
• altering the transition progression ratio observed in the programme.
• and alternatively varying the individual cost parameters in the programme.
The key variables or parameters, which might affect the overall programme cost
of carotid endarterectomy, include:
• the number/proportion of "new" consultations of all the consultations at the
NVC;
• number / proportion of duplex investigations of the "new" consultations;
• number / proportion of follow-up consultations after duplex investigations;
• an angiogram performed or not done;
• Magnetic Resonance Angiography (MRA) performed instead of digital
subtraction angiography (DSA) (conventional carotid angiography) and
• the cost estimates for each of the individual parameters.
4.2.7.2 Procedure cost sensitivity analysis: probabilistic analysis.
Patient specific cost data collected in the prospective costing study allow for a
probabilistic sensitivity analysis. The key parameters for this sensitivity analysis
include:
• the cost of the peri-operative investigations with and without an angiogram;
• the cost of the hospitalisation divided into bed days and theatre cost and
• the cost of the post-operative stage.
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The plausible ranges are specified using the 95% confidence interval around the
mean for these key parameters.
4.2.8 Measurement of time intervals in the work-up to CEA.
Since the optimum benefit derived from carotid endarterectomy is soon after a
person has experienced a transient ischaemic event, (Humphrey, 1994; Brown et
al., 1992; ECST, 1991) time-to-event variables in the work-up to carotid
endarterectomy were collected from the Lothian Stroke Register and CEA cost
description study. The data collected on these time-to-event variables were only
analysed to describe the time delays that might occur in the referral of these
patients for appropriate health care.
Data were collected on the time intervals from most recent transient ischaemic
attack to first visit with the health care system; from first visit with the health
system to first appointment with either a consultant neurologist, stroke physician
or vascular surgeon; from consultation with a consultant neurologist or vascular
surgeon to duplex investigation; from duplex investigation to carotid
angiography and from angiography to carotid endarterectomy.
These variables include:
• Time in days from most recent transient ischaemic attack to first assessment at
the neurovascular clinics and or vascular clinic;
• Time in days from assessment at neurovascular clinics to duplex investigation;
• Time in days from duplex investigation to carotid angiogram and
• Time in days from carotid angiogram to carotid endarterectomy.
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4.3 Data management and analysis
Data recorded on data collection forms for the carotid endarterectomy cost
description study were punched, verified and stored using Microsoft, Excel
Version 5. All cost calculations were done using Microsoft Excel version 5.
Separate files for demographic variables, time to event variable, pre-operative
investigations, hospitalisation, human resources in theatre, surgical equipment and
instruments, anaesthetic equipment and medications were merged using SPSS
version 7 for Windows.
Policy makers, purchasers and providers need to know the total cost of
implementing a treatment. The fundamental information for cost data is therefore
the arithmetic mean since it is possible to estimate the total cost of an intervention
from the arithmetic mean. Measures such as the median, mode and geometric
mean cannot provide an estimate of the total cost. Although the distribution of
costs is often highly skewed, it does not imply that the use of the arithmetic mean
is inappropriate. Because of the skewness of the data the standard deviation alone
is not the best way to present the spread of costs between individuals. Describing
the variability in costs between individual is however important and it is useful to
present the interquartile range.
The arithmetic means, as measure of location, and interquartile ranges are
reported. The inter-quartile ranges (IQR) were defined as Q 025 - Q 0 75 The
median cost, which can be interpreted as the most "typical" cost for individual
patients are also reported. P-values or confidence intervals are not reported since
costs between alternative treatments are not compared. Standard errors and
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confidence intervals are not reported. Although they reflect the precision of the
estimated mean, these measures are not considered appropriate ways to describe
how costs differ between individuals (Altman et ah, 1983; Barber and Thomson,
1998). Normal probability plots were used to assess the empirical distributions
for evidence of departure from normality. The mean, median and IQR for the
time-to-event variables in the work-up to CEA are reported.
All statistical analyses were performed using SPSS for Windows (Professional
and Advanced Statistics options) and all the sensitivity analyses were performed
using MS Excel version 5.
4.4 Results
4.4.1 The total direct "work-up" cost ofa cohort ofpatientsforpotential CEA.
The Neurovascular clinic appointment book.
A total number of 964 patients were seen at the neurovascular clinics during the
one-year period studied. Of these attendances, 790 appointments were 30 minutes
or longer and were regarded as first time attendances for "new" neurological
patients. The 790 patients identified represented the "pool" of potential CEA
candidates who might be considered suitable candidates for CEA and might be
entered into the LSR depending on the clinical assessment findings. (Table 4.1)
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The Lothian Stroke Register.
Baseline characteristics.
Of 790 first or "new" consultations at the neurovascular clinics, 660 patients
were entered into the register for the study year investigated, 412 (52%) patients
were entered in the Lothian Stroke Register as having had a carotid territory
ischaemic event and having a modified Rankin score of less than three. Four
hundred and one (97.3%) duplex investigations were performed on the 412
patients identified with carotid territory ischaemia. Eleven patients did not have a
duplex investigation for a variety of reasons. The main reasons were subsequent
ischaemic events prior to the duplex investigation, which rendered them
unsuitable for further investigations for possible CEA (Table 4.1).
Of the 412 patients identified, 244 (59%) were male and 168 (41%) were female.
The age distribution of these patients was not normal and displayed a distribution
curve that was slightly skewed to the left. The majority (47%) of patients was
between 66 and 80 years of age (193/412), with 33% (136/412) being between
50 and 65 years of age. Ten percent of the study population was represented in
the under 50 year age group as well as the above 80 years age categories, but with
more (52%) females in the over 80 group compared to 42% females in the under
50 age group. The age group 50 to 65 years had the lowest percentage of female
patients at 35% (Table 4.2 and Figure 4.2).
Of the 401 patients having carotid duplex investigations, a total of 237 (59%)
patients did not have any degree of stenosis reported in either of the internal
carotid arteries. "No" stenosis was defined as not having any degree of stenosis
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(0%) reported, based on the findings of the carotid duplex investigation. Twenty-
four (6%) patients had "no" stenosis reported in one artery and stenosis less than
70% reported in the other artery. Twenty-five (6%) patients had stenosis less than
70% in the both arteries reported. A combination of "no" stenosis in one artery
with stenosis of 70% or more was found in 28 (7%) patients. Twenty-five
patients (6%) had stenosis less than 70% in the one artery with 70% or more in
the other artery. Stenosis of 70% or more was reported for both the internal
carotid arteries in 19 (5%) patients. Seventeen patients (4.2%) had "no" stenosis
in one artery with occlusion in the other artery. Occlusion on the one side with
less than 70% stenosis on the other side was reported in 19 patients (5%). Six
patients (1.5%) had stenosis of 70% or more on the one side with occlusion on
the other side. Occlusion of both the right and left internal carotid artery was
reported in one patient. Of the 401 patients, 286 (71%) had "no" stenosis or
stenosis of less than70% with duplex examination (Table 4.3 and Figure 4.4).
Of the 401 patients, 78 (19.5%) had had stenosis more than 70%. Nineteen (5%)
had stenosis of 70% or more reported for both internal carotid arteries. For the
remaining 59 with stenosis of more than 70% in one artery, 28 were found to
have "no" stenosis in the other artery and 25 had less than70% stenosis in the
other internal carotid artery. Six patients had a combination of an occluded artery
and more than 70% stenosis in the other artery. Only 26 (33%) of these 78
patients with stenosis of 70% in either internal carotid artery were referred for
carotid angiography. Sixteen patients, who had stenosis of 70% or more but did
not have an angiogram, had documented existing comorbidities, which rendered
them unsuitable for carotid surgery. For the remaining 36 patients explanations as
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to why angiograms were not performed could only be postulated and ranged from
patient's preference, time period from most recent transient ischaemic symptoms
to assessment by a consultant too long to derive any benefit from CEA
(Figure 4.4).
Fifteen of the 26 patients (58%) who had an angiogram proceeded to carotid
surgery. The reasons why nine patients who had an angiogram performed, but did
not have carotid surgery ranged from stenosis less than 70% determined with
angiography, occlusion of the symptomatic artery, transient ischaemic
complications suffered during the angiogram procedure, patient's preference not
to proceed with surgery and anatomical difficulties.
Of the cohort having carotid transient ischaemic attacks 97% (401/412) had a
duplex investigation, 6.3% (26/412) had an angiogram and 4.4 % (18/412)
eventually had a carotid endarterectomy. Three of the eighteen patients from this
cohort who had carotid endarterectomy performed, did not have an angiography
prior to carotid surgery. Considering all patients with symptoms suggestive of
transient ischaemic attacks or the "pool" of patients referred to the neurovascular
clinic for investigation for possible carotid endarterectomy, only 2.3% (18/790)
were operated on (Figure 4.2).
The work-up cost of the study cohort of patients who might be suitable
candidates for carotid endarterectomy was subsequently determined by applying
the deterministic cost estimates from published data sources to the proportions of
patients found at each of the levels using the data from the neurovascular
appointment book and the LSR. These levels include the preoperative
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consultations, duplex investigations, follow-up consultation and carotid
angiograms.
The total cost for the pre-operative consultations and investigations was
estimated by multiplying the number of neurovascular clinic consultations (790)
with the unit cost of a visit of £88. A total cost of £69 520 was estimated
identifying patients for possible carotid endarterectomy from a "pool" of
potential candidates. The total cost of duplex investigations for this cohort was
calculated at £28 070. The patients referred for a duplex investigation usually
have a follow-up consultation visit for a discussion of the findings of the duplex
investigation. The total cost of the follow-up visits was estimated at £17 644. The
total cost of "all" the consultations for this cohort was estimated at £87 164. The
total cost of the 26 angiograms performed was £24 700. The "work-up" cost for
this cohort from consultation at a neurovascular clinic to duplex, to follow-up
visit to angiography was estimated at a total cost of £139 934 (Table 4.4).
4.4.2 The total direct CEA procedure cost.
Carotid endarterectomy cost description study.
4.4.2.1 Baseline characteristics (Table 4.5).
The total direct procedure cost of 64 consecutive carotid endarterectomy patients
at two centres was estimated. Forty-two (66%) of the patients were investigated
and operated on in the Royal Infirmary in Edinburgh. Twenty-two (34%) patients
in Glasgow had all their pre-operative investigations and were admitted for
surgery, but only 19 (30%) were operated on. Of the three patients who did not
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have surgery, one suffered a stroke the day before the scheduled surgery, one
could not give informed consent because of cognitive impairment and the third
patient suffered a fatal myocard infarction on the eve of the operation.
The age distribution of the study population represented a normal distribution
with the mean age of 67 years and a standard deviation of 8.1 (Figure 4.5). The
majority of patients, 39 (64%), operated on was in the 66 to 80 year age category.
75% of the patients in the study population were men.
The work-up cost of this CEA cohort was estimated based on data from all 64
patients who were prepared for surgery. The procedure cost was based only on
the 61 patients who had surgery.
4.4.2.2 Resources used during thepre-operative stage.
The resources used during the work-up of the patient, the pre-operative stage, to
carotid endarterectomy included medical consultations, haematology and
biochemistry investigations, carotid ultrasound and carotid angiography. The
mean total cost estimated for this cohort during the work-up prior to CEA was
£1359 (IQR 857 - 1976; median cost £1416) (Table 4.6). A total of 128 duplex
investigations were performed on these 64 patients. Fifty-five of these patients
had had two duplex investigations, one during the work-up to carotid
endarterectomy and the second duplex the day prior to carotid endarterectomy.
Six of the patients had only one duplex performed, but two patients had three
duplex examinations and another patient had a total of four duplex investigations
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during the period of assessment prior to surgery. Angiograms were performed in
66% of the patients prior to the carotid endarterectomy (Table 4.7).
Itemised costing of all haematology and biochemistry investigations were
expressed per unit using the NHS scale and included the total cost of the
equipment, overheads and human resource cost with a mean of cost £54 (median
£51; IQR: £40 - £71).
The mean cost of the duplex investigations, the carotid angiography (procedure
only) and computed tomography for the 64 patients was estimated at £533 with
the interquartile range (IQR) £310 to £658. The mean total cost of the angiogram
(bed days and procedure) for this cohort was £890 with a median cost of £950
(IQR: £354 - £950) (Table 4.8).
4.4.2.3 Hospitalisation.
The resources used during hospitalisation included hospital stay or number of bed
days, resources used in theatre and medication prescribed during the period after
surgery.
a) Resources used in theatre.
The four main variable cost components in theatre included the human resource
component, anaesthetic drugs and equipment, surgical instruments and materials
and theatre overheads. The cost of the first three components has been
prospectively collected (Appendix 6), while the theatre overhead cost was
estimated using data from five comparable hospitals where the CEA procedure is
performed (Aberdeen Royal Infirmary, Gartnaval Hospital, Glasgow, Glasgow
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Royal Infirmary, Southern General hospital Glasgow, Ninewells Hospital
Dundee).
The mean cost per carotid endarterectomy for the human resources in theatre was
estimated at £443 (median £422; IQR: £295 - £564); £124 (median £134; IQR:
£71 - £162) for anaesthetic drugs and equipment and for surgical instruments and
materials £204 (median £179; IQR: £151 - £209). Theatre overheads, using data
from the five comparable hospitals, were estimated at £88 per hour, resulting in a
mean cost of £265 per CEA (median £258; IQR: £212 - £328) (Table 4.9).
The cost of all complications following surgery or complications during the
period immediately after surgery, which required surgical intervention, was
added to the hospitalisation cost. Two subjects required surgical intervention
post carotid endarterectomy, both these patients were from the centre in
Edinburgh. One patient developed a wound haematoma on the second post¬
operative day and was returned to theatre. The second patient suffered an
intracerebral haemorrhage four days after the carotid procedure, was transferred
to the Western General Hospital where a Burr hole was performed and
intraventricular catheter was inserted. He was subsequently admitted to intensive
therapy unit at the WGH where he stayed till his death 18 days after the initial
carotid surgery. One patient from the centre on Glasgow suffered a major
disabling stroke 24 hours after carotid surgery and died seven days after the
carotid endarterectomy.
b) Bed days
Bed days contributed the greatest proportion to the cost of hospitalisation, with a
mean cost of days in intensive therapy unit of £819 (median £0; IQR: £0 - £967),
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a mean cost of £399 (median £517; IQR: £259 - £776) in the high dependency
unit (Table 4.8). The mean cost in the general surgical ward inclusive of the days
prior to surgery, the days after surgery and medications used after surgery was
estimated at £1101. (median £914; IQR: £761 - £1068) (Table 4.10). The mean
length of stay was 5.16 days (median of four days), a minimum of three bed days
and a maximum of 23 days (Table 4.11).
4.4.2.4 Resource use during the post-operative stage.
The postoperative stage of care contributed the least to the cost of the procedure
at only £154 (median £158; IQR: £158 - £158). It included only the human
resource component during the postoperative follow-up visit with the vascular
surgeon usually six weeks after the procedure and the carotid ultrasound
performed at that time. All cost incurred immediately after the carotid procedure
were accounted for in the surgical bed day cost and the medications during
hospitalisation (Table 4.8). The proportional breakdown of the cost for carotid
endarterectomy is presented in Table 4.12.
4.4.3 Estimation of the "total direct" cost for the carotid endarterectomy
programme (work-up andprocedure).
The cost distribution of the carotid endarterectomy programme as estimated in this
study population does not display a normal distribution and is highly skewed to the
right which is frequently the case with cost data. The mean carotid endarterectomy
programme cost (work-up and procedure cost) for this cohort was estimated at
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£4868 with a median cost of £4300 and an interquartile range (IQR) of £3711 -
£5064 (Table 4.6 and Figure 4.6). Using a deterministic approach the direct cost
incurred in the work-up of a cohort of potential candidates for carotid
endarterectomy was estimated at £139 934 (Table 4.13).
In the NVC-LSR study cohort consisting of potential carotid endarterectomy
patients, 18 patients were identified as having had the procedure. Applying the
arithmetic mean cost estimate per carotid endarterectomy obtained from the
prospective costing study using patient specific cost data, a direct cost was
calculated for the 18 patients who had carotid surgery. The mean cost estimate
per carotid endarterectomy of £4868 was adjusted to exclude the cost of £1152 of
the pre-operative investigations (already accounted for in the work-up of the
cohort, (Table 4.13), resulting in a unit cost of £3716 for the actual carotid
endarterectomy procedure in hospital. The direct cost of the 18 carotid
endarterectomies performed in the cohort investigated was estimated at £66 888.
The total direct cost of carotid endarterectomy from selecting a patient from a
cohort of potential candidates (790) for a carotid endarterectomy to performing
carotid surgery in the few selected patients (18) was estimated at a total cost of
£206 822 (Table 4.13). £139 934 or 68% of the total direct programme cost of
carotid endarterectomy was incurred before the actual carotid endarterectomy
procedure.
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4.4.4 Sensitivity analysis.
4.4.4.1 Deterministic sensitivity analysis applyingpoint estimates in the analysis.
Transition ratios.
The transition base case ratio was determined using the study cohort numbers
identified from the neurovascular appointment book. For this study, a cohort of
790 patients presented with symptoms suggestive of transient ischaemic attacks
for clinical assessment at the neurovascular clinics, 412 patients were clinically
assessed as having anterior /carotid territory transient ischaemic symptoms which
warranted further investigation, i.e. duplex examination of the carotid bifurcation.
401 patients had a subsequent duplex investigation. All the patients, who had a
carotid duplex, had a follow-up consultation to be informed of the duplex
findings. Of these 401 patients 26 patients were suitable candidates for a carotid
angiography and 18 patients proceeded to carotid endarterectomy. Using these
proportions, a transition ratio of 50: 25: 25: 1.5:1 was calculated for this study
population. Though only 15 of these 18 patients had a carotid angiogram, the
ratio did not change significantly (Table 4.14).
Applying the point cost estimates to this ratio the cost of the base cohort was
estimated. The baseline parameters for the sensitivity analysis are presented in
table 4.14 and the results of the sensitivity analysis are summarised in table 4.15.
The sensitivity analysis was found to be relatively insensitive to small variations
in the individual parameters in the base transition ratio model. The parameter that
influenced the sensitivity analysis the most was found to be carotid
endarterectomy.
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Since clinical practice in the work-up to CEA has changed over the last couple of
years with selective use of angiography prior to the surgery, a one-way analysis
was performed with no angiogram and all other parameters constant. A cost
reduction of 12% was found when investigating a cohort for possible carotid
surgery under these conditions. This was considered an unrealistic model because
if an angiogram is omitted it would either be replaced by an additional duplex
investigation or a magnetic resonance angiogram. By substituting an angiogram
with either a duplex or MRA investigation or both, a cost reduction of 11% was
found for the additional duplex, of 9% for the MRA and of 8% for the
combination of a duplex and MRA investigation compared to the base transition
ratio model (Table 4.15).
Performing a two-way deterministic sensitivity analysis by decreasing the
consultation parameter by 25% and by decreasing the angiogram parameter by
50% in the transition ratio model, a 15% decrease in investigating a cohort of
patients with TIA-like symptoms for a possible CEA was found. The reduction in
programme cost of 15% was the most favourable outcome obtained in addressing
the uncertainty associated with the proportions of patients at the different
investigation levels. Performing a multi-way analysis by decreasing the duplex
and follow-up visit parameter by 25% and angiogram parameter by 50% in the
base transition model, and keeping the consultation and CEA parameters
constant, a cost reduction of 12% was observed (Table 4.15).
Performing two carotid endarterectomies for every 50 patients assessed at the
NVC with all the other parameters constant in a one-way analysis a cost increase
of 30% was found which was the most costly alternative when investing a cohort
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of TIA patients for possible CEA. This investigation pathway of two CEA for
every 50 patients assessed did not become more favourable even when the
catheter angiogram was substituted for a MRA, one or two duplex investigations.
Cost increases of 21% for the MRA and of 19% and 20% when one or two
duplex investigations were performed (Table 4.15).
Individualparameters. (Table 4.16: a- f)
Performing a multi-way analysis on the individual cost parameters in the clinical
pathway of carotid endarterectomy with a 25% increase in the base case
consultation cost, a 100% increase in the cost of a duplex investigation but with
no angiogram cost and with the cost of a CEA procedure at £3716, the most
favourable "programme" cost for CEA was found, a difference in real term of
£847 or 17% (b) compared to the cost of £4868 for the base case. Repeating the
analysis under the same conditions, but increasing the cost of the CEA procedure
by 10% a reduction of 10 % (e) was found. Substituting the conventional
angiogram for a MRA under the same conditions, resulted also in a cost
reduction of 10% (c) compared to the base cohort and even increasing the cost of
the CEA procedure resulted in a 2.5% decrease in the base case cost (f).
Applying the 25 % increase in the base case consultation costs, a 100% increase
in the cost of a duplex investigation, the procedure cost of CEA remaining
constant or even increasing the procedure cost of CEA by 10%, and maintaining
the conventional angiography as part of the clinical pathway for CEA, an
increase in the base case cost of 2% (a) and 10% (d) was found respectively.
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4.4.4.2 Procedure cost sensitivity analysis: probabilistic analysis
Patient specific cost data collected in the prospective costing study allow for a
probabilistic sensitivity analysis. The plausible ranges were specified using the
95% confidence interval around the mean for the key parameters (Table 4.17).
Applying the lower and upper bound of the 95% confidence interval for all the
variables identified in the patient specific data set, a difference in overall cost of
20% was observed to either side of the mean cost calculated for the CEA
programme for the various scenario settings (Table 4.18).
4.4.5 Time to event analyses:
4.4.5.1 Lothian Stroke Register data set (Table 4.19).
The time intervals observed in the clinical work-up or pathway for patients
experiencing a transient ischaemic attack through the different transition levels to
carotid endarterectomy were expressed in days.
Days between most recent TIA and assessment at NVC.
The mean number of days from the most recent transient ischaemic attack, to
assessment by a consultant at the neurovascular clinics at the Western General
Hospital for the cohort identified from the LSR was 21 days, with a median time
interval of 10 days. The IQR from the most recent transient ischaemic attack to
neurovascular clinic assessment was two to 27 days, indicating that a neurologist
assessed 50% of the patients within four weeks from onset of the most recent
symptom.
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Days between assessment at NCV and duplex
The mean number of days between clinical assessment at the neurovascular
clinics (NVCs) and duplex ultrasound for the 401 patients identified in the LSR
was 5.8 days. A minimum of minus 54 days between clinical assessment at the
neurovascular clinics and duplex examination was observed, indicating that some
patients had a duplex investigation 54 days or less "prior" to clinical assessment
by a consultant. This suggested that the referring general practitioner or physician
probably requested the duplex and that the duplex was performed prior to the
assessment by the consultant. The maximum number of days observed between
assessment at the neurovascular clinic and duplex investigation was 99 days.
Days between Duplex and carotid angiogram.
The mean number of days observed between duplex and carotid angiogram was
33, with a median time interval of 26 days, a minimum of 0 and a maximum of
148 days or almost five months.
Days between carotid angiogram and CEA
The mean number of days between carotid angiogram and carotid endarterectomy
for this cohort was 81 days with a median time interval of 51 days, a minimum of
17 and maximum of 410 days, or 13.6 months. However, fifty percent of the
patients who had a carotid endarterectomy were operated on between 40 and 75
days or within two and a half-months of the carotid angiogram (IQR: 40 - 75
days) (Table 4.19).
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Days between NVC and CEA
The mean number of days between assessment at the neurovascular clinics and
carotid endarterectomy was 130 days with a median of 85 days, a minimum of
eight and a maximum of 521 days. Fifty percent of patients had a carotid
endarterectomy between 56 and 134 days or between just less than two months
and 4.5 months (Table 4.21).
4.4.5.2 CEA cost description study data set (Table 4.20 and 4.21).
Data of the first contact with the health care system after patients had suffered a
TIA were also collected in the CEA cost description study. This additional
information in the referral chain from most recent transient ischaemic attack to
CEA could indicate whether unacceptable time delays occur from the first
contact with the health care system to assessment by a consultant. Data were also
collected on the time intervals observed in referring patients who have been fully
worked-up (i.e. having had a carotid angiogram) by neurologist and then referred
to the vascular surgeon for the procedure. Similar data were not available in the
LSR data set.
The mean number of days from most recent transient ischaemic attack to first
contact with the health care system i.e. the general practitioner in this prospective
study was 52 days (median: 7 days; IQR: 1-31).
A mean number of 34 days was found from most recent symptoms to assessment
at a neurovascular clinic, with an interquartile range of zero to 52 days. From
clinical assessment either by a neurologist or vascular surgeon to duplex
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examination, the mean number of days observed was minus one day (IQR: minus
21 to 17 days). The mean number of days between duplex and angiogram was 53
days, (median 26 and IQR of 29 to 70 days). The mean number of days between
angiogram and CEA was 29 days (IQR: 7-38 days). The minimum number of
days between angiogram and CEA was two days and the maximum number of
days 109 (Table 4.20). The corresponding figures for the LSR data set from
angiogram to CEA were 81 days and 410 days.
The mean number of days from referring a patient (i.e. arranging an appointment)
from the neurovascular clinic at the WGE1 to the vascular clinic at the RIE was 31
(median 22 days; IQR 13 -34days). The mean number of days between the
assessment at neurovascular clinic at the WGE1 and the vascular clinic at the
Royal Infirmary, Edinburgh (RIE) for this cohort was 33 days, but with a
maximum number of days of 141 days. (Table 4.20) The mean number of days
from the vascular clinic at the RIE to CEA was 30 days with a median of 27 days
and interquartile range of 9 to 47 days (Table 4.22).
4.5 Discussion.
This study reports the results of the programme cost of carotid endarterectomy
which was defined as the work-up cost of a cohort of patients who might be
considered for CEA and the CEA procedure cost. This total direct carotid
endarterectomy programme cost for this cohort of 790 cases was estimated at
about £207 000 with 68% of the total direct programme cost accounted for before
carotid surgery was performed. The total direct CEA cost per individual patient
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including the work-up cost was estimated at £4868 with only 25% of the total
CEA cost attributed to the work-up. This study is likely to be the first study
reporting on the programme cost of CEA since studies investigating both the
"work-up cost" of identifying patients with carotid territory ischaemic attacks for
a probable CEA as well as the "procedure cost" of CEA could not be identified in
the published literature. A number of studies (Smurawska et al., 1998; Back et
ah, 1997; Mellisano et ah, 1997; Garrard et ah, 1997; Dardik et ah, 1997; Ballard
et ah, 1997; Pollard et ah, 1997; Hirko et ah, 1996; Smithies et ah, 1996; Ammar,
1996; Kriass et ah, 1995; Luna et ah, 1995; Patel et ah, 1995; Radestock, 1992;
Maini, 1990; Green et ah, 1987) addressed the cost of carotid endarterectomy, but
in such a manner that the results obtained are not readily transferable to other
settings.
Only one study (Elankey et ah, 1990) in which the cost of investigating patients
prior to carotid endarterectomy was described, referred to the "programme" cost.
Hankey and Warlow concluded that estimating the programme cost to the NHS
to identify patients presenting with symptoms, which might justify further
investigation for possible treatment, was an extremely difficult task when relying
on current available data sources.
This study found that more than half (56%) of the cost of a CEA programme is
attributable to the consultations at the neurovascular clinics and duplex
investigations in the work-up of a cohort of patients who might be suitable for
CEA. The actual procedure contributed only about 32% of the overall cost of the
CEA programme.
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The consultation cost of patients referred for evaluation of cerebral ischaemia at
the neurovascular clinics in this study contributed to 34% of the overall
programme cost, making it the highest cost component in the programme with
the procedure cost of CEA at 32%. The main reason for this being the large
number of patients referred to these clinics for evaluation, only about half of
them (52%) having carotid territory related symptoms, and only a small number
of patients (2.3%) having carotid surgery. Only one patient out of every 50
patients referred to the neurovascular clinics for evaluation had a CEA. This is
considerably higher than the one in 27 patients who were referred for evaluation
of cerebral ischaemia and were found to be fit for CEA in a US Veterans Affairs
study (Mayberg 1991).
It is however contentious whether the cost of assessing patients referred for a
specialist consultation should be added to the overall cost of the programme cost
of CEA as it can be argued that this cost should be borne by the health service
anyway. Assessing the CEA cost of £4868 for the individual patient, only 25%
of the total cost were attributed to the "work-up" cost prior to CEA and 75% of
the cost was for the actual procedure.
Fifty percent (69 520/139 934) of the work-up cost (Table 4.4) was attributed to
the initial consultation at the neurovascular clinic. This might indicate that
patients are being referred "too easily" and that the "gatekeepers" or primary care
physicians need to either refine their diagnostic skills in managing patients with
symptoms suggestive of transient ischaemia or have easier access to carotid
ultrasonography since the cost of a duplex investigation is less than specialist
consultation fees and the costs associated with a consultation. Considering also
Chapter Four: CEA cost
that only 78 (19%) of the 401 patients referred for duplex investigation were
found to have stenosis of 70% or more presents a strong case for primary health
care physicians to use duplex ultrasound as a "screening" tool before referring a
patient to a consultant. The cost of a duplex investigation is relatively small and
the advantage gained by performing this examination in clinical decision making
can not be questioned.
The results from this study suggest that the CEA procedure is relatively
inexpensive in the context of a CEA programme and that most (68%) of the
programme cost is generated during the work-up of a cohort of patients who
might be suitable for CEA. The CEA cost estimate (£4868) obtained in this study
is similar to the cost estimate based on Healthcare Resource Group (HRG) costs
reported by Smithies et al (1997) from one of the NHS Trusts in their study.
Healthcare Resource Groups (HRGs) for the estimation ofcosts.
HRGs are a way of aggregating patient treatment episodes that are similar in their
resource consumption. HRGs further classify case mix by categorising patients
into a manageable number of groups which are clinically homogenous, expected
to consume similar amounts of resources and based on the ICD classification of
diseases. HRGs should be distinguished from Diagnosis Related Groups (DRGs)
which is the US counterpart. Though HRGs might assist in cost estimations for
specific procedures, these costs are based on aggregates and can thus only be
considered as approximations. The huge discrepancies observed in the cost of
CEA based on HRGs in the five NHS Trusts investigated by Smithies and others
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confirmed the prior belief that cost estimates based on HRG might not be
accurate. I acknowledged that HRGs were not primarily designed to estimate
procedure specific costs. The cost estimate obtained in this prospective study at
the Royal Infirmary Edinburgh and Southern General Glasgow should however
provide a more accurate cost estimate for CEA to be used in assessing the cost-
effectiveness of a procedure of which the main objective is the prevention of a
stroke.
Obtaining accurate information about the direct cost of carotid endarterectomy to
the NHS of the investigation of patients with transient ischaemic attacks for
possible carotid surgery is not straightforward. Most information for the Scottish
Health Services Costs (SHSC) 1996/97 is derived from financial and statistical
returns from hospital running costs and community services.
Costs are divided into direct costs and allocated costs. Direct costs being all
costs directly associated with medical treatment and care of the patient. Allocated
costs include all other costs in providing a service to patients, also known as
hotel costs. Indirect and intangible costs are seldom quantified and described,
purely because accurate or plausible estimates of these costs are almost
impossible to obtain.
The present study reported here, although addressing some of the problems
identified in previous studies, acknowledges the difficulties experienced by
others investigating this topic. This study is not "pure" since more than one
approach was used to determine the cost of carotid endarterectomy. To estimate
the programme cost of identifying suitable patients for the procedure, a top-down
deterministic approach was employed. Describing the cost of the carotid
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procedure patient specific cost data in a bottom-up approach, were predominantly
applied. Point estimates were however used for certain resources in the pre¬
operative stage and for all the resources in the post-operative stage. It should also
be mentioned that although necessary measures were taken to avoid double
counting in the costing methods, the risk could not be completely eliminated,
since routinely collected data sources were used in conjunction with patient
specific cost data. Considering these dilemmas encountered in the design of this
study, sensitivity analyses were performed to address the uncertainties associated
with these estimates.
Routinely collected data sources.
One of the major constraints in this study was the estimation of unit costs for
resources used. The Scottish Health Services Costs 1996/97 was used as
reference source for many of the calculations. This source does however not, take
the different levels of expertise (consultant versus specialist registrar) into
account when estimating a cost per attendance at an outpatient department. All
"new" consultations are considered to be similar; visits of different time duration
(30 - 60 minutes) or by medical personnel with different levels of seniority are
regarded as the same. Another concern was the attendance at a dedicated
outpatient consultant clinic, which was not accounted for in the SHSC source.
The published data in the reference source do not have data on the cost per
attendance at neurovascular clinics, but only of neurology and general surgery.
The published figure for a neurology outpatient attendance was therefore used.
The use of this apparently higher cost per attendance seemed justified since only
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one and a half attendance was counted, where in fact most patients for carotid
endarterectomy have a minimum of two consultations and some patients have
even more.
The published total expenditure in a general surgery ward was used to calculate
the cost per bed day. The reasons substantiating this decision were the following:
patients were usually admitted for a day post-surgery to the high dependency unit
in the Royal Infirmary and for a day to the intensive therapy unit in Glasgow. No
direct theatre cost per case was allocated for the bed days in the intensive therapy
unit at the Royal Infirmary and the Southern General. Such a cost was however
allocated for the Western General hospital, but carotid surgery is not routinely
performed at the WGH. The theatre and laboratory costs published for the bed
days in intensive therapy unit were considered high for a typical carotid
endarterectomy patient since these patients are dissimilar to typical patients being
treated routinely in ITU. Data were extensively collected from case notes to
account for all direct cost incurred during the intensive therapy and high
dependence unit stay. Since the stay in these two units was relatively short, the
cost per bed day as calculated from the published SHSC was applied. All these
discrepancies described here emphasise the problems associated with the use of
routinely collected data.
Operational data from hospitals.
Another constraint in this study was the identification of the potential cohort of
patients who might be suitable for carotid endarterectomy. Ideally the "pool" of
patients from where the carotid endarterectomy patients originated should include
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more than one year of observation. Since the proportion of patients proceeding to
carotid endarterectomy is relatively small, observation ofmore than one year will
increase the size of the study population and also account for the influence of
unexplained seasonal and year-to-year variation that might occur when studying a
one year period only (Personal communication: GD Murray, Professor: Medical
Statistics, University of Edinburgh). The major problem in having more than one
year of observation was related to the availability of reliable data sources for
previous years. Only two data sources, the neurovascular appointment book at the
Department of Clinical Neurosciences and the electronic hospital network,
HOMER were available to estimate the number of appointments at the
neurovascular clinics. Concerns about the accuracy of both these sources have
been expressed by the neurology consultants involved in the clinic activities, thus
an estimation of the number of neurovascular appointments for both sources was
necessary to establish the most reliable source. Although the appointment book
was identified as providing a more reliable and accurate reflection of the clinic
activity and was used as the data source to estimate the number for the "pool" of
patients ("the base of the pyramid") from where patients were selected for carotid
surgery, it highlighted the problem of the accuracy of operational data sources for
research purposes.
The importance to perform a CEA as soon as possible a fter a carotid TIA.
The risk of stroke is about 12% in the first year after a TIA and then about 6%
per annum for the next four years. It is therefore important that people with
transient ischaemic attacks should be identified soon after an attack, preferably
Chapter Four: CEA cost
within four to six months, if any benefit conferred by carotid endarterectomy is to
be gained. It needs to be mentioned that the most recent recorded transient
ischaemic attack before assessment by a neurologist was used in determining the
time delays in the work-up to carotid endarterectomy. This obviously has
significant implications for performing a carotid endarterectomy during the time
window where optimal benefit associated with the procedure might be obtained.
A more accurate and reliable entry date in determining the delays in the progress
to carotid endarterectomy would have been the very first symptom experienced
by patients. Information of this nature was unfortunately not available and it is
against this background that patients assessed in this cohort for a possible CEA
were evaluated. Identifying these patients form a defined cohort should thus be
considered as active case finding since these patients present to the health care
systems with symptoms suggestive of transient ischaemic attacks. It is more than
likely that a "referred" cohort might not be representative of all potential
candidates for CEA in the population who might in some instances benefit more
from the procedure than those referred.
For both the LSR cohort and the CEA cost description cohort, 75% of patients
were operated on within acceptable time intervals to maximise the potential
benefit of a risk reduction in stroke. The maximum time intervals in all these
transitions indicate extreme time delays, and it is worrying that 25% of CEA
patients did not proceed rapidly to have the procedure. Delays were observed
throughout the referral chain and it would be difficult to identify one specific
referral transition being responsible for these delays. Referring only to the 25%
of patients where unacceptable long time intervals were observed, the delays
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found for both cohorts were similar. The CEA cost description cohort's referral
pattern appeared to be quicker from assessment at a neurovascular clinic to CEA,
but long delays occurred from most recent transient ischaemic attack to CEA.
Considering the 18 CEA patients who were referred for CEA from the LSR
cohort, only 14 patients might have obtained any "real" benefit in terms of a
reduction in stroke risk by having the procedure within the recommended six-
month window. Four of these patients were unlikely to have benefited, but
contributed to the overall cost. The cost-effectiveness of the procedure in these
patients who were operated on after six-months from most recent transient
ischaemic attacks is questionable. The time-to-event analyses performed both in
the case of the LSR data set and the CEA cost description study indicated that
75% of patients assessed were operated on within five months from presenting
with a carotid TIA. This suggested that current clinical practice in the work-up to
CEA needs to be improved to derive optimal clinical as well as any cost benefit
from this surgical intervention (Brown and Humphrey, 1992). It is apparent form
the median times observed for both cohorts that 50% of patients were assessed
within reasonable time frames, suggesting that it is possible to obtain optimal
referral times for half of carotid TIA patients.
Sensitivity analysis.
Sensitivity analysis has until very recently been the main method used addressing
the uncertainty associated with economic evaluations. Although more stochastic
data are becoming available to apply classical statistical approaches, the need for
sensitivity analysis will not disappear, since some data will always be
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deterministic in nature. It is therefore prudent that available results should be
applied to the best possible use, whether it is in a sensitivity analysis or whether
the results are to be transferred from one setting to another.
The base transition ratio model was found to be relatively insensitive to
variations in the individual parameters in the model even varying the individual
parameters in the model by performing a one- or multi-way sensitivity analysis.
Multi-way analyses, which recognise the uncertainty associated with more than
one parameter at a particular point, and are preferred to one-way analyses as it
mimics conditions of clinical situations more appropriately, were not found to be
more sensitive. Although it was found that the most favourable transition models
will be obtained by varying the consultation, duplex and angiogram parameters,
the interaction between the ratios of the individual parameters was insensitive to
minor variations. The parameter of CEA in the model has been regarded as a
constant throughout most of the analyses, since it was assumed that for the
purposes of this study and the "programme", that patients are investigated to have
one CEA and would not be evaluated for bilateral staged carotid procedures.
However, applying the findings of the US Veterans Affairs Study of one CEA for
every 27 patients evaluated of cerebral ischaemia (Mayberg et al., 1991), one
could expect to perform two carotid endarterectomies for about every 50 patients
with cerebral ischaemia. As demonstrated by the sensitivity analysis, when two
carotid endarterectomies were to be performed for every 50 patients with cerebral
ischaemia evaluated, the cost of investigating a cohort of patients with cerebral
ischaemia increased substantially.
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It was also apparent from the sensitivity analysis, addressing uncertainty in the
point estimates for the programme cost of investigating patients for probable
carotid endarterectomy, that a favourable cost scenario will be obtained if only
patients for whom a high index of clinical suspicion of the presence of carotid
territory ischaemic events exists, are referred for consultant assessment and
evaluation. A high proportion of these "selected" patients with probable carotid
stenosis will qualify for duplex investigation thereby increasing the yield of
patients with stenosis of 70% or more who might be suitable for carotid surgery.
A "programme" to identify suitable candidates for carotid endarterectomy,
concentrating only on the most likely candidates for the procedure to be assessed
at a neurovascular clinic will however be against the ethos of health care
delivery. Such a "programme" would also place an unjust burden on primary
health care providers in making decisions outside their domain of clinical
expertise unless access to duplex ultrasound could be given to them. It could be
argued that many patients are referred to neurovascular clinics because of
pathologies other than carotid stenosis and that access to duplex by general
practitioners would not decrease the number of patients evaluated at these clinics
as duplex scanning might not be the first line of investigation for these patients.
However if general practitioners could refer patients, with a high index of clinical
suspicion of transient ischaemic attack, for duplex investigation prior to
consultant referral, patients with stenosis less than 70% would not be referred for
consultant opinion and patients with other pathologies would be referred anyway.
This might reduce the number of outpatients consultant visits and hence the cost,
207
Chapter Four: CEA cost
since only 20%of patients in this study with symptoms suggestive of transient
ischaemic attacks were found to have stenosis ofmore than 70%.
From the transition ratio observed in this study, investigating a 1000 patients
with symptoms suggestive of transient ischaemic attacks, 520 patients will be
clinically diagnosed as having carotid related ischaemic attacks. Only 508 of the
1000 patients will have a subsequent duplex examination, 99 will be diagnosed
with duplex as having stenosis of 70% or more in one or both carotid arteries. 33
of them will have a carotid angiogram and 23 patients will have a carotid
endarterectomy. Or about 45 out of 1000 patients with carotid related transient
ischaemic symptoms will have a carotid endarterectomy (or 45 out ofabout 2000
patients with cerebral ischaemic symptoms i.e. the "pool" of potential CEA
patients). If we then need to perform nine CEA to prevent one stroke, 200
patients with carotid-related symptoms need to be investigated. Or for every 200
patients with carotid-related ischaemic symptoms we can expect to perform nine
carotid endarterectomies and thus prevent one stroke at a cost of £103 080
(Figure 4.7).
Though a ratio of one consultation to one duplex to one follow-up visit to one
angiogram (1:1:1:1) can be assumed from first consultation to subsequent
investigations, this study has shown that these assumptions did not hold
absolutely true. A ratio of one consultation to one duplex to 1.5 angiogram to one
CEA was found in the work-up of the patients with carotid territory ischaemic
attacks identified in the LSR-data set. Thus cost estimates based on a
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deterministic approach might either be an underestimation or overestimation of
health service and financial requirements as were shown in the sensitivity
analyses.
Describing the ratio of duplex to angiography to carotid endarterectomy based on
this cohort of 64 patients, it is apparent that the assumed ratio of 1:1:1 was not
adhered to for this group of patients either. A ratio of two duplex investigations
to 0.66 angiogram investigations to one carotid endarterectomy was observed in
the prospective costing study suggesting a changing nature in the "work-up" for
carotid endarterectomy. It is however acknowledged that the study population of
the CEA cost description study was small and might not be representative of
larger cohorts. Based on the observations in the CEA cost description study, it is
also anticipated that the frequency of duplex investigations per patient will
increase with fewer patients having an angiogram prior to carotid surgery. It is
also anticipated that the conventional angiography will be replaced in the future
for some patients by non-invasive MRA investigations.
Angiography per se does not contribute much to the overall programme cost of
carotid endarterectomy, even in this study where 1.5 angiographies had to be
performed for every one CEA. More than half (56%) of the programme cost has
accrued before patients were referred for angiography. The proportion
angiography contributed to the overall cost of investigating a cohort for possible
CEA was only 12% and the remaining 32% was for the CEA procedure self.
Angiography however contributed almost 20% to the overall cost of carotid
endarterectomy in the case of the individual patient.
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Altering the length and type of hospital stay variables in this cohort had little
effect on the cost of the procedure, since the overall stay in hospital for these
patients was relatively short as well as the stay in intensive therapy units.
Reducing the total length of hospital stay will therefore have no substantial cost
implications and was therefore not considered as a key parameter in the
sensitivity analysis. From the sensitivity analyses it is apparent that the most
favourable cost estimate will be obtained in the absence of a carotid angiogram.
Although hospital stay ass relative short (mean of 5.16 days) and was primarily
in a general surgery or a ward equivalent to it, bed days contributed much to the
overall cost of the procedure.
4.6 Summary.
This study has found that an individual CEA is not too costly and comparable with
other similar vascular procedures (Jepson et al. 1997, UK Small Aneurysms Study
Group 1998). The cost to prevent one stroke is about £44 000 when the CEA cost
estimate of £4868 is applied to the number needed to treat (nine) to prevent one
stroke. When the cost of assessing a cohort of patients who might be potential
candidates for CEA is considered, the overall cost increases substantially to about
£103 000 per stroke prevented. Most of the cost in a CEA programme is spent during
the work-up of a potential cohort of patients who might be suitable for CEA resulting
in the actual CEA procedure being relatively inexpensive.
It is imperative that the delivery of health care for this selected group of patients
who have had a carotid territory transient ischaemic attack should be improved if
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the benefit of CEA is to be optimised. One-stop TIA clinics or neurovascular
clinics should be given priority and implemented as soon as possible to minimise
these delays which are occurring in the current fragmented delivery system thus
maximising the potential benefit of this procedure for the selected few
(Sandercock, 1998).
Duplex investigation is currently considered the best diagnostic "tool" to
determine carotid stenosis since it is safe, non-invasive, with good sensitivities
and specificities and is relatively inexpensive. It seems therefore appropriate to
recommend primary health care physician access to this investigation to ensure
that only patients who would be most likely to benefit from CEA would be
referred for specialist consultation.
Developing clinical pathways for the work-up of patients with carotid territory
related transient ischaemic attacks to CEA which do not require the routine
investigation of carotid angiography, and substituting it for an additional duplex
investigation or even a more costly investigating such as MRA compared to the
cost of a duplex examination will result in a favourable cost "package".
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Table 4.1: Patient proportions from neurovascular clinic to carotid endarterectomy:
(Neurovascular clinic appointment book and Lothian Stroke Register.)
Patient pool Carotid distribution
symptoms
Neurovascular clinic 790 412/790 (52%)
Lothian stroke register 660 412/660(62%)
Duplex ultrasound 401/790 (51%) 401/412 (97%)
Carotid angiogram 26/790 (3.3%) 26/412 (6.3%)
Carotid endarterectomy 18/790 (2.3%) 18/412 (4.4%)
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Table 4.2: Age and sex distribution: Lothian Stroke Register cohort.
Age category Male Female Total
(%)*
<50 years 25 18 43(10%)
50 - 65 years 88 48 136(33%)
66 - 80 years 108 85 193(47%)
>80 years 19 21 40(10%)
Total 240 172 412(100%)
* percentage ofmales and females per age category of the total number ofpatients
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Table 4.3: Carotid stenosis according to duplex investigations for the 401 patients in
the LSR data set.
Category Number of patients
"No" stenosis in either internal carotid artery 237 (59%)
"No" stenosis one artery and stenosis < 70% other artery 24 (6%)
Stenosis < 70% both internal carotid arteries 25 (6%)
"No" stenosis one artery and stenosis > 70%other artery 28 (7%)
Stenosis > 70% one artery and < 70% other artery 25 (6%)
Stenosis > 70%: both internal carotid arteries 19(5%)
Occlusion on one side with "no" stenosis other artery 17(4.2%)
Occlusion on one side with stenosis < 70% other side 19(5%)
Occlusion on one side with stenosis > 70% other side 6(1.5%)
Occlusion "both" sides 1 (0.3%)
Total number of Duplex investigations 401
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Table 4.4: Baseline parameters and unit costs in the work-up of the study cohort to
carotid endarterectomy: Neurovascular clinic and Lothian Stroke Register.
Level of investigation Patients (n) Unit cost (£) Total cost(£)
Neurovascular clinic: new attendance 790 88 69 520
Duplex examination 401 70 28 040
Neurovascular clinic: follow-up visit 401 44 17 644
Carotid angiography 26 950 24 700
Direct "work-up" cost excluding CEA £139 934
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Table 4.5: Baseline characteristics of carotid endarterectomy patients in cost







Number in study 42 22 64
CEA Number 42 19 61
Male (%) 31(73.5%) 17(78.9%) 48(75%)
Mean age 67 70 67.2( 65.15; 69.24)
Age category:
<50 years 1 2 3
50 -65 years 16 5 21
66 - 80 years 24 15 39
> 80 years 1 0 1
Presenting symptom:
TIA 16 5 21
Minor stroke 7 6 13
Amaurosis fugax 4 4 8
Combination 14 4 18
Asymptomatic 1 3 4
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Table 4.6: CEA cost description study: Resources used during the different stages
for the 61 CEA patients at the Royal Infirmary Edinburgh and the Southern
General Glasgow.
Resources used during: Mean (£) Median (£) IQR (£)
Work-up to CEA 1359 1416 857 - 1976
Hospitalisation for CEA: 3356 2695 2434-3148
(Bed days and theatre)
Bed days: 2319 1717 1420-2291
Theatre: 1037 1018 780 - 1250
Post-operative stage 154 158 158-158
Total cost 4868 4300 3711 - 5064
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Table 4.7: Number of angiograms performed before CEA at the Royal Infirmary
Edinburgh and Southern General Hospital Glasgow.
Angiogram performed Males Females Total
Yes 34(81%) 8(19%) 42(66%)
No 14 8 22(34%)
Total 48 16 64
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Table 4.8: Breakdown of the resources (£) used during the different stages for CEA
patients at the Royal Infirmary Edinburgh and Southern General Glasgow.
Stage Arithmetic mean (£) Median (£) IQR(£)
Work-up:
Medical consultation 135 132 132 - 132
Haematology and biochemistry 54 51 40 -71
Ultrasound &Angiography & CT 533 508 310-658
ECG & cardiology investigations 75 29 29-29
Cost of angiogram:
(bed days and procedure)
890 950 354 - 950
Hospitalisation - Procedure:
Human resources 443 442 295 - 564
Anaesthetic drugs and equipment 124 134 71 - 162
Surgical instruments, materials 204 179 151 -209
and sutures
Theatre overheads 265 258 212-328
Total theatre cost 1037 1018 780- 1250
Hospitalisation - Bed days:
ITU 819 0 0-967
HDU 399 517 0-517
Surgical bed days pre -op 340 298 298 - 298
Surgical bed days post -op with 759 611 325 - 910
medications after CEA
Total length of hospital stay 2319 1717 1420-2291
Post-operative stage
Human resources and carotid 154 158 158 - 158
ultrasound
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Table 4.9: Breakdown of procedure cost in theatre at the Royal Infirmary,
Edinburgh and Southern General Hospital, Glasgow. Mean, median cost and
interquartile range of the human resources, anaesthetics, surgical components and
theatre overheads (£).
Hospital Royal Infirmary, Southern General Both
Edinburgh Hospital: Glasgow hospitals
Human resources:
Mean cost (£) 533 243 443
Median (£) 520 223 442
IQR 437 - 586 173 - 281 295 - 564
Anaesthetic drugs and equipment:
Mean cost (£) 150 67 124
Median (£) 153 67 134
IQR 133 - 170 62 - 72 71 - 164
Instruments and materials:
Mean cost (£) 214 186 205
Median (£) 170 196 179
IQR 151 -202 145 -218 151 -209
Theatre overheads:
Mean cost (£) 305 152 264
Median (£) 298 169 258
IQR 257- 344 120 -210 212 -328
Total theatre cost:
Mean cost (£) 1202 671 1037
Median (£) 1105 633 1018
IQR 1011 - 1308 589 - 777 780 - 1250
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Table 4.10: Cost of hospital stay by unit in the carotid endarterectomy cost
description study.
Cost of: Mean (£) Median (£) IQR (£)
Days in general ward before surgery 340 298 0
Days in Intensive Therapy Unit 819 0 0-967
Days in High Dependency Unit 399 517 0-517
Days in general ward after surgery 759 611 325 - 910
Total days in surgical ward 1101 913 901 - 1209
Total length of hospital stay. 2319 1717 1420 - 2291
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Table 4.11: Cost description study: Bed days in hospital and time in theatre.
(Minimum and maximum number ofbed days, interquartile range, and mean number
ofbed days with, 95% confidence intervals).
Minimum Maximum IQR Mean stay
General surgery ward: 1 5 0 1.14
Before surgery (0.99; 1.30)
Intensive Therapy Unit 1 18 1 0.82
(0.18; 1.46)
High Dependency Unit 1 2 1 0.80
(0.62; 0.92)
General surgery ward: 0 11 2 2.41
After surgery (1-97; 2.85)
General surgery ward: 1 12 1 3.57
Before and after surgery (3.14; 4.01)
Total length of hospital 3 23 1.5 5.16
stay. (4.40; 5.93)
Theatre time in minutes 75 330 180 184.4
170.1; 198.4
Theatre time in hours 1.25 1.35 3.00 3.08
2.84; 3.31
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Table 4.12 Cost description study: Proportional breakdown of cost.
Resources Mean cost (£) Proportion
Prior to CEA 1359 27%
Bed days and medication 2319 48%
Theatre 1036 21%
After CEA 154 4%
Total 4868 100%
Hospitalisation:
Surgical days 1101 32%
ITU days 819 25%
HDU days 399 12%
Theatre 1036 31%
Total 3355 100%
Source: Scottish Health Service Costsl996/97
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Table 4.13: The programme cost of investigating a cohort of patients for potential
CEA. (Number ofpatients at each level and unit costper investigation)
Investigation level Patient number Unit cost
(£)
Total cost(£)
Neurovascular clinics: 790 88 69 520
LSR entries 412 - -
Duplex ultrasound 401 70 28 040
Follow-up consultation 401 44 17 644
Angiogram 26 950 24 700
Total "work-up" cost £ 139 934
Total procedure cost 18 3716 £ 66 888
*Carotid endarterectomy
Total programme cost £ 206 822
* excluding work-up; including surgery, hospitalisation and post operative care
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Table 4.14: Baseline parameters for transition ratio model using a deterministic
sensitivity analysis.
Transition levels Ratio Unit cost (£) Base cohort cost (£)
Consultation 50 88 4400
Duplex 25 70 1750
Follow-up visit 25 44 1100
Angiogram 1.5 950 1425
Carotid endarterectomy 1 3716 3716
Total CEA cost 4868 12 391
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Table 4.15: Deterministic sensitivity analysis applied to the transition ratio.
Consultation Duplex Follow-up Angiogram CEA Cohort Impact
(£88) (£70) (£44) (£950) (£3716) cost
Base 50 25 25 1.5 1 12 391
ratio
All parameters in ratio constant; altering only angiogram
50 25 25 - 1 10 965 12%!
50 25 25 0.75 1 11 677 6%!
50 25 25 Duplex 1 11 035 n%!
50 25 25 MRA 1 11 319 9%!
50 25 25 Duplex and 1 11 389 8%!
MRA
Increasing and decreasing consultations by 25%; varying angiogram ratio
62.5 (25%t) 25 25 1.5 1 13 490 9% T
62.5 (25%t) 25 25 - 1 12 066 3%!
37.5(25%!) 25 25 0.75 1 10 579 15%!
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Table 4.15: Deterministic sensitivity analysis applied to the transition ratio.
(Continue)
Consultation constant; Altering Duplex , follow-up visit and angiogram ratios
50 31.25 31.25 1.5 1 13 104 6%T
(25%T) (25%T)
50 18,75 18.75 1.5 1 11 622 6%I
(25%1) (25%i)
50 31.25 31.25 0.75 1 12 392 0%t
(25%T) (25%T) (50%1)
50 37.5 37.5 1 12 380 0%l
(50%T) (50%T)
50 31.25 31.25 Duplex 1 11 749 5%i
(25%T) (25%T)
50 18,75 18,75 0.75 1 10910 12%l
(25%i) (25%i) (50°/U)
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Table 4.15: Deterministic sensitivity analysis applied to the transition ratio.
(Continue)
Increasing consultations, duplex and follow-ups by 25%; altering angiogram transition
62.5 (25%t) 31.25 31.25 0.75 1 13 492 9%t
(25%T) (25%t) (50%i)
62.5 (25%T) 31.25 31.25 - 1 12 779 3%T
(25%T) (25%T)
75 (50%T) 31.25 31.25 0.75 1 14 592 18%T
(25%T) (25%T) (50%l)
50 50 50 - 1 13 816 12%T
(100%t) (100%T)
Consultation, duplex, follow-up visit constant; Altering angiogram with duplex or MRA
with two CEA for every 50 patients assessed at the NVC.
50 25 25 1.5 2 16 105 30% T
50 25 25 Duplex 2 14 750 19% t
(xl)
50 25 25 Duplex 2 14 820 20% t
(x2)
50 25 25 MRA 2 15 030 21% t
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Consultation 88 110(t25%) 110(T25%) 110(t25%)
Duplex 70 140(Tl00%) 140(Tl00%) 140(Tl00%)
Follow-up 44 55(t25%) 55(t25%) 55(t25%)
Angiogram 950 950 0 0
MRA (353) 0 0 353
CEA cost 3716 3716 3716 3716





Consultation 88 110(t25%) 110(T25%) 110(t25%)
Duplex 70 140(Tl00%) 140(tl00%) 140(1" 100%)
Follow-up 44 55(t25%) 55(t25%) 55(t25%)
Angiogram 950 950 0 0
MRA (353) 0 0 353
CEA cost 3716 4088(tl0%) 4088(tl0%) 4088(Tl0%)
Total CEA cost 4868 5343(t25%) 4393(4'10%) 4746(^2.5%)
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Table 4.17: Baseline parameters for procedure cost: probabilistic sensitivity
analysis.
CEA procedure Base case Lower bound Upper bound
cost (£) 95%C.I. 95%C.I.
Work-up:
with angiogram £ 1359 1165 1552
Without angiogram £ 599 539 659
Without angiogram and £ 669 609 729
one additional duplex
Hospitalisation: £ 3355 2632 408
Bed days: £2319 1629 3009
Theatre:
£ 1036 946 1128
Post operative stage £ 154 147 160
CEA cost with angiogram £4868 4093 5643
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Table 4.18: Procedure cost sensitivity analysis.
Work-up with angiogram 95% Confidence intervals
Base case Lower bound Upper bound
Work-up 1359 1165 1552
Bed days 2319 1629 3009
Theatre 1036 946 1128
Postoperative stage 154 147 160
Carotid endarterectomy cost 4868 3887(420%) 5849(420%)
Work-up without angiogram 95% Confidence intervals
Base case Lower bound Upper bound
Work-up without angiogram 599 539 659
Bed days 2319 1629 3009
Theatre 1036 946 1128
Postoperative stage 154 147 160
Carotid endarterectomy cost 4108 3261(420%) 4956(420%)
Work-up without angiogram but with one additional duplex investigation
95% Confidence intervals
Base case Lower bound Upper bound
Work-up without angiogram but 669 609 729
one additional duplex
Bed days 2319 1629 3009
Theatre 1036 946 1128
Postoperative stage 154 147 160
Carotid endarterectomy cost 4179 3331(420%) 5026(420%)
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Median IQR Minimum Maximum
Most recent symptoms 21 10 2-27 0 225
to Neurovascular clinic (1.5)
Neurovascular clinic to 5.8 0 0-2 -54 99
Duplex (0.73)
Duplex to Angiogram 33 26 8-39 0 148
(7.5)
Angiogram to CEA 81 51 40- 17 410
(30.4) 75
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Table 4.20: Time intervals in days: CEA work-up in CEA cost description study.
Interval Mean
(Standard error)
Median IQR Minimum Maximum
Most recent symptom 29 7 1 -28 0 529
to first visit (7.5)
Most recent symptoms 34 20 0-52 -7 52
to assessment (5.4)
Neurovascular clinic to -1 0 -21 - -117 160
Duplex (5.8) 17
Duplex to Angiogram 53 57 29- 0 151
(5.8) 70
Angiogram to CEA 29 20 7-38 2 109
(4.6)
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Table 4.21: Summary - Time intervals to carotid endarterectomy costing data set
and Lothian Stroke Register data set.
Mean Median IQR Minimum Maximum
(Standard Error) days Days
CEA Costing data set
Most recent 135 126 93 - 159 9 608
transient ischaemic (11.4)
attack to CEA*
1st health care visit 107 106 76 - 143 7 268
to CEA (6.9)
Neurovascular 74 63 42 - 99 2 247
clinic to CEA (5.6)
LSR data set
Most recent 159 118 78 - 186 9 529
transient ischaemic (28.1)
attack to CEA
Assessment to CEA 130 85 56 - 134 8 521
(29.2)
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Table 4.22: Time intervals in days: CEA referral in CEA cost description study.
Interval Mean Median IQR Minimum Maximum
First symptom to first visit 29 7 1 - 13 0 529
Referral from Neurovascular 31 22 13-34 0 229
clinic to vascular clinic
Days from Neurovascular 33 26 0-64 0 141
clinic to vascular clinic
Vascular clinic to CEA 30 27 9-47 1 129
Neurovascular clinic to CEA 63 58 27-97 1 196
Assessment to angiogram 45 46 14-69 -68 134
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Figure 4.1: The carotid endarterectomy programme.
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Figure 4.2: Schematic presentation of the progress of patients with Transient
Ischaemic Attack-like symptoms to carotid endarterectomy.
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Figure 4.3: Age distribution of probable carotid territory ischaemic attack patients:
Lothian Stroke Register. (Standard deviation =12; Mean = 5.8, n= 412)
Age distribution in 5-year intervals
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Figure 4.4: Schematic presentation of internal carotid arteries investigated with
duplex ultrasound.
401 patients (802 internal carotid arteries)
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Figure 4.5: Age distribution of patients in the carotid endarterectomy cost
description study at the Royal Infirmary Edinburgh and the Southern General
Glasgow. (Mean age = 67 years; Standard deviation = 8.1; n = 64)
20
Age distribution in 5-year intervals
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Figure 4.6: The cost distribution for the carotid endarterectomy procedure in the
cost description study at the Royal Infirmary Edinburgh and the Southern General
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Figure 4.7: Schematic presentation of the clinical pathway of CEA and the
associated costs for a CEA programme.
Clinical pathway Associated costs
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CHAPTER FIVE: CAROTID ENDARTERECTOMY IN SCOTLAND,
RANDOMISED CONTROLLED CLINICAL TRIALS AND
ASSOCIATED COSTS.
5.1 Introduction
The benefit associated with carotid endarterectomy in terms of "stroke-free" survival
for patients with symptomatic carotid artery stenosis of more than 70% has been
established by the two randomised controlled trials published during the 1990s
(European Carotid Surgery Trialists' Collaborative Group, 1991; North American
Symptomatic Carotid Endarterectomy Trial Steering Committee, 1991; ECST
Collaborative Group, 1998; NASCET Steering Committee, 1998). Though there is
now little doubt concerning the efficacy of this procedure, for some selected
subgroups, the cost implications of this procedure has not yet been satisfactorily
addressed, neither has the outcome of this procedure in populations representative of
"real life" and not associated with a trial, been investigated previously (Brittenden et
ah, 1999; Hallett at ah, 1998).
In this chapter, I firstly compare the outcomes of "stroke-free" survival and overall
survival at five years in a Scottish cohort of patients randomised to carotid
endarterectomy (CEA) in the European Carotid Surgery Trial (ECST), with the
outcomes in Scottish patients operated on outside the trial. "Stroke-free" survival is
defined as surviving for a total period of five years after successful carotid surgery,
without experiencing any hospitalised stroke event. Overall survival is defined as
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surviving for a total period of five years after successful carotid surgery without
experiencing a fatal stroke or a death from any cause.
Secondly, I estimate the difference in cost between the Scottish cohort of patients in
the ECST randomised to surgical treatment (Scottish-ECST surgical cohort) and
those patients randomised to medical treatment (Scottish-ECST medical cohort). The
estimated cost difference between the two randomised treatment groups was used, in
conjunction with the effectiveness data reported from the ECST and published
modelling studies, to calculate a cost-effectiveness ratio.
The proposed objectives were achieved by testing several null hypotheses regarding
the "stroke-free" and overall survival in a Scottish-CEA cohort (Scottish ISD-CEA
data set). The primary null hypothesis was that there was no difference between the
five-year "stroke-free" survival and five-year overall survival of Scottish patients
who were randomised to surgery in the European Carotid Surgery Trial (Scottish
ECST surgical cohort) and the corresponding survival of all Scottish cases who had a
carotid endarterectomy outside the ECST (Scottish ISD-CEA non-ECST cohort)
during the same period as the trial (trial patients versus non-trail patients). To reduce
bias, in addition to the comparison with all the Scottish CEA cases (ISD-CEA non-
ECST cohort), the Scottish patients randomised to surgery in the ECST were also
compared with an age-sex-date-of-operation matched control cohort from the ISD-
CEA data set (Scottish ISD-CEA non-ECST matched cohort).
The secondary null hypothesis was again of no difference in outcome between the
five-year "stroke-free" survival and five-year overall survival, but this time by
244
Chapter Five: CEA, RCTs and cost -effectiveness
comparing the same patients, but using data obtained from two different data sources
(ISD-CEA data set versus Scottish-ECST data set).
The cost incurred by the Scottish-ECST cohort, inclusive of all the Scottish patients
randomised either to surgery or best medical care into the ECST, was estimated using
two approaches. In one method, resource use was assessed by applying findings from
the CEA cost description study (Chapter Four) to the episodes of care obtained from
routinely collected data. In the second scenario the mean cost estimate of a
Healthcare Resource Group (HRG) as defined in the National Schedule of Reference
Costs for Elective In-Patients of the Department of Health (1998) was applied to the
routinely collected data for each episode of care.
5.2 Methods
5.2.1 Description of the studypopulations
The study population investigated in this study was described in Chapter Two, and
included all patients in Scotland who had a CEA during the period 1981 to 1996. All
the Scottish patients who were also randomised to surgery in the ECST during the
entire period of the trial were identified (Scottish ECST-surgery cohort). Scottish
patients randomised to best medical care were identified in the ISD database
(Scottish ECST-medical cohort). Patients in the ECST were randomised between 14
October 1981 and 31 March 1994. The randomisation period (1981 - 1994) for the
trial corresponded largely to the period (1981 - 1996) used to identify patients who
had a carotid endarterectomy in Scotland from the routinely collected data source of
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ISD, the ISD-CEA data set. The Scottish patients randomised into the ECST, the
Scottish ECST cohort, were identified from the ECST data set archived at the
Department of Clinical Neuroscience at the Western General Hospital. Using the
centre code where the operation was performed the centres in Scotland which
participated in the trial were identified and consequently the patients from Scotland
randomised into the surgery arm in the ECST. Record linked methods were used to
link the Scottish patients randomised to surgery in the ECST (Scottish ECST-surgical
cohort) to the ISD-CEA data set as discussed in Chapter Two.
Scottish patients randomised to medical care in the ECST were identified through
linkage to the national patient database at ISD (Scottish ECST-medical cohort). The
linkage was achieved by using the patient's name, date of birth, gender, date of
operation, and randomisation centre as key variables. The index event for both the
surgical and medical group was the date of randomisation into the trial and
information about all subsequent episodes of care from that date onwards up to
December 1997 was "collected". The linkage for the Scottish patients randomised to
medical care was essential in order to quantify resource use after randomisation in
patients treated medically.
5.2.2 Outcomes measures
The primary outcome measures related to the "transferability" of trial results were
five-year "stroke-free" survival and five-year overall survival in a Scottish cohort of
patients randomised to surgery in the ECST (Scottish ECST-surgical cohort)
compared with non-trial patients in the Scottish cohort having had a carotid
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endarterectomy between 1981 to 1996 (Scottish ISD-CEA non-ECST cohort). The
outcome variables included not only death associated with a stroke event, but also
"stroke-free" survival of any type of stroke admitted to hospital and all cause
mortality. All stroke events identified were hospitalised stroke events only. This
applied to both the Scottish ECST-surgery cohort as well as the Scottish ISD-CEA
non-ECST cohort. Since data were obtained from the same data source, the ISD data
set, any degree of potential bias was minimised.
The outcome measure related to the economic evaluation of CEA was expressed as
in-patient hospital episodes of care of a Scottish cohort of patients randomised to
surgery in the ECST (Scottish-ECST surgical cohort) compared with the resource use
of the Scottish cohort of patients randomised to best medical care in the ECST
(Scottish-ECST medial cohort).
The outcome measure of clinical effectiveness of CEA defined as "stroke-free" life
expectancy was obtained from the final results of the ECST (ECST Collaborative
Group, 1998) as well as from a modelling study using NASCET results as reference
(Nussbaum et al., 1996). The outcome measures of the economic evaluation and of
clinical effectiveness were applied to calculate a cost-effectiveness ratio (difference
in cost/ difference in outcome).
5.2.3 Methods used to test the transferability ofRCT results.
Primary null hypothesis.
Firstly, the five-year "stroke-free" survival and five-year overall survival of all cases
in Scotland who had a carotid endarterectomy outside the ECST (Scottish ISD-CEA
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non-ECST cohort) between 1981 and 1996 were compared with the five-year
"stroke-free" and five-year overall survival of Scottish patients in the ECST (Scottish
ECST-surgical cohort).
Secondly, the five-year "stroke-free" and five-year overall survival of the Scottish
patients randomised to surgery in the European Carotid Surgery Trial and identified
in the routinely collected ISD-CEA data set, (Scottish ECST-surgery cohort) were
compared with a cohort matched for age, sex and date of operation of Scottish
patients who had carotid endarterectomy outside the ECST (Scottish ISD-CEA non-
ECST matched cohort). An age-sex-date-of-operation cohort of Scottish patients who
had a carotid endarterectomy outside the trial, but at the time of the trial was matched
to the Scottish surgical participants in ECST on a one-to-one basis. The data set
matched for sex, age and year of operation was created using the Scottish patients
randomised to carotid surgery in the ECST as reference. The date of birth of patients
in the ISD database is not available in order to protect patients' identity. Since the
ISD-CEA data set was extracted from the ISD database this variable was not
obtainable and the age of the patients who had carotid surgery in the trial was
therefore used to identify a similar patient within an age band of plus-minus two
years. The date of the operation was known for all Scottish CEA patients, (ECST
patients and non-ECST patients) and a more precise matching could be obtained,
within a two-month range in most cases, using the operation date. The age-sex-
operation-date matched subset survival analysis was considered to be more
informative in detecting differences in five-year "stroke-free" and five-year overall
survival than comparing the small number of ISD-CEA ECST participants to all the
carotid endarterectomy patients in the ISD-CEA non-ECST data set.
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Secondary null hypothesis.
The five-year "stroke-free" and five-year overall survival of the Scottish ECST-
surgery cohort were compared using data obtained from the routinely collected data
source from ISD and data obtained from the randomised controlled trial, the
European Carotid Surgery Trial. The data set used for analysis in Chapter Two, the
Scottish ISD-CEA data set, was again used here, and all the Scottish participants in
the ECST were identified distinguishing between trial patients (Scottish ECST-
surgical cohort) and non-trial patients (Scottish ISD-CEA non-ECST cohort). The
Scottish patients randomised to surgery in the ECST were extracted from the Scottish
ISD-CEA data set, creating a small sub-data set. The Scottish patients randomised to
surgery in the ECST were extracted from the ECST data set archived at the WGH,
creating another small sub-data set. These two small data sets were merged and an
independent data set consisting of two entries for the same patient was created with
observed outcomes obtained from two different sources. This data set was used to
test the second hypothesis relating to outcomes observed in a trial data set and a
routinely collected data set. A binomial variable was created to indicate whether
patients' data for analysis were obtained from routinely collected data or whether the
data came from the ECST data set.
Since it was not possible to distinguish between ipsi- and contra-lateral stroke events
in the routinely collected Scottish ISD-CEA data set, time-to-event analysis was
performed, using the time-to-death and time-to-stroke variables as defined in the
ECST. Clinical variables are not routinely collected in the ISD database, except for
the presenting diagnosis (up to six diagnostic fields) and operation codes (up to four
fields). Information on the degree of stenosis and the relation of the ischaemic event
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(ipsilateral or contralateral) to the stenotic artery is not available in the routinely
collected Scottish ISD-CEA data set. It was thus not possible to compare patients in
the two groups with different degrees of stenosis or to test hypotheses related to
specific outcomes for the two groups against the degree of stenosis operated on. Thus
all analyses performed did not distinguish between low, moderate or severe stenosis
as classified in the ECST data set. No assumptions were made on the severity of
stenosis in any of the comparisons between the Scottish ECST-surgical cohort and
the Scottish ISD-CEA non-ECST cohort. It was however possible to describe the
proportions of the different degrees of stenosis for the Scottish ECST-surgical cohort
using the ECST data set and to compare these proportions obtained for the Scottish
ECST cohort to the proportions of all the ECST patients. The rationale for this was
that all outcomes after CEA in the Scottish ISD-CEA data set were evaluated against
the results from the ECST on severe carotid stenosis. The proportions of stenosis
present in the Scottish ECST-surgical cohort might point to the stenosis-mix of the
different degrees of stenosis present in the patients being routinely operated on in
Scottish hospitals. For the purpose of this analysis, it was assumed that patients
operated on outside the trial could have had any degree of stenosis, but were most
likely to have stenosis of 70% or more and were also symptomatic.
5.2.4 Methods used to assess the cost-effectiveness ofthe procedure.
The cost measure: Cost difference between the sursical and medical cohort.
All episodes of care of the Scottish ECST participants identified in the ISD database
were used to determine the resource consequences for the Scottish surgical and
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medical cohorts in the ECST. The resource consequences referred only to in-patient
care and did not include resources consumed at an outpatient level. All episodes of
care from the date of randomisation for a five-year follow up period were included.
These episodes of care were obtained from ISD for both the Scottish-ECST surgical
and Scottish-ECST medical cohorts. It was assumed that best medical care included
the use of aspirin, treatment of hypertension, advice on stopping smoking and
treatment of other comorbidities for these patients. The cost of all medications
including aspirin was not separately assessed in estimating resource use.
In the first approach the cost difference in resources used between the Scottish-ECST
surgical and Scottish-ECST medical cohort was estimated by applying the results
from the CEA cost description study, reported in Chapter Four, to the CEA
procedure and to the length of hospital stay over the five-year follow-up period.
Because the carotid endarterectomy cost estimate from the prospective study reported
in chapter four was recent and similar to previous cost estimates from the United
Kingdom (Radestock, 1992, Smithies et al., 1997), this estimate was considered to be
the most appropriate available estimate and was used in these costing methods. The
length of hospital stay was calculated for each patient in both the Scottish-ECST
surgical and Scottish-ECST medical cohorts using routinely collected data. The cost
of CEA and cost of hospital stay for each patient over the five-year period were
estimated for the Scottish-ECST surgical cohort. The cost of hospital stay and of
CEA where performed for each patient in the Scottish-ECST medical cohort over the
five-year period were also estimated and the difference in cost between the two
cohorts was calculated.
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The second approach used the mean average cost for 50% of the NHS Trusts as
published in the National Schedule of Reference Costs for Elective In Patients (1998)
by the Department of Health for the Healthcare Resource Groups (HRGs) to estimate
the cost of all procedures and admissions over a five-year period for the 308 Scottish
patients randomised into the ECST.
Carotid endarterectomy and its associated costs were considered the main procedure
of interest. The corresponding HRG code for the procedure code (OPCS 3 or OPCS
4) of carotid endarterectomy was identified as Q05 (Extracranial or Upper Limb
Arterial Surgery) in the National Schedule of Reference Costs for Elective In¬
patients. The mean cost for this HRG was found to be £2298 with a minimum cost
of £1564 and a maximum cost of £3011. The mean cost of £2298 was applied to all
the CEA procedures performed in this cohort. The cost of £2298 was 38% less than
cost of £3716 obtained from the patient specific cost data in the CEA cost description
study. Where the CEA procedure was coded as an invalid or poorly coded diagnosis,
the HRG code was substituted with the more appropriate code of Q05 to estimate an
adjusted cost.
The National Schedule of Reference Costs does not include the HRG codes for
Invalid Primary Diagnosis or Invalid Dominant Procedures neither for Poorly Coded
Primary Diagnosis or Poorly Coded Dominant Procedures. These codes were
however used by ISD for the Scottish patients investigated. A pilot study by ISD
Scotland, assessing the cost of HRG codes specific for Scotland, based on the
National Schedule of Reference Costs, produced costs for both Invalid Primary and
Poorly Coded Primary Diagnosis. These mean average costs for both Invalid Primary
and Poorly Coded Primary Diagnosis were used in this study in conjunction with the
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published costs from the National Schedule of Reference Costs for In-Patients. The
mean average cost for an Invalid or Poorly Coded Dominant Procedure was however
not available. For the purpose of this study, the arithmetic mean cost of the Invalid
Primary and Poorly Coded Primary Diagnosis obtained in the pilot study in Scotland
was used as an approximation for mean costs for invalid or poorly coded procedures.
Data on ah other operations and procedures performed on these patients, as well as
other diagnoses for which these patients required a hospital admission during the five
years after CEA, were collected. The OPSC code for operations and procedures or
ICD9 code for diagnoses was linked to the appropriate HRG code and the mean cost
obtained in the National Schedule of Reference Costs. All costs reported, using the
HRG code as reference, are adjusted cost estimates.
The arithmetic mean cost of the Scottish-ECST surgical and Scottish-ECST medical
cohorts were calculated and the mean cost difference between the two cohorts was
obtained. All costs reported reflect 1998 prices as reference year.
The effectiveness measure: Life expectancy difference between the surgical and
medical cohort.
The outcome measure of clinical effectiveness of CEA defined as "stroke-free" life
expectancy and expressed as life-years gained was obtained from the final results of
the ECST and from published modelling studies. (Lavender et ah, 1998; Nussbaum
et ah, 1996; Matchar et ah, 1987) Life expectancy was expressed as life-years gained
and also as quality adjusted life-years (QALYs) where available. Using the published
final results obtained in the ECST (ECST Collaborative Group, 1998) life expectancy
for the surgical and medical cohort in the ECST, curtailed at five years, was
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determined by calculating the area under the survival curves to obtain the difference
between life-years gained in the two groups. (Gould et al., 1999; Personal
Communication: GD Murray, Professor: Medical Statistics, University of
Edinburgh). Life-years gained in this instance were not quality adjusted. The
findings from the published modelling study by Nussbaum and others who applied
the results from NASCET in their simulation models to estimate "stroke-free" life-
years and QALYs gained were used in all cost-effectiveness ratio calculations.
5.2.5 Defining the analyses
The choice of statistical methods was determined by the nature of the variables in the
data set as well as by the study objectives. Normal probability plots were used to
assess any departure from normality. All categorical variables were compared by
means of the chi-square test statistic. All p-values reported are two-sided.
Continuous variables include time to event variables and length of hospital stay.
Variables have been computed using the date of carotid endarterectomy procedure as
the date of entry into the study. Arithmetic means are reported for all costs with 95%
confidence intervals where appropriate. The inter-quartile ranges were defined as
Qq 25. Q0 75 All analyses were performed using SPSS version 7 and Microsoft Excel
version 5.
5.2.5.1 Time-to-event analyses
The null hypotheses tested were primarily concerned with time-to-event analyses.
Thus all analyses comparing "stroke-free" and overall survival in the Scottish ECST
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surgical cohort with a "real life" Scottish CEA population not in the trial (Scottish
ISD-CEA non-ECST cohort) were performed using Kaplan-Meier product limit
estimates of time to calculate years free from carotid stenosis related endpoints
("stroke-free" survival and death). "Real life" referred to everyday practice and
clinical situations encountered in the health care setting.
The log-rank statistic and the Breslow tests were used to compare the survival curves
obtained for the groups All analyses compared survival between patients in the
different ISD-CEA cohorts. These cohorts are defined as the Scottish ECST- surgical
cohort; the "real life" Scottish ISD-CEA non-ECST cohort and the age-sex-
operation-date matched control group (Scottish ISD-CEA non-ECST matched
cohort).
The statistical analysis performed on the ECST data was based on the intention-to-
treat principle. Although patients in the medical group who crossed over to surgical
treatment after randomisation could be identified in the ISD data set, only patients
randomised to surgery and having had a subsequent carotid endarterectomy after
randomisation were used to test the null hypotheses.
5.2.5.2 Economic evaluation
An incremental cost-effectiveness analysis was performed in which the net cost and
net effectiveness of the surgical intervention were compared with medical care and
expressed as a ratio. An incremental analysis refers to the difference in cost effect
observed between two alternatives. A cost-effectiveness ratio was calculated by
dividing the difference in the cost of care between the surgical and the medical
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groups of the Scottish-ECST cohort by the difference in effect ("stroke-free"
survival) between the surgery group and the medical group of patients from the
European Carotid Surgery Trial and modelling studies.
The difference in cost was calculated by subtracting the "total direct" cost incurred
by Scottish-ECST patients randomised to best medical care from the "total direct"
cost incurred by the Scottish-ECST patients randomised to carotid endarterectomy.
"Total direct" costs were defined as the cost incurred by every patient from the date
of randomisation and including the cost all subsequent episodes of care over the five-
year follow-up period.
The effectiveness measures, expressed as the difference in the "stroke-free" life-years
between the surgery and medical cohorts, and used in this study were obtained from
the final ECST results (ECST, 1998) and from the modelling study based on
NASCET results (Nussbaum et al., 1996). The number of life-years gained was used
as the denominator in the cost-effectiveness ratio calculations. The cost results used
in this analysis have been adjusted using the data from the CEA cost description
study reported in this thesis.
5.3 Results
5.3.1 Baseline characteristics of the studypopulations
A total of 308 patients were randomised into the ECST over the entire trial period in
four centres in Scotland. Of these 186 (60%) were randomised to surgical treatment
and 122 to best medical care. The 60:40 randomisation ratio for the Scottish-ECST
cohort was in keeping with the randomisation ratio in the ECST. This asymmetrical
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but unbiased allocation allowed slightly more extensive power to ascertain the
adverse effects of surgery (ECST Collaborative Group, 1991). Of the 186 surgical
patients, five patients crossed over to medical care after randomisation and 14
patients (7.5%) could not be identified through record linkage. A total of 172 patients
(92%) who were randomised to surgery in the ECST were identified, inclusive of the
five patients who crossed over to medical care. Of the 186 Scottish-ECST surgical
cohort, 167 were identified in the ISD-CEA data set to have had carotid surgery.
Two of the 167 carotid endarterectomy patients had a second carotid endarterectomy
performed shortly (within 30 days) after the initial carotid surgery for which the
patients were randomised (Table 5.1).
There were 122 patients from Scotland randomised to medical treatment (Scottish-
ECST medical cohort). Only one patient could not be identified using record linkage.
Fourteen of these medical patients crossed over to the surgery arm and were all
identified, with record linkage, in the ISD database as having had carotid surgery
over the entire study period. Five of these patients had carotid surgery within one
year from being randomised to medical care in the ECST, while the remaining nine
patients were operated on four years or longer after randomisation into the trial.
Seven patients had carotid surgery within five years from the date of randomisation.
These fourteen carotid endarterectomies were not included in the time to event
analysis of the 167 who were initially randomised to surgery (Table 5.1).
The baseline characteristics of the ECST patients in Scotland having CEA and the
matched control cohort having CEA in Scotland, but outside the trial, are described
in Table 5.2. The mean age for the Scottish-ECST surgical cohort was 61.1 years.
No departure from normality was observed for the age distribution for either the
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surgical cohort of Scottish participants in the ECST or for the matched control group
obtained from ISD data (p = 0.089) (Figure 5.1).
The degree of stenosis as reported from the angiogram results in the ECST for both
the Scottish-ECST surgical cohort and the surgical participants from all the other
centres are summarised in table 5.3. Of the 186 Scottish-ECST surgical patients 126
(68%) had severe stenosis recorded compared to 699 (43%) with severe stenosis
reported for the surgical patients from other centres in the ECST data set. The
differences observed for the low, moderate and severe stenosis categories between
the Scottish-ECST cohort and the ECST patients from the other participating centres
were statistically highly significant (p < 0.001).
Early stroke events and all-cause mortality within 30 days ofCEA .
Early stroke events within 30 days ofCEA (Table 5.4)
A total of 128 (4.4%) hospitalised cerebrovascular events of any kind (major or
minor stroke event) was observed during the 30 days after CEA for the Scottish ISD-
CEA cohort of 2892 patients. The baseline characteristics of the 2892 patients in the
Scottish ISD-CEA cohort were described in Chapter Two. Of these 128 hospitalised
cerebrovascular events, 117 (4.3%) occurred in the Scottish ISD-CEA non-ECST
cohort having CEA outside the trial and 11 (7%) stroke events occur in the 167
Scottish ECST-surgery cohort. The difference found was statistically not significant,
(p = 0.16) Only seven strokes were observed for the age-sex-date-of-operation
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matched control group, suggesting that cerebrovascular events in the trial patients
were more accurately recorded (p = 0.3).
Early all-cause mortality within 30 days ofCEA (Table 5.5).
Among the 2892 Scottish ISD-CEA patients who had a carotid endarterectomy
between 1981 - 1996, there were 66 (2.3%) deaths within the first 30 days after the
surgery, two of which were in the Scottish ECST-surgery cohort. Of the 66 deaths,
44 (67%) were stroke related deaths. Considering only the 167 Scottish patients
randomised to surgery in the ECST and identified in the ISD-CEA data set, two
deaths (1.3%), one stroke related, were observed during the first 30 days after
surgery. For the rest of the Scottish ISD-CEA non-ECST cohort, 64 deaths (2.4%)
were recorded of which four were stroke related. The differences observed between
these cohorts were not significant (p= 0.3). For the matched control group, five
deaths were reported during the 30-day period after CEA. Compared to the Scottish
ECST-surgery cohort, this difference was also not significant (p = 0.3).
Late stroke events and all-cause mortality within the five years after CEA.
Late stroke events within thefive years after CEA (Table 5.4).
In the Scottish ISD-CEA data set of 2892 a total 545 (18.8%) hospitalised
cerebrovascular events of any kind was observed during the five-year period after
CEA. For the Scottish ECST-surgery cohort 27(16%) stroke events were observed
compared to 518 (19%) stroke events for the Scottish ISD-CEA non-ECST cohort
The difference observed between the Scottish ECST-surgery cohort and the Scottish
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ISD-CEA non-ECST cohort was not significant (p = 0.36). For the matched control
group a total of 49 (29%) stroke events were observed during the five-year period
after a CEA. The differences observed between the Scottish ECST-surgery cohort
and the Scottish ISD-CEA non-ECST matched cohort was highly significant (p =
0.004). This finding should however be interpreted with caution since only a small
number of events were observed.
Late all-cause mortality within the five years after CEA (Table 5.5).
484 (16.7%) deaths were reported for the Scottish ISD-CEA cohort during the five
years after CEA was performed. Of these 38 deaths (22.8%) were in the 167 Scottish
ECST-surgery cohort, and 446 (16.4%) were in the rest of the Scottish ISD-CEA
non-ECST cohort. The difference observed reached statistical significance (p = 0.03).
For the matched control a total of 42 (25%) deaths was observed during the five-year
period after a CEA. Comparing these deaths with the deaths in the Scottish-ESCT-
surgery cohort identified in the ISD-CEA data set, the difference was not significant
(p = 0.7).
Resource use expressed as episodes ofcare (Scottish-ESCT cohort).
A total of 2436 episodes of care were recorded for both the patients in the Scottish-
ESCT surgical and medical cohorts for the entire period of follow-up from
randomisation. For the surgery group 1627 episodes of care were recorded for the
172 patients identified through record linkage and a total of 809 episodes for the 121
patients in the medical group. The total number of episodes for a five-year period of
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follow-up was 1525: 978 (64%) for the surgery group and 547 for the medical group
(Table 5.6). These episodes of hospital care were mainly in general surgery and
general medicine. With regards to general surgery the frequency for the surgery
group was 36% and for the medical group, 27%. For general medicine a frequency of
25% for the surgery group and 27% for the medical group was observed. The
episodes of care in Neurology were 6.9% and 8.6% for the surgery and medical
groups respectively and in the Intensive Therapy Unit (ITU). 4.5% for the surgery
group and 4.4% for the medical group. The remaining episodes of care were
associated with "other" specialities (28% for the surgery group and 34% for the
medical group) (Table 5.7).
The majority of the patients, 267 (93%) had between one and ten episodes of care
over the five-year period of follow-up. Sixteen patients had between 11 and 30
episodes of care and 14 of these 16 patients were in the surgery group. Ten patients
had more than 30 episodes of care. The differences observed regarding the episodes
of care between the surgery and medical groups were highly significant (p = 0.007).
Four patients (1.7%) had no record of any episodes of care after the date of
randomisation, two being randomised to surgery and two to medical care. Both of
these patients randomised to medical care died two years or more after the date of
randomisation. Of the two patients randomised to surgery, one crossed over to
medical care and died more than two years after randomisation and the other patient
died five months after randomisation to surgery. However this patient could not be
identified as having had surgery in the ISD-CEA data set, during the five-month
period after randomisation.
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Of these episodes of care, 33% were for cerebrovascular disease related diagnoses,
28% for cardiovascular related diseases and the remainder (39%) constituted a
variety of clinical conditions (Table 5.8). The diagnostic categories related to
cerebrovascular disease for the episodes of care were 35% for the surgery group and
29% for the medical group. For cardiovascular disease 30% of the episodes of care
was for the surgery group and 26% for the medical group. For other diagnostic codes
the episodes of care were 37% for the surgery group and 44% for the medical group.
The differences observed between the surgical and medical cohorts regarding the
admission type by ICD9 diagnosis code were statistically significant (p = 0.008).
5.3.2 Findings from hypotheses testing.
Of the total of 2892 CEA performed in Scotland between 1981 and 1996, 167
patients were identified in the ISD-CEA data set as being in the ECST (Scottish
ECST-surgery cohort) and 2725 were not operated on under trial conditions.
(Scottish ISD-CEA non-ECST cohort) Twenty-seven strokes (16.1%) and 38
(22.7%) deaths were recorded for the 167 patients in the Scottish ECST-surgery
cohort for a period of five years. For the Scottish ISD-CEA non-ECST cohort of
2725, 518 (19%) stroke events and 446(16.4%) death events were recorded.
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Theprimary null hypothesis.
i. Transferability of trial results. Comparing trial patients (Scottish ECST-surgery
cohort) and non-trialpatients (Scottish ISD-CEA non-ECST cohort).
The Kaplan-Meier survival estimates comparing the "stroke-free" survival between
the ISD-CEA non-ECST cohort and the Scottish ECST-surgery cohort reached
statistical significance with the Log-rank test statistic (p = 0.05). The Breslow test,
emphasising the early part of the curve, i.e. the period after surgery, was just outside
the conventional cut-off point for statistical significance with a p-value of 0.06
(Table 5.9 and Figure 5.2). The mean "stroke-free" survival for the Scottish ISD-
CEA non-ECST cohort was 4.2 years. (95% C.I. 4.09 - 4.23) The corresponding
mean "stroke-free" survival time for the Scottish ECST-surgery cohort was 4.4 years
(95% C.I. 4.2 - 4.6). The cumulative "stroke-free" survival for the Scottish ECST-
surgery cohort at five years after surgery was 84% and 77% for the Scottish ISD-
CEA non-ECST cohort (Table 5.9).
The Kaplan-Meier estimates obtained for the Scottish ISD-CEA non-ECST cohort
compared to the Scottish ECST-surgery cohort for death were not significant (Log-
rank p = 0.8 and Breslow p = 0.5) (Table 5.10 and Figure 5.3).
The mean survival time for the Scottish ECST-surgery cohort was 4.48 years (95%
C.I. 4.30 - 4.66) and for the Scottish ISD-CEA non-ECST cohort was 4.38 years
(95% C.I. 4.33 - 4.44). The cumulative survival from all causes of death at five years
for the Scottish ECST-surgery cohort and for the Scottish ISD-CEA non-ECST
cohort was remarkably similar: 76% for the Scottish ECST-surgery cohort and 75.8%
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for the Scottish ISD-CEA non-ECST cohort. The overall survival of Scottish ECST-
surgery cohort was however better than the survival of the Scottish ISD-CEA non-
ECST cohort throughout the observation period with a cumulative survival of the
Scottish ECST-surgery cohort of 86% and the Scottish ISD-CEA non-ECST cohort
of 83% at three and a halfyears after the carotid procedure. The curves however
came together at about four and stayed together thereafter (Table 5.10 and Figure
5.3).
ii. Scottish ECST patients and an ape-sex-and operation date matched control
ofScottish patients not in the trial (Scottish ISD-CEA non-ECSTmatched cohort).
The number of stroke events in the Scottish ISD-CEA non-ECST matched cohort
was 49 (29%) compared to 27 (16%) strokes observed in the Scottish ECST-surgical
cohort. A total of 34 (18%) stroke events were recorded for the 186 Scottish patients
randomised to surgery in the ECST data set. The mean "stroke-free" survival time for
the Scottish ISD-CEA non-ECST matched cohort was 3.9 years (95% C.I. 3.7 - 4.2)
and 4.4 years (95% C.I. 4.2 - 4.6) for the Scottish ECST-surgical cohort from the
ISD data set. The mean survival time for the Scottish-ECST surgical patients from
the ECST data set was 4.3 years (95% C.I. 4.0 - 4.5).
The cumulative "stroke-free" survival for the Scottish ISD-CEA non-ECST matched
cohort was 70%. The cumulative "stroke-free" survival for the for the Scottish ECST
cohort was 84% and 76% respectively using the ISD-CEA and ECST data set (Table
5.11 and Figure 5.4).
The "stroke-free" survival at 30 days after CEA for the Scottish ISD-CEA non-ECST
matched cohort, for the Scottish ISD-CEA ECST cohort and for the Scottish-ECST
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surgical cohort using ECST data set was almost identical with the cumulative
"stroke-free" survival at 96%, 93% and 95% for the respective cohorts. There were
only six strokes recorded for the Scottish ISD-CEA non-ECST matched cohort,
eleven for the Scottish-ECST surgical cohort using the ISD-CEA data set and ten for
the Scottish-ECST surgical cohort using the trial data set.
The fewer number of strokes reported for the matched cohort suggested an
underestimation in the identification of stroke events in non-trial patients. The
number of strokes observed in each of these cohorts was too small to report on the
significance of these differences observed (Figure 5.5).
The difference between "stroke-free" survival at five years for the Scottish ISD-CEA
non-ECST matched cohort, compared to the Scottish-ECST surgical cohort using the
ISD-CEA data set and the Scottish-ECST surgical cohort from the trial data set was
highly significant (Log-rank p = 0.005). The difference observed between "stroke-
free" survival during the early part of the survival curve (i.e. during the 30 days after
the procedure) was significant with the Breslow test statistic (p = 0.006). This
significant difference was observed between the matched controlled group and the
ECST participants regardless whether data used in the analysis was obtained from the
routinely collected data set or from the trial data set.
Among the Scottish ISD-CEA non-ECST matched cohort, 46 (27.5%) death events
were observed in the 167 patients. The number of deaths observed in the 167 patients
from the Scottish-ECST surgical cohort was very similar at 38 (22.8%) deaths. The
mean survival time for all cause mortality was slightly shorter for the matched
control group at 4.3 years (95% C.I. 4.1 - 4.5) compared to the mean survival time of
4.5 years (95% C.I. 4.3 - 4.6) for the Scottish-ECST surgical cohort irrespective
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whether the data were obtained from the routinely collected data set or the trial data
set. These differences observed were not statistically significant (Log-rank p = 0.8,
Breslow p = 0.7) (Table 5.12 and Figure 5.6).
5.3.3. Resource use estimation using CEA cost description results.
Resource use is reported for the year in which the patient was randomised and for
another four years after the year of randomisation, to estimate resource use over a
total period of five years. The median follow-up time for the entire Scottish-ECST
cohort was 5.7 years with a mean follow-up of 5.6 years and 1589 years of patient
observation. The median follow-up time was 5.2 years for the surgical cohort and 5.9
for the medical cohort. The corresponding mean follow-up time was 5.3 and 5.9
respectively.
Resource use in terms of bed days occupied could be estimated for 293 of the 308
Scottish patients randomised into the ECST. Of the 186 patients randomised to
surgery, information on health care utilisation based on episodes of care in a hospital,
could be determined for 172 patients including the five patients who crossed over to
surgery. For the 122 patients randomised to medical care only one patient could not
be identified to describe resource use after randomisation.
The total number of bed days used by 293 patients of the Scottish-ECST cohort
during the year of randomisation was 3568 days with a mean number of 12.2 bed
days. The total number of bed days used by the 172 Scottish ECST-surgical patients
was 2628 with mean bed day occupancy of 15.3 days per patient during the year of
randomisation (Table 5.13). A total of 169 Carotid endarterectomies were performed
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during the year of randomisation among the 167 patients identified in the ISD-CEA
data set as being randomised to surgery. Two patients had a second CEA within one
month of the first procedure. For the 122 randomised to medical care in the ECST,
121 patients had recorded hospital admissions with a total of 940 bed days used, or
7.8 bed days per patient during the year of randomisation. (Table 5.13) Five Carotid
endarterectomies were performed in the Scottish ECST medical cohort during the
year of randomisation and a further two, four years after randomisation. A mean cost
of £3716 per CEA was used to estimate the cost of the carotid surgery in the
Scottish-ECST cohort and a mean cost of £300 per bed day was used in estimating
resource use associated with bed occupancy
The total mean cost for the 293 Scottish-ECST patients, surgical and medical, from
the date of randomisation for a five year follow-up period was £13 008 with a median
cost of £7316 (IQR 4363 - 12 416). For the surgery group the total mean cost
estimated was £ 14 751 (median £9416; IQR 6716 - 15 611) and for the medical
group the total mean cost was £10 534 (median 3896; IQR 1196 - 7856). The cost
distribution for the Scottish-ECST cohort was not normal (Table 5.14 and Figure
5.7). The cost distribution for the Scottish-ECST surgical cohort based on the CEA
cost description results also did not exhibit a normal distribution as it was highly
skewed to the left (Normal probability plots and Kolmogorov-Smirnov with Liffifors
correction: p = 0.001) (Figure 5.8).
The total mean cost per year based on the CEA cost description results over the five-
year follow-up period investigated was the highest (£4934) during the third year after
randomisation for the Scottish-ECST medical cohort. High bed occupancy (72 bed
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days per patient) for this group contributed to the cost. This high mean cost observed
for the medical group during the third year after randomisation was not analysed in
terms of speciality utilisation. The corresponding mean cost for the surgical group
during the third year was £2505, a difference of 49%. The lowest mean cost per year
was seen during the fourth year after randomisation for both the Scottish-ECST
medical and surgical cohorts with a mean cost of £541 for the medical group
compared with a mean cost of £635 for the surgical group, a cost difference of 15%
(Table 5.15 and Figure 5.9 and 5.10).
5.3.4 Resource use estimation using HRG reference costs.
Of the 186 patients in the Scottish-ECST surgical cohort, 172 patients were identified
including the five patients who crossed over to medical care. Of the 172 identified,
only 166 (97%) had an OPCS code that could be linked to a HRG reference code. Of
the 166, only 58 (35%) were linked to the appropriate HRG reference code (Q05).
Fifty-seven of the 58 carotid procedures were all coded correctly using the OPCS 4
classification, which came into effect after 1988 and one was coded incorrectly using
a wrong OPCS 3 code, but an appropriate HRG code. Ninety-five carotid procedures
had the correct OPCS 3 code, but displayed an inappropriate HRG reference code,
the majority, 93 (95%) being coded as an invalid dominant procedure, for which an
associated cost is not published. Eight patients were coded with an OPCS 3 code not
associated with the appropriate OPCS 3 code for carotid endarterectomy, and a
corresponding HRG code of invalid primary diagnosis. Two patients who had CEA
coded with the correct OPCS 3 code, had a HRG reference code associated with
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admission for a transient ischaemic attack. Five patients had inappropriate OPSC
codes as well as HRG reference codes. For ten of the patients, who had a CEA, the
OPCS code was missing and the associated HRG code was also incorrect. Invalid
primary diagnosis could be linked to seven cases, invalid dominant procedure to two,
and one case was coded as a poorly coded primary diagnosis (Table 5.16).
A mean adjusted cost of £7832 was estimated for this cohort of 293 patients using
HRG reference costs over a five-year period from the date of randomisation (median
6463; IQR 4221 - 10 419). The mean cost estimated for the surgical cohort of 172
patients was £9128 (median 7832; IQR 5018 - 11 942) and for the medical cohort
was £5997 (median 4935; IQR 3176 - 7601) (Table 5.17 andFigure 5.11).
Using the total mean cost based on the HRG reference costs, the mean cost per year
for the surgery group was higher for each of the five years investigated, with this
difference most pronounced during the year of randomisation. The mean cost of the
surgical group for the first year was £4088 compared to £1584 for the medical group,
a cost difference of 61% (Table 5.18 and Figure 5.12).
The cost associated with the HRG for CEA (Q05) is substantially lower (£2298) than
the cost estimate obtained in the CEA cost description study. It was expected that the
overall resource use based on the national reference cost estimates would be less than
the resource cost based on bed days since the cost estimates for HRGs utilise
episodes of care as reference instead of bed days. The percentage cost difference
between the surgical and medical cohorts based on the CEA cost description study
was 29% compared to 36% when HRG reference costs were used.
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5.3.5 Stroke-free life expectancy.
Stroke-free life expectancy curtailed at five years calculated from the final results of
the ECST was 4.55 life years in the surgery group compared to 3.94 life-years in the
medical group. The difference in stroke-free life expectancy was 0.61 life-years or
7.2 months.
In the modelling study by Nussbaum and others the number of "stroke-free" life-
years among patients who received aspirin after TIAs was estimated to be 7.26 years
compared with 7.63 years after CEA-NASCET (Nussbaum et ah, 1996). A
difference of 0.37 life-years (4.4 months) in "stroke-free" life-years for these two
cohorts was calculated. Quality-adjusted life expectancy was estimated to be 6.25
with aspirin and 7.18 years after CEA-NASCET resulting in a difference of 0.93
quality-adjusted life-years (QALYs) gained or 11 months ofquality adjusted life.
Calculating a cost-effectiveness ratio (Table 5.19).
The cost-effectiveness ratio is expressed as cost per life year gained and cost per
stroke prevented.
Cost description study results and stroke-free life expectancyfrom ECST.
Applying the results from the CEA cost description study a mean cost of £14 746
was estimated for Scottish-ECST surgical cohort and a mean cost of £10 534 for the
Scottish-ECST medical cohort. The cost difference of £4212 between these two
groups divided by the difference in life years gained (0.61) from ECST resulted in a
cost-effectiveness ratio of £6905 per life year gained or £62 144 per stroke prevented.
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Cost description study results andpublished stroke-free life expectancy from the
literature.
A cost-effectiveness ratio of £11 384 per life year gained was calculated by dividing
the difference in cost (£4212) by the difference in life-years gained (0.37) between
these cohorts. In terms of stroke prevention however, this ratio increased to £102 454
per stroke prevented, the most expensive alternative. Substituting the QALYs
difference of (0.93) in the equation thus dividing the cost difference of £4212 by
0.93, a cost-effectiveness ratio of £4529 per life year gained and £40 761 per stroke
prevented was calculated.
HRG results and stroke-free life expectancy from ECST.
The cost difference (£3330) based on the HRGs divided by the difference in stroke-
free life expectancy (0.61) as calculated from the ECST findings, resulted in a cost-
effectiveness ratio of £5459 per life year gained or £49 131 per stroke prevented.
HRG results andpublished stroke-free life expectancy from the literature.
Using the cost difference (£3330) between the Scottish-ECST surgical and medical
cohorts based on the National Reference Cost schedule and divided by the published
stroke-free life expectancy difference (0.37) a ratio of £9000 per life-year gained was
calculated or £81 000 to prevent one stroke of any type.
Using the QALYs difference of 0.93 to calculate a cost-effectiveness ratio based on
the cost difference (£3330) obtained from the National Reference Schedule of In-
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Patient costs, the cost-effectiveness ratio decreased to £3581 per life year gained and
the cost to prevent one stroke to £32 226 the most favourable scenario.
By increasing the cost difference (CEA cost description study results) between the
surgical and medical cohorts by 20% to £5054 but keeping the number of life-years
gained constant (0.37), the cost-effectiveness ratio increased to £13 661 per life-year
gained and to £122 945 per stroke prevented. Increasing the number of "stroke-free"
life years gained by carotid surgery to 12 months will result in a relative favourable
cost-effectiveness ratio of £4212 (£3330) per life year gained and £37 908 (£29 970)
per stroke prevented (National Reference costs figures in brackets).
A sensitivity analysis on the cost-effectiveness ratio and the cost-effectiveness in
terms of strokes prevented was also performed by using the ranges of the estimated
change in total major stroke-free life expectancy in months, published in the final
results of the ECST, and the cost differences between surgical and medical cohorts
from the CEA cost description study and the HRG reference costs (Table 5.20 and
5.21). The most favourable ratio obtained in terms of stroke prevention was £22 836
per unadjusted life-year gained when the "stroke-free" life expectancy gained by
CEA was 20 months or 1.66 years. The worst ratio was £114 873 per unadjusted life-
year gained when the "stroke-free" life expectancy gained by CEA was only 4
months or 0.33 years.
5.4 Discussion
This study found that the trial results from the ECST were not transferable to Scottish
CEA patients who were operated on during the same period as the trial and that
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carotid endarterectomy was very expensive in terms of life years gained or the
number of strokes prevented if the benefit in clinical effectiveness of the procedure
was very small.
This study rejected the primary null hypothesis that there is no difference between
the five-year "stroke-free" survival of all Scottish patients undergoing a carotid
endarterectomy outside the ECST compared with the Scottish patients who were
randomised to surgery in the ECST during the period 1981 - 1994. The alternative
hypothesis of a difference in the five-year "stroke-free" survival between trial
patients and non-trial patients should therefore be accepted.
The null hypothesis should also be rejected for the cohort of surgical patients
matched for age, sex and date of operation to the ECST patients and for the two
patient cohorts using a trial data set, the ECST data and a routinely collected data
source, the ISD data.
The findings of this study however indicated that the null hypothesis of no difference
in the five-year overall survival between trial patients and non-trial patients should
be accepted whether a matched control cohort or all Scottish-CEA non-trial patients
are considered regardless of data source used, since the cumulative survival in the
three groups (all Scottish ISD-CEA non-trial patients, Scottish ISD-CEA matched
control patients and Scottish-ECST CEA patients) was very similar. This finding was
not surprising and was expected, since all deaths are registered at the General
Register Office for Scotland.
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The second objective of this study was to assess the cost-effectiveness of carotid
endarterectomy in stroke prevention. We found that carotid endarterectomy was very
expensive in terms of life years gained or the number of strokes prevented if the
benefit in clinical effectiveness of the procedure was very small. The relative cost-
effectiveness of carotid endarterectomy was stronger associated with the benefit of
"stroke-free" survival obtained from carotid surgery than with the cost difference
between alternative treatments.
Transferability oftrial results to the "general" population - the null hypotheses.
The absence of clinical variables in routinely collected data raises questions whether
the benefits of carotid endarterectomy in the general population are similar to those
reported in clinical trials. Although it is generally assumed that the overall results of
clinical trials are generalisable to all patients in the trial and all future similar
patients, this assumption has rarely been tested.
Hallett and others (1998) compared the results from NASCET to a geographically
defined population and found that the early outcomes were similar to the trial results
and also documented the remarkable long-term benefit of CEA. However, the
population studied was small (about 100 000) and only 322 carotid endarterectomies
were performed over 25 years (1970 - 1995) which reduces the generalisability of
their findings. Similar findings were also reported from the Netherlands, though the
study periods before and after publication of the trial results were relatively short, in
both instances only two years (Dijkema et ah, 1998).
Carotid endarterectomy before and after the publication of the randomised controlled
trials was also investigated by Brittenden et al (1999) in Scotland. A fourfold
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increase was observed in the number of carotid endarterectomies since 1991 and
despite an increasing proportion of high-risk patients among those receiving the
operation, the results have improved progressively. These findings applied however
only to one unit in Scotland and were not representative of the overall situation in
Scotland.
Reanalysing the results of the ECST by using independently derived and validated
prognostic models, it was found that the relative treatment effect varied with the
absolute baseline risk of stroke (Rothwell et al., 1996). This suggests that the overall
results of the ECST can not be generalised to all symptomatic patients with severe
stenosis because of the potential bias in the data and the potential lack of
comparability of cases and controls.
The two large RCTs (ECST, 1991; NASCET, 1991) have shown the efficacy of this
procedure in certain subgroups of patients, but several caveats apply when these
results are extrapolated to patients in the general population with symptoms related to
carotid disease. The surgeons participating in these trials were selected for their high
level of expertise and excellent track records. Secondly, the results from the RCT
might not apply depending on the methods use to measure the stenosis. Also the
measurement of stenosis by means other than angiography might not be transferable
and thirdly, baseline risk factors appear to have an important effect on peri-operative
and long-term outcomes of CEA (Barnett et al., 1998). Although it can be assumed
that patients not associated with the trial might have been operated on by different
surgeons, it seems unlikely to have been the case in Scotland, since Scotland is a
geographically contained area with probably a limited number of vascular surgeons
performing this operation.
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Trials frequently relate to cohorts of heterogeneous patients for whom costs and
outcomes vary. The benefit from an intervention expressed as the absolute or relative
risk reduction does not refer to outcomes in terms of life expectancy nor does it
attach a cost to the benefit obtained.
A study published by the Rand Corporation in the United States inl988 showed that
32 percent of CEA performed in the United States in Medicare recipients were
performed for inappropriate indications (Winslow et al., 1988). Re-assessing their
findings in the context of the published RCTs, none of the data from these trials
suggested that any of those operations should now be considered appropriate.
Hlatky et al (1984) applied the eligibility criteria of three large randomised controlled
trials of coronary bypass surgery to a selected patient population and found that only
4 - 13% of the patients met the eligibility criteria for these trials (European Coronary
Surgery Group, 1979; Murphy et ah, 1977; CASS principal investigators and their
associates, 1983). This suggested that the results of these RCTs apply only to a
small proportion of patients "and it is uncertain whether one can extrapolate from the
results in a highly selected subgroup to the general population of patients" (Hlatky et
ah, 1984). These concerns might also hold true for the transient ischaemic attack
patient population.
An increase in the number of carotid endarterectomies has been reported after the
publication of both the ECST and the NASCET. Tu and others assessed whether
patients who had CEA in the early 1990s were selectively referred to regional centres
of excellence (high-volume hospitals with low peri-mortality rates) as recommended
by NASCET collaborators and whether the increase in the rates of CEA after the
publication of NASCET occurred in these centres and found that the publication of
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new scientific evidence did not change surgeons and physicians pattern of service
(Tu et ah, 1998).
Although the findings obtained in my study suggested that the five-year "stroke-free"
survival of all Scottish CEA patients who were not in the ECST were less favourable
than the "stroke-free" survival of the Scottish CEA patients in the ECST,
inconsistencies were noted. Comparing the matched control cohort with the Scottish-
ECST cohort, using routinely collected data as source, the five-year "stroke-free"
survival of the trial patients appeared "better", as was expected. When the five-year
"stroke-free" survival of the Scottish-ECST surgical cohort was compared using data
from the trial data set and data from the routinely collected data set, the difference
observed in the five-year "stroke-free" survival favoured the routinely collected data
source.
Possible explanations for these findings are put forward: The "better" five-year
"stroke-free" survival obtained for the Scottish-ECST surgical cohort when routinely
collected data were used compared to trial data, suggested that "all stroke events"
were probably not recorded in the routine data set (Underreporting of stroke events).
This highlight a general concern regarding the accuracy of routinely collected data
and the potential source ofbias when routinely collected data are investigated.
Assessing the Scottish-ECST surgical cohort and the matched control cohort using
the routinely collected ISD data set, the five-year "stroke-free" survival of the trial
patients (83.7%) was much more favourable compared to the matched control cohort
(70%). This again indicated another source of bias associated with the case-mix and
pre-existing comorbidities in these two cohorts, since matching could only be done
on the very basic variables such as age, sex and operation date.
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Limited clinical variables in routinely collected data sets
In addition to the lack of accuracy associated with routinely collected data, which
will be discussed later on, another constraint encountered using the data from a
routinely collected data set, was the absence of clinical variables in the data set. The
lack of clinical variables hampered any detailed analysis comparing subjects in trial
data for whom these variables were recorded with subjects in a routinely collected
database where these variables were absent. It is therefore highly likely that those
who were not selected for the trial were by definition different. Analyses were thus
much curtailed and concentrated on basic variables such as age, sex, death, and
hospitalised stroke events. With regards to stroke events, the data available in the
Scottish ISD-CEA data set do not distinguish between a minor or major stroke event
using the Rankin classification. All stroke events and transient ischaemic events were
thus defined as "stroke events", grouped together regardless of severity and analysed
as such. This obviously contributed to almost "crude" findings and not as refined, as
one would have hoped for.
Clinical variables indicating the degree of stenosis and existing comorbidities would
have allowed a much more precise matching. The absence of these variables
restricted more definitive comparison between patients in a trial and non-trial
patients. Similar concerns were expressed by Tu et al in assessing CEA over time in
the United States and Canada. It is also possible that the patients operated on outside
the ECST might have been operated on by surgeons who did not have the same skills
and expertise as those surgeons participating in the trials.
The five-year "stroke-free" survival results obtained in this study also suggested that
the results from randomised clinical trials can not be transferred to "other"
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populations and other settings without being conscious of the disparity between a
trial population and the general population.
The main limitation in the study population(s) used to compare the trial results with
is found in the data source investigated, namely routinely collected data. Although
these data sources provide large numbers at relatively low costs, accuracy and
completeness of the data remain a big problem. The absence of clinical variables in
routinely collected data sets further restricted the comparisons and influenced the
validity of the results obtained.
Randomised controlled trials also have certain constraints. Though trials usually
relate to cohorts of heterogeneous patients, strict entry criteria into a trial will
certainly exclude patients with associated comorbidities who might be at a higher
risk of an intervention. Furthermore, the inclusion criteria applicable in these trials
might "exclude" many patients outside of trial situations and these criteria might not
always be adhered to in "real-life" practice.
Randomisation usinz the uncertainty principle.
Eligibility into the ECST was determined mainly by the uncertainty principle
whereby patients were only randomised to surgical or best medical care when the
doctor was "uncertain" which treatment to recommend. Although randomisation
based on the uncertainty principle maximises the heterogeneity of the study and also
avoids ethical problems, this selection method dilutes the assumption adhered to in
this study that patients operated on outside trial conditions were similar and thus
comparable with those having carotid surgery in the trial. It was assumed that
patients who were operated on outside trial conditions, in "real life", in the Scottish
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ISD-CEA data set were patients where the doctor/surgeon was "reasonably certain"
that surgery would benefit the patient.
The cost of surgical and medical care for the Scottish-ECST cohort - the cost
measure.
Although it was possible to obtain a crude estimate on the cost difference of a cohort
of patients treated with CEA compared to a cohort receiving best medical care using
results from RCTs, estimating the cost of treatment in everyday practice populations
remains difficult. Routinely collected data from this historic Scottish-ECST cohort
were used to determine the cost of CEA. The use of resources was only reported for
five years since randomisation. Many assumptions were needed, which obviously
increased the potential for bias. The cost data on carotid endarterectomy during the
1980s and early 1990s were not available when the majority of these procedures in
the trial were performed. Cost specific data as obtained in the current CEA cost
description study as well as costs based on the HRG were used to estimate the "total
direct" cost of the procedure and costs associated with other admissions.
Although resource use of the activity in Scottish hospitals is classified using HRG-
codes in the ISD national database, a Scottish national reference cost for these HRG-
codes was not available. A pilot exercise was performed a few years ago to develop
national reference costs for the HRG-codes in the NHS in Scotland. This was
however not complete and in the absence of a Scottish National Cost Reference the
English National Cost Reference, generated and produced by the National Case Mix
Office in England, was used to estimate resource use for the Scottish-ECST cohort.
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Two methods were used to estimate resource use for a cohort of patients treated
either surgically or medically. In the first method, bed days were used as a proxy for
cost of all diagnoses and procedures other than the CEA procedure cost that was
obtained from the prospective study. Although the use of bed days as a proxy for cost
is considered a crude and unrefined approach it appears from the results obtained in
this study that it might still be a better approximation of actual resource use than
HRGs.
Ninety-eight (59%) of patients who had a CEA had a HRG reference code defined as
an Invalid Primary Procedure, for which no reference cost is currently published. Ten
patients displayed HRG reference codes associated with a primary diagnosis, which
it is considered to substantially underestimate of the cost of the procedure.
Using these reference costs to obtain an estimate of resource use of the surgical
Scottish-ECST cohort it was apparent that this would result in an underestimation of
resource use, simply because more than half of the CEA had no cost associated with
the procedure and in 6% of cases the cost for the procedure was lower than the
appropriate reference cost. To arrive at a reasonable estimate for the resource use of
the Scottish-ECST cohort when applying the HRG reference cost estimates, it was
considered appropriate to apply the cost of a CEA to all cases where the procedure
was incorrectly coded. And secondly, to apply the arithmetic mean cost of the
Invalid Primary Diagnosis and Poorly Coded Primary Diagnosis to the HRGs coded
as Invalid Dominant Procedures for which a reference cost was not published.
Consequently all reported costs using the HRGs as reference were adjusted to
ameliorate to some extent the effect of underestimation of resources used.
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In the second approach the results from the CEA cost description study were applied
to the Scottish-ECST cohort. Since the cost of CEA estimated in two previous
studies in the UK (Radestock 1992; Smithies et al., 1997) was similar to the results
from the CEA cost description study, it seems appropriate and realistic to use the
recent CEA cost estimate. Furthermore the estimation of resource use based on
HRGs from the National Schedule of Reference Cost produced a much lower
estimate, suggesting that the classification of procedures or diagnoses, which are
considered to utilise similar resources quantities, might in fact represent an
underestimation of the actual amount of resources used. Though the difference
between the mean costs was not "significant", it might influence the outcome when
used in subsequent calculations to determine incremental cost-effectiveness ratios.
Applying these low estimates in equations to assess the cost-effectiveness of
procedures might suggest that a procedure is within the acceptable ranges for cost-
effectiveness of interventions and thus "affordable" when it is not necessarily true.
The conversion of operations, diagnoses and patients characteristics into Diagnosis-
Related Groupings (DRG) or HRGs for use in clinical budgeting has been identified
as a potential source of error. The appropriateness of such groupings for use in
clinical budgeting has been questioned (Sanderson et al, 1989). This study
demonstrated that only 34% of OPCS codes were correctly linked to the appropriate
HRG reference code. It needs to be mentioned, however, that the low accuracy
obtained was essentially associated with the OPCS 3, which are no longer in use. It is
also acknowledged that the accuracy achieved using the OPCS 4 classification was
almost a 100% (57/58), which might suggest that more accurate estimations in the
future might be obtained using these groupings.
Chapter Five: CEA, RCTs and cost -effectiveness
Errors in diagnosis-related groupings (DRG) were found in approximately 24% of
joint replacements in three general hospitals in Leicester. These procedures like CEA
and other surgical procedures are assumed to be relatively "easy" to code. Most of
these errors occurred with the OPCS coding at local hospitals. OPCS codes are
converted to HRGs or DRGs, which is converted to the National Reference Cost
(Smith et al., 1991). The findings in the present study regarding the OPCS coding
errors reflected what was found by Smith and others and might explain the lower cost
estimates obtained when the HRG reference costs were applied to the patients in the
Scottish-ECST cohort. The need to use two sources to estimate resource use,
increased the potential for error, indicated that an accurate and reliable source to
estimate resource use is not available at present and that existing sources have many
inaccuracies and biases.
To quantify the resource use associated with two alternative therapies with proven
efficacy in managing TIAs (CEA and best medical care), the cost of all in-patient
admissions for Scottish-ECST surgical and medical cohorts was evaluated and
expressed as a cost-effectiveness ratio.
It could be argued that subsequent admissions after randomisation into the ECST
could have been totally unrelated to any subsequent ischaemic event and therefore
inappropriate to be used in estimating resource use. However, data on all subsequent
admissions were collected for both the surgical and medical cohort to estimate
resource use after randomisation into the ECST thus reducing any degree of the bias,
which might occur. The resource use was not specifically designed to capture only
stroke-related events, but to estimate health care resource use over time of a selected
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group of patients who presented with similar clinical symptoms, but were managed
differently.
Routinely collected data: Accuracy and completeness.
In performing a sensitivity analysis using the number of Scottish participants in the
ECST as the reference or "gold" standard, a sensitivity of 95% (293/308) was
calculated of identifying Scottish- ECST participants in a routinely collected data set.
Considering only the 186 patients randomised to surgical treatment in the ECST the
sensitivity decreased slightly to 92% (172/186). Though the percentage of the
Scottish-ECST surgical patients eventually identified in the routinely collected
database is higher than the 90% reported previously for routinely collected data
(Harley and Jones, 1996), this relatively high percentage was only attainable because
accurate patient information was available from the ECST data set. Achieving this
high identification required many consultations with ISD to identify "missing"
patients in the ISD-CEA who we knew had had carotid surgery, but were not
identified during the first linkage.
It is thus a matter of concern that the capturing of surgical procedures did not
perform better and might be as low as 83% (155/186) as was found with the first
linkage of Scottish-ECST surgery patients. This suggested that a substantial amount
of patient information might be lost when routinely collected data are collated.
Though this study did not set out to determine the accuracy of routinely collected
data sources, it is evident that a percentage as high as 90% or even 99% as reported
recently (Ellis et al., 1999) might be an overestimation of the accuracy of routine data
from ISD and might only be attainable under special circumstances.
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The benefit associated with this procedure - the clinical effectiveness measure.
The interim results on moderate carotid stenosis published during 1996 showed that
the stroke-free life expectancy was shorter in surgery patients than in the non-surgery
control groups in patients with moderate stenosis (ECST, 1996). The "stroke-free"
life expectancy between surgery and control groups was not published in the final
results of the ECST. By calculating the areas under the survival curves this could be
calculated and applied in the cost-effectiveness ratio equation.
The final results however suggested that carotid endarterectomy is indicated for most
patients with a recent non-disabling carotid-territory ischaemic event when the
stenosis is greater than about 80% and that men probably derive more benefit from
the procedure than women. A Cox proportional hazards model was used to predict
the differences in total major-stroke-free life expectancy between surgery and control
groups and is presented as a function of age and of stenosis, and by sex. It is
proposed that these prediction models should be used in clinical decision making
whether to offer surgery to a particular patient or not. From these graphs it is clear
that men derive more benefit from surgery than women, that there was an increased
benefit with increasing severity of stenosis and that younger patients displayed
distinct benefit over a narrower range of severe stenosis than was the case for older
patients. While this model assists in clinical decision making for the individual
patient, it does however not translate easily into the overall benefit in terms of stroke-
free life years gained for a cohort of CEA patients. These estimated ranges were
however applied in a sensitivity analysis to determine the most favourable cost-
effectiveness ratio in terms of stroke prevention for a CEA "population".
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The absolute risk reduction for major stroke or death reported in the ECST was
11.6%, or expressed as the number needed to treat this suggests that nine carotid
endarterectomies need to be performed to prevent one stroke of any type. Analysing
the percentage without any disabling or fatal stroke using Kaplan-Meier estimates, it
appears that 20 carotid endarterectomies might cause one death or disabling stroke,
while preventing two, though the confidence limits on this net benefit were wide.
Considering the prediction of benefit from carotid endarterectomy in individual
patients using a risk modelling approach, it is suggested that a 100 CEA need to be
performed when a relatively low risk score is present (Rothwell et al., 1999). In the
case of a high risk score it is suggested that only three CEA need to be performed to
prevent one stroke and when not stratified by risk factors, 14 CEA need to be
performed to prevent one stroke. This model used the baseline characteristics of the
ECST to predict which patients might benefit the most from carotid endarterectomy.
The primary objective of the RCT is to evaluate the efficacy in strictly defined
populations. It is not designed to predict the clinical course in individual patients, nor
is the best therapy for patients not meeting RCT eligibility criteria well defined.
Using baseline characteristics of a highly selected patient population to predict risk in
every day clinical practice might therefore be inappropriate (Hlatky et al., 1984).
Risk modelling prediction might be more suitable when baseline characteristics of
patients from an observational database are used instead. Obviously these extreme
numbers needed to treat found by risk modelling will have extensive implications on
the cost-effectiveness of this procedure. Using the NNT of three might also exclude
patients who might benefit from the procedure which will increase cost over time as
more stroke patients would have to be cared for.
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Interpretation ofthe cost-effectiveness ratio calculated.
It is imperative that in settings of limited health care resources those available should
be allocated in such a manner as to maximise the health benefit per pound spent. An
accurate assessment of the cost-effectiveness of a particular intervention requires
knowledge of the cost of the intervention, the cost of the alternatives and the effects
of the various interventions on the life-years gained. In assessing the cost-
effectiveness of CEA in terms of stroke prevention, the cost of stroke needless to say
is closely associated with this assessment.
Comparisons between health care interventions in terms of their relative cost-
effectiveness, in cost per life-year or cost per quality-adjusted life-year gained, have
become increasingly popular during recent years. Williams, as far back as 1983
published the first "league table" of cost-effectiveness for the United Kingdom.
Similar tables were published in North America by Torrance and Zipurski (1984) and
Schulman et al (1991) and in Canada, Laupacis and others (1992) classified health
technologies into five grades of recommendation based on their incremental cost per
QALY.
The two main motivations for league tables are that investigators or analysts can
assess their findings in a broader context and also can compare estimates of the cost
per life-year gained with other interventions. The exact limits of acceptable cost-
effectiveness are controversial. Laupacis et al classified interventions, which cost less
than $50 000, or less per QALY as generally acceptable, interventions between
$50 000 and $100 000 per QALY as borderline and interventions more than
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$100 000 per QALY as not cost-effective. Goldman et al and Kupersmith and co¬
workers however developed different cost-effectiveness categories. Interventions
which cost less than $20 000 per QALY or years of life saved are regarded as highly
cost-effective; interventions less the $40 000 as effective; $40 000 to $60 000 as
expensive and interventions more than $100 000 as very expensive (Goldman et al.,
1992; Kupersmith et al., 1995). As an alternative to these proposed classifications,
league tables of cost-effectiveness can be used to assess the cost-effectiveness
interventions. For example antihypertensive treatment to prevent stroke costs
£940/QALY; coronary artery bypass graft surgery (one vessel, moderate angina)
costs £18 830/QALY and neurosurgical intervention for malignant intracranial
tumours costs £107 780. All the costs are in pound sterling and reflect 1990 prices
(Maynard, 1991; Drummond et al., 1997).
Considering these controversies and discrepancies in these proposed classifications
of cost-effectiveness and the criticism directed against the use of cost-effectiveness
league tables specifically regarding the use of these tables for the allocation of health
care resources, the cost effectiveness of CEA was only crudely assessed in an
unrefined manner (Drummond, 1997; Mason et al., 1993).
The sensitivity analysis using estimated ranges of "stroke-free" life expectancy from
the ESCT final results, suggested that with an increase in "stroke-free" life
expectancy, the cost effectiveness ratio decreased substantially and the cost incurred
per stroke prevented put this intervention within the "acceptable published limits" of
cost-effectiveness. These cost-effectiveness ratios however might be achievable for
only a small minority of selected patients and would certainly not be generalisable to
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all carotid endarterectomy patients. A more realistic "stroke-free" life year
expectancy gain for the majority of CEA patients to be used in calculating cost-
effectiveness ratios, which would be generalisable, would probably be between four
and eight months (Table 5.19 and 5.20).
The CEA cost-effectiveness ratio in terms of life years gained, expressed as either the
cost per life year or QALY gained, were classified with interventions in the middle
and lower upper ranges of the cost-effectiveness league table (Appendix 7). For
example interventions such as kidney transplant, breast cancer screening, heart
transplantation and cholesterol testing and treatment even at the most favourable
benefit and cost scenarios.
The most unfavourable cost-effectiveness ratio calculated in terms of stroke
prevented was £114 873 when only 4 life months were gained and the cost difference
between the alternative treatments was about £4200 which makes CEA as a stroke
prevention strategy an extremely expensive option in terms of the published
categories for assessing cost-effectiveness of procedures. The best cost-effectiveness
ratio in terms of stroke prevented was £18 054 when 20 stroke-free months were
gained and the cost difference between the alternative treatments was about £3330
(Tables 5.21).
Gaining 12 months or more in "stroke-free" life expectancy will result in highly
favourable cost-effectiveness ratios per stroke prevented almost irrespective of the
cost differences between surgical and medical cohorts treated over time. Whether
benefits of this magnitude could be obtained for the majority of CEA patients
remains questionable. It is apparent from the sensitivity analysis that the cost -
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effectiveness ratio per stroke prevented is highly sensitive to the "stroke-free" life
expectancy gained by CEA and less sensitive to the cost difference between the
alternative interventions. Furthermore, a more desirable cost-effectiveness ratio was
obtained when life-years gained were quality adjusted.
Carotid endcirterectomv and the cost ofstroke
The cost of carotid endarterectomy and thus the cost-effectiveness of the procedure
can not be discussed without assessing the cost of stroke. Since the primary objective
of carotid endarterectomy is the prevention of stroke and the benefit of CEA is
expressed in terms of "stroke-free" survival, it is imperative to assess the cost-
effectiveness ratio of CEA against the cost of stroke care. The cost of stroke care can
essentially be divided into acute care and the long-term stroke care costs. These two
cost components constitute the "life-time" cost of stroke. Though the direct cost of
the acute care of stroke patients has been estimated (Bergman et ah, 1995;
Smurawska et ah, 1994), few studies have investigated the "life-time" cost of stroke
(Jorgenson et ah, 1997; Taylor et ah, 1996; Terent et ah, 1994; Asplund et ah, 1993).
The average acute care cost per hospital stroke in-patients in Scotland was estimated
at about £8500 (Forbes and Dennis, 1995). The lifetime cost of stroke in the United
Kingdom has been estimated at £59 000 (Pollock, 1997). The corresponding figure
for the lifetime cost in the USA has been estimated at about $100 000 (Kent et ah,
1995). In the absence of a more accurate estimate of the life-time cost of stroke,
applying the cost of £59 000 per stroke patient over a "life-time" as reference cost in
this analysis, it is "evident" that carotid endarterectomy might be quite costly in
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preventing stroke and might only be cost-effective under exceptional circumstance
for carefully selected patients.
5.5 Summary.
This study found that the five-year "stroke-free" survival of all Scottish patients who
had a CEA outside the ECST compared with the Scottish patients who were
randomised to surgery in the ECST was not the same. This suggested that trial patients
do "better" than patients not associated with a trial. The most favourable cost-
effectiveness ratios were between £18 054 and £22 836 per life-year gained when the
stroke-free life-years gained was 20 months. These favourable cost-effectiveness ratios
appear to be unlikely to be achieved under efficacy outcomes presently obtained.
Although is it generally assumed that the overall results of randomised controlled
clinical trials are generalisable to all patients in the trial and all future similar patients,
this assumption has been shown to be invalid in this study. The relative cost-
effectiveness of CEA was stronger associated with the benefit of "stroke-free" survival
obtained from carotid surgery than with the cost difference between alternative
treatments.
"The great scientific accomplishments of the randomised controlled trials will not be
fully realised until we have established mechanisms for ensuring that patients who
cannot benefit from carotid endarterectomy do not undergo it and that patients who
are appropriately selected receive its full benefit" (Chassin, 1998).
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Table 5.1: Breakdown of Scottish ECST cohort randomised to surgery and medical
care (1981 -1994).




CEA performed 167 (14*) 181
No CEA 0 107 107
Cross-overs 5 14* 5
Missing 14 1 15
Total 186 122 308
*CEA from medical care cross-overs
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Table 5.2: Baseline characteristics of the Scottish ECST-surgery cohort and the
Scottish non-ECST matched control cohort from ISD (1981 - 1994).
Scottish-ECST surgery cohort Scottish non-ECST matched
(n = 172) cohort (n = 172)
Males 111 (66%) 111(66%)
Females 56 (34%) 56 (34%)
Mean age (SD) 61.1 (7.74) 61.1 (7.69)
Age categories:
< 50 years 14 12
50 - 65 years 101 105
66 - 80 years 52 50
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Table 5.3: Degree of internal carotid artery stenosis for the surgical patients in the
ECST from the reported angiogram findings in the ECST data set.
ECST surgical participants
Scottish cohort Other centres All ECST
Degree of stenosis (n = 186) (n= 1621) participants
(n= 1807)
0 - 29% (Low) 15 (8%) 290(18%) 305 (17%)
30 - 69% (Moderate) 38 (20%) 557 (34%) 595 (33%)
70 - 99% (Severe) 126 (68%) 699 (43%) 825 (46%)
Not recorded 7 (4%) 75(5%) 82(4%)
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Table 5.4: Early and late strokes observed for the different cohorts in the Scottish
ISD-CEA data set: 1981 - 1996.
Stroke events (s)
<30 days 30 days - 5 years 0 days - 5 years
Scottish non-ECST non- 110 359 469
matched cohort: (n = 2558) (4.3%) (14%) (18.3%)
Scottish non-ECST 7 42 49
matched control: (n = 167) (4.2%) (25%) (29.3%)
Scottish ISD-CEA non- 117 401 518
ECST: (n =2725) (4.3% 14.7%) (19%)
Scottish-ECST cohort 11 16 27
(n = 167) (7%) (9.6%) (16.2%)
Total events: Scottish 128 417 545
ISD-CEA data set: (n = 2892) (4.4%) (18.8%) (18.8%)
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Table 5.5: Early and late deaths observed for the different cohorts in the ISD-CEA
data set: 1981 -1996.
Deaths (d)
<30 days 30 days - 5 years 0 days - 5 years
Scottish non-ECST non- 59 345 404
matched cohort: (n = 2558) (2.3%) (13.5%) (15.8%)
Scottish non-ECST 5 41 42
matched control: (n = 167) (3%) (24.6%) (25%)
Scottish ISD-CEA non- 64 386 446
ECST: (n = 2725) (2.3%) (14.2%) (16.4%)
Scottish-ECST cohort 2 36 38
(n = 167) (1%) (21.6%) (22.8%)
Total deaths: Scottish 66 418 484
ISD-CEA data set: (n = 2892) (2.3%) (16.7%) (16.7%)
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Table 5.6: Number of recorded episodes of care for the Scottish-ECST surgical and
medical cohorts by diagnostic group for the entire period and for a five-year period
of follow-up.
Episodes of care Surgery group Medical group Scottish-ECST cohort
(n = 172) (n = 121) (n = 293)
Entire period of 1627 (67%) 809 2436
follow-up
Five years of 978 (64%) 547 1525
follow-up
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Table 5.7: Breakdown of admission by speciality for the Scottish-ECST surgery and
medical cohorts by ICD9 diagnosis code for a five-year period from date of
randomisation.
Surgery cohort Medical cohort Scottish-ECST cohort
(n - 172) (n = 121) (n = 293)
General surgery 348(36%) 146 (27%) 494
General medicine 246 (25%) 147 (27%) 393
Neurology 68 (6.9%) 47 (8.6%) 115
ITU 44 (4.5%) 24 (4.4%) 68
Other 272 (28%) 183 (34%) 455
Total episodes 978 (64%) 547 (36%) 1525
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Table 5.8: Breakdown of admission by type for the Scottish-ECST surgery and
medical cohorts by ICD9 diagnosis code for a five-year period from date of
randomisation.
Scottish-ECST cohort (n= 293)
ICD 9 diagnosis Surgery cohort Medical cohort Total
(n= 172) (n =121) (n = 293)
Cerebrovascular 345 (35%) 158 (29%) 503 (33%)
Admissions
Cardiovascular 276 (28%) 148 (27%) 424 (28%)
Admissions
Other 357 (37%) 241 (44%) 598 (39%)
admissions
Total admissions 978 547 1525
299
Chapter Five: CEA, RCTs and cost -effectiveness
Table 5.9: Cumulative "stroke-free" survival for all the carotid endarterectomy
patients in Scotland (1981 -1996) according to ECST status.
Scottish ECST cohort ISD-CEA non-ECST cohort
Time Cumulative Number Cumulative Number
(years) survival remaining survival remaining
0 0.9934 166 .09938 2708
0.5 0.9341* 156 0.8991 2360
1 0.9222 154 0.8712 2085
1.5 0.8982 150 0.8520 1853
2 0.8802 147 0.8351 1667
2.5 0.8622** 143 0.8208 1477
3.0 0.8062 1281
3.5 0.8500 138 0.7981 1101




5 0.8373 129 0.7713 747
*0.78 years **2.6 years
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Table 5.10: Cumulative survival for all cause mortality survival tables for all CEA
patients in Scotland (1981 -1996) according to ECST status.
Scottish ECST cohort ISD-CEA non-ECST cohort
Time Cumulative Number Cumulative Number
(years) survival remaining survival remaining
0.1 0.9940 166 0.9941?? 2724??
0.5 0.9701 162 0.9580 2514
1 0.9521 159 0.9388 2251
1.5 0.9401 157 0.9205 1994
2 0.8993 1790
2.5 0.9041 150 0.8796 1586
3 0.8799* 144 0.8587 1366
3.5 0.8615 140 0.8335 1182
4.00 0.8242 132 0.8142 1039
4.5 0.7928 126 0.7880 870
5 0.7610** 118 0.7583 744
*3.26 years; **4.9 years
Log-rank: p= 0.48; Breslow: p = 0.32
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Table 5.11: Cumulative "stroke-free" survival over five years of the Scottish-ECST
surgery cohort from ECST data set and the Scottish ECST-surgicai cohort and the
Scottish ISD-CEA non-ECST matched cohort from the ISD-CEA data set.
ECST data set ISD data set
Scottish cohort* ECST cohort Matched control
Time Cumulative Number Cumulative Number Cumulative Number
(Years) survival remaining survival remaining survival remaining




1 0.8917 161 0.9222 154 0.8323 139
2.5 0.85221 148 0.8622 143 0.7843 130
3 0.8288 141 0.85612 142 0.7478s 120
4 COoo© 135 0.8438 136 0.7290 116
5 0.75834 126 0.8373 129 0.7037 110
*Scottish-ECST surgery cohort
0 2.1 years;2) 2.7 years; 3) 3.5 years; 4) 4.4 years 5) 3.6 years
Log-rank p = 0.01; Breslowp = 0.015
302
Chapter Five: CEA, RCTs and cost -effectiveness
Table 5.12: Cumulative overall survival over five years of all cause mortality of the
Scottish-ECST surgery cohort from ECST data set and the Scottish ECST-surgical
cohort and the Scottish ISD-CEA non-ECST matched cohort.
ECST data set ISD data set
Scottish cohort* ECST cohort Matched control
Time Cumulative Number Cumulative Number Cumulative Number
(years) survival remaining survival remaining survival remaining
0 0.9946 185 0.9940 166 0.9940 166
0.5 0.9731 181 0.9701 162 0.9521 159
1 0.9570 178 0.9521 159 0.9341 156
2.5 0.9024 163 0.9101 151 0.8801 146
3 0.8802 158 0.8860 147 0.8318 137
4 0.8268 135 0.8304 133 0.7762 124
5 0.7583 119 0.7670 118 0.7445 116
*Scottish-ECST surgery cohort
Log-rank p = 0.8; Breslow p = 0.7
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Table 5.13: Resource use for the Scottish-ECST surgical and medical cohorts
expressed in terms of bed days and based on the CEA cost description study results
over a five year period from randomisation.







Randomisation year 172(100%) 15.3 121 (100%) 7.8
Year two 41 (23%) 22 26 (22%) 13.4
Year three 49 (28%) 29 28 (23%) 72
Year four 43 (25%) 8.5 19(16%) 10
Year five 37 (22%) 12.3 24(20%) 9.5
Over the five years 172 38.0 121 33.4
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Table 5.14: Total mean cost (£) for the Scottish-ECST surgical and medical patients
from date of randomisation for five years of follow-up based on CEA cost
description study results.
Surgical cohort Medical cohort Scottish- ECST cohort
(n = 172) (n = 121 (n= 293)
Mean (£) 14 751 10 530 13 008
Median (£) 9416 3896 7316
IQR (£) 6716- 15 611 1196 - 7856 4346- 12 416
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Table 5.15: Total mean cost (£) for the Scottish-ECST surgical and medical cohorts
from the date of randomisation for each of the five years of follow-up based on the







Randomisation year 8292 2405 5861
Year two 1551 1012 1328
Year three 2505 4934 3508
Year four 635 541 596
Year five 792 683 747
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Table 5.16: OPCS coding and HRG coding for the Scottish-ECST surgical cohort.
OPCS OPCS 3 OPCS 3 OPCS 4 Total
code code code code
missing incorrect correct correct
Appropriate - 1 57 58
HRG (35%)
Invalid dominant 2 5 91 - 98
procedure (59%)
Invalid primary 8 2 - 10
diagnosis (6%)
Subtotal 10 6 93 57 166
HRG missing 20* - - - 20
Total 30 6 93 57 186
* 20 = 5 cross overs, 14 patients not linked, 1 missing
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Table 5.17: Total mean adjusted cost (£) for the Scottish-ECST surgery and medical
cohorts from date of randomisation for five years of follow-up based on HRG
reference costs.
Total mean cost (£)
Surgical cohort Medical cohort Scottish-ECST cohort






5018- 11 942 3176 - 7601 4221 - 10 419
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Table 5.18: Total mean adjusted cost (£) for the Scottish-ECST surgical and medical
patients from the date of randomisation for each of the five years of follow-up based
on HRG reference costs.







Randomisation year 4088 1584 3054
Year two 652 326 518
Year three 829 581 727
Year four 835 781 813
Year five 867 535 730
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Table 5.19: Cost-effectiveness ratios (CER) expressed as cost (£) / life years gained
using cost estimates and effectiveness estimates from the final results of the ECST
and a modelling study.
Cost estimates: CEA cost description results (£4212)
Effectiveness data ECST Modelling QALY
(life-years gained) (0.61) (0.37) (0.93)
CER per life year 6905 11 384 4529
gained (£)
CER per stroke 62 145 102 456 40 671
prevented (£)
Cost estimates: HRG cost reference (£3330)
Effect estimates ECST Modelling QALY
CER per life year 5459 9000 3581
gained (£)
CER per stroke 49 131 81 000 32 226
prevented (£)
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Table 5.20: One-way sensitivity analysis applying the cost difference (5 cost) of the
CEA cost description study between the surgical and medical cohorts to the




Cost /life year gained Cost / stroke prevented
0.33 (4 months)* 12 764 114 873
0.66 (8 months)* 6 382 57 436
1 (12 months) 4212 37 908
1.33 (16 months) 3167 28 502
1.66 (20 months) 2537 22 836
*females
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Table 5.21: Sensitivity analysis applying the cost difference (5 cost) between the
surgical and medical cohorts based on the HRG reference costs to the estimated




Cost /life-year gained Cost / stroke prevented
0.33 (4 months)* 10 091 90 818
0.66 (8 months)* 5045 45 409
1 (12 months) 3330 29 970
1.33 (16 months) 2504 22 534
1.66 (20 months) 2006 18 054
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Figure 5.1: Age distribution in five-year intervals for the surgical cohort of Scottish-
ECST participants.
Age distribution in 2.5-year intervals
(SD = 7.69; Mean 61.1; n = 167; Kolmogorov- Smirnov statistic = 0.089)
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Figure 5.2: Kaplan-Meier estimates of any hospitalised stroke (curtailed at five
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Figure 5. 3: Kaplan-Meier estimates of death for any cause {curtailed at five years)
Scottish ISD-CEA non-ECST cohort and Scottish ECST-surgical cohort.
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Figure 5.4: Kaplan-Meier estimates of stroke from any cause (curtailed at five
years) after CEA for the Scottish-ECST cohort (trial data set); Scottish-ECST
























Chapter Five: CEA, RCTs and cost -effectiveness
Figure 5.5: Kaplan-Meier estimates of stroke form any cause at 30-days after CEA
for the Scottish-ECST cohort (trial data set); Scottish-ECST cohort (ISD-CEA data
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Figure 5.6: Kaplan-Meier estimates of death from any cause (curtailed at five years)
after CEA for the Scottish ECST cohort (trial data set); Scottish-ECST cohort (ISD-
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Figure 5.7: The mean total cost (£) distribution for a period of five years from
randomisation for the Scottish-ECST surgery and medical cohort based on CEA
cost description study results. (Mean = £13 008; n =293)
300
250-
In patient mean cost (£)
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Figure 5.8: The mean total cost (£) distribution for a period of five years from
randomisation for the Scottish-ECST surgery group based on CEA cost description
study results. (Mean = £14 751; n =172)
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Figure 5.9: Resource use (£) over five years for the Scottish-ECST surgical and
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Figure 5.10: Resource use (£) over five years for the Scottish-ECST surgical and
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Figure 5.11: The mean total cost (£) distribution for five years from randomisation
for the Scottish-ECST surgery and medical care cohorts based on HRG costs.
(Mean = £7832;n = 172 (surgical) n = 121 (medical))
In-patient mean cost (£)
323
Chapter Five: CEA, RCTs and cost -effectiveness
Figure 5.12: Cumulative mean cost (£) for Scottish-ECST surgical and medical
























Carotid endarterectomy is a cost-effective strategy to prevent stroke in carefully
selected patients provided that the cost of the procedure is within the lower cost
limits (£3330) of this study and provided stroke-free life expectancy of 12 months or
more are gained. Carotid endarterectomy as a universal recommendation for all
patients with severe carotid stenosis (70 - 99%) is not cost-effective.
The systematic review of the literature reporting on the cost and cost-effectiveness of
carotid endarterectomy and the pre-operative investigations has highlighted the need
for more rigorously designed and conducted economic research. Economic
assessment of interventions should form an integral part of clinical research and
should not be attached as an afterthought to already completed clinical research.
The cost of carotid endarterectomy estimated in the prospective study suggested that
the actual procedure is relatively inexpensive (£3700), and comparable with similar
vascular procedures. The cost of "working-up" a cohort of patients who might benefit
from carotid endarterectomy accounted for most (68%) of the "total" carotid
endarterectomy programme cost. Although the total programme cost of carotid
endarterectomy, (i.e. the work-up cost and procedure cost) was estimated, it might be
considered inappropriate to include the work-up cost of all patients who might be
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potential carotid endarterectomy candidates in the total cost of carotid
endarterectomy, since this is a cost to the basic health care delivery service anyway.
Unacceptable time delays in this study from the most recently recorded transient
ischaemic symptoms to carotid endarterectomy which, diminish the benefit derived
from carotid endarterectomy, were found in about 25% of patients from assessment
at a neurovascular clinic to carotid surgery. If the first recorded transient ischaemic
attack symptom were used, instead of the most recent symptom, it is more than likely
that these time delays described in this study would have been greater, thereby
reducing the benefit derived form carotid endarterectomy even further. Achieving
cost-effective carotid endarterectomy will require a concerted effort by all health care
providers to ensure that the management of patients who have the most to gain is
expedited. Maximising the cost-effectiveness of carotid endarterectomy will also
demand a certain amount of knowledge and understanding by the general population
to recognise transient ischaemic events and to report them timeously to health care
providers.
This study assessing a cohort for potential carotid endarterectomy, provided original
information in determining a patient ratio from initial assessment at a neurovascular
clinic, to duplex, to angiogram to carotid endarterectomy which might be invaluable
in the planning and development of neurovascular clinic services such as "one-stop"
clinics.
Although it was considered that cost estimates based on National Reference Costs to
assess the resource use in a cohort of patients who presented with similar symptoms,
but who were treated either surgically or medically, presented an underestimation of
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actual resource use, using a bottom-up approach might again lead to an
overestimation of costs. The use of inaccurate information to allocate resources
might have serious implications for health care planners, purchasers and providers.
Assessing carotid endarterectomy over a period of almost twenty years in Scotland,
an increased frequency was found over time, which could be linked to the publication
of the results form the two large carotid endarterectomy randomised controlled trials.
Routinely collected data were used as the primary data source in this investigation,
and demonstrated again the importance of previous concerns regarding the accuracy
of these data sources. I acknowledge that the routinely collected data source, the
Scottish medical record linkage database, is exceptional because of its size,
comprehensiveness and "proven" quality of records. However, the high degrees of
accuracy previously quoted (90 - 99%) were not easily achieved. Although data on
the number of admissions, by diagnostic code (ICD 9-code), operation code (OPCS 3
and 4) and by speciality, as well as length of hospital stay are available, these data
are poor proxies for the more directly relevant information such as clinical variables
(for example the degree of carotid stenosis where relevant, blood pressure, body mass
index, serum cholesterol, etceteras).
This study found that the majority of hospitals in Scotland performing carotid
endarterectomies after the publication of the randomised controlled trials are so-
called low-volume hospitals performing one to twelve operations per year. Most of
the carotid endarterectomies performed were in a small number of high-volume
hospitals. This is in sharp contrast to the minimum numbers of operations of 50 per
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year per centre as suggested in the Scottish Intercollegiate Guidelines Network on the
Management of Carotid Stenosis and Carotid Endarterectomy. The findings in this
study suggest that these recommendations might not be appropriate for Scotland with
a relatively small and geographically dispersed population.
In assessing the transferability of results from randomised controlled trials into
general everyday practice settings, it is suggested that routinely collected data sets
should be extended to capture more clinically relevant information, thus increasing
the potential for definitive comparisons.
The cost-effectiveness of carotid endarterectomy as a stroke prevention strategy can
only be assiduously assessed once the life-time cost of a stroke is known and once
the cost of the alternative treatment modalities are carefully considered. We have at
best only approximations of the total lifetime cost of a disease, which is considered
the third leading cause of death and disability in the developed world. The cost of the
alternative treatments to carotid endarterectomy, medical as well as surgical, has not
yet formally been assessed. The cost of medical care, as was also the case in this
study, is usually crudely defined. Although it is recognised that the cost of one year
treatment of aspirin might be negligible, and thus not have a pronounced influence on
the cost-effectiveness measure obtained in this study, this might not be the case with
the newer more costly antiplatelet treatments which might result in an economic
outcome more in favour of carotid endarterectomy. The cost ofmanaging the adverse
effects experienced by some patients, such as gastrointestinal haemorrhage which is a
major complication of chronic aspirin use, should be accounted for in any rigorous
economic evaluation of costs and benefits.
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6.2 Future related research and recommendations.
Several further areas of research arise from this thesis and I summarise some of them
with suggested recommendations below:
6.2.1 Administrative routinely collected data sets
• Although not directly derived from the results of this study, it was clear
throughout the investigation that the absence of clinical variables in the data
sources investigated limited the potential of the study. Therefore, consideration
should be given to incorporating clinically relevant variables in routinely collected
data sets.
• Wider consultation should be encouraged between researchers, academic
institutions and national institutions in order to decide on data to be collected in
national data sets that are relevant to national health objectives.
• Again not directly derived from the results, but evident during investigation that
coding errors could be minimised if clinicians and health care professionals
responsible for submitting records to national organisations should be made aware
of the importance of these returns in terms of quality, accuracy and application of
routinely collected data.
• A sense of "ownership of data" should be aimed at in order to improve the quality
and validity of data.
• The development of a National Reference Cost for the Healthcare Resources
Groups in the NHS, Scotland should be pursued since the current study had to rely
on the National Reference cost for the UK with discrepancies in HRGs between
Chapter Six: Conclusions
what is published for the UK and HRGs used in Scotland. E.g. Invalid primary
diagnosis used as HRG in Scotland but not in the National Reference cost on the
UK.
6.2.2 Health Service Delivery.
• Since most of the cost in the work-up of a cohort who might be considered for
potential CEA is associated with the consultation at the neurovascular clinics, it
seems prudent to allow primary health care physicians autonomy to refer patients
with symptoms suggestive of transient ischaemic attacks directly for carotid
duplex ultrasound prior to referring these patients for a specialist consultation.
• One-stop transient ischaemic attack clinics should be implemented as an extension
of the existing neurovascular clinics to avoid delays in the work-up of patients
who might benefit from carotid endarterectomy and to maximise the cost-
effectiveness of this procedure.
6.2.3 Cost aspects
• A study estimating the lifetime cost of stroke in the United Kingdom is long
overdue. Closely associated with such a study should be measures to assess
quality of life preferences in stroke patients.
• A well-designed study measuring the direct cost of medical interventions is





In this thesis, I have demonstrated that carotid endarterectomy is relatively
inexpensive, and that an increase in the numbers of carotid endarterectomy is evident
since the publication of the randomised controlled clinical trials. I have further
demonstrated that the results from randomised controlled trials might not be
transferable to settings outside trials conditions, though this finding was influenced
by the data source investigated. I have also illustrated that carotid endarterectomy
might be cost-effective in carefully selected patients, provided maximum benefit in
terms of stroke-free life expectancy, is conferred by surgery. The important finding
from this study is that we need a more precise estimate of the life-time cost of stroke
as well as more reliable cost estimates for the alternative treatments to carotid
endarterectomy. It will not be possible to give a definitive answer to the question of
the cost-effectiveness of carotid endarterectomy as a stroke prevention strategy until




For the purpose of this investigation the following definitions and terms applied
except where otherwise defined in the text.
All cause mortality is defined as a death from any cause including a fatal stroke and
reflects overall survival.
Stroke was defined as a clinical syndrome characterised by "rapidly developing
symptoms and/or signs of focal and at times global loss of cerebral function, lasting
longer than 24 hours or leading to death, with no apparent cause other than that of
vascular origin" (Aho et al., 1980).
"Stroke-free" survival was defined as surviving for a total period of five years after
successful carotid surgery, without experiencing any hospitalised stroke event.
Any stroke event included a major stroke as defined with symptoms lasting longer
than seven days; disabling stroke was a stroke that after six months was associated
with disability as recorded on the modified Rankin Scale of 3, 4 or 5. A fatal stroke




A minor stroke was an acute disturbance of focal neurological function with
symptoms lasting more than 24 hours and less than seven days. A minor stroke was
by definition not disabling after one week of onset.
A transient ischaemic attack was an acute disturbance of focal neurological or
mononuclear function with symptoms lasting less than 24 hours and (after adequate
investigation) assumed to be due to vascular disease of an embolic or thrombotic
kind. (UK-TIA study group, 1991)
All stroke events included any stroke event and transient ischaemic attacks.
"Stroke-free" survival was defined as surviving for a total period of 5 years after
successful carotid surgery, without experiencing any hospitalised stroke event.
ECST refers to the European Carotid Surgery Trial.
NASCET refers to the North American Symptomatic Carotid endarterectomy Trial.
ACAS refers to the Asymptomatic Carotid Atherosclerotic Study.
Programme cost of CEA includes the work-up cost of a cohort of patients for CEA
and the procedure cost ofCEA of the patients who received surgery.
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CEA Cost description study refers to the prospective cost description study
performed at the Royal Infirmary Edinburgh and the Southern General Glasgow.
ISD database refers to the Scottish National database of the Information and
Statistics Division of the National Health Service in Scotland.
CEA ISD-CEA data set refers to all the patients who had a CEA between 1981 and
1996 and were extracted from the ISD database using CEA as identifying event.
Scottish-ECST cohort refers to all Scottish participants (both medical and surgical)
in the ECST.
Scottish-ECST surgical cohort refers to all Scottish participants who were
randomised to surgery and best medical care in the ECST.
Scottish-ECSTmedical cohort refers to all Scottish participants who were
randomised to medical in the ECST.
Real life populations refer to patients encountered in everyday clinical and practice
situations.
Pre-operative refers to the assessment and work-up period before surgery usually as
an outpatient with the exception of the angiogram for which the patient requires
admission.
Glossary
Perioperative refers to the period in hospital prior to the carotid surgery.
CEA refers to carotid endarterectomy.
RCT refers to randomised controlled trial.
LSR refers to the Lothian Stroke Register
NVCs refer to the neurovascular clinics at the Western General Hospital, the
Southern General Hospital and the vascular clinics at the Royal Infirmary Edinburgh.




Appendix 1: MEDLINE and EMBASE search strategies.
MEDLINE search strategy (Databases: 1966 - 1998)
1. exp economics/
2. expl health care resources
3. exp length of stay.





9. (length adjlO stay),tw,
10. 1 or 2 or 3 or 4 or 5 or6 or 7 or 8 or 9
11. exp endarterectomy/
12. exp carotid arteries/
13. exp carotid artery disease/
14. carotidS.tw
15. 11 or 12 or 13 or 14
16. 10 and 15
17. human/
18. animals/
19. 17 and 18
20. 18 not 19
21. 16 not 20
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Appendix 1 (Continue): EMBASE search strategy (Databases 1974 - 1998)
1. exp economic aspect/
2. exp audit/
3. exp health care cost/
4. exp hospital running cost/
5. exp biomedical technology assessment/
6. exp medical audit/




11. (length adjlO sray).tw.




16. Exp health economics/
17. or/1 -16
18. exp carotid artery/
19. exp carotid artery disease/
20. exp carotid artery surgery
21. endarterectomy/
22. carotidS.tw.
23. 18 or 19 or 20 or 21 or 22
24. human ti, ab,hw, tn, mf. or "888".tg
25. animal ti, ab,hw, tn, mf. or "777".tg
26. 24 and 25
27. 25 not 26
28. 17 and 23
29. 28 not 27
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Appendix 2: Checklist for the economic evaluation.
Referees' checklist (also to be used, implicitly by authors)





1 .The research question is stated □ □ □
2.The economic importance of the research
question is stated □ □ □
3. The viewpoint(s) of the analysis are clearly
stated □ □ □
4. The rationale for choosing the alternative
programmes or interventions compared is stated. □ □ □
5. The alternatives being compared are
described. □ □ □
6. The form of economic evaluation used is
stated. □ □ □
7. The choice of form of the economic evaluation
is justified in relation to the question addressed. □ □ □
Data collection
8. The source(s) of effectiveness estimates used
are stated. □ □ □
9. Details of the design and results of
effectiveness study are given (if based only on a
single study) □ □ □ □
10. Details of the methods of synthesis or meta¬
analysis of estimates are given (if based on an
overview of a number of effectiveness studies)
□ □ □ □
11 .The primary measure(s) for the economic
evaluation are clearly stated. □ □ □
12. Methods to evaluate health states and other
benefits are stated □ □ □ □
13. Details of the subjects from whom valuations
were obtained are given.













15. The relevance of productivity chances to the
study question is discussed.
16. Quantities of resources are reported
separately from their unit costs
17. Methods for the estimation of quantities and
unit costs re described.
18. Currency and price data are recorded
19. Details of currency of price adjustments for
inflation or currency conversion are given
20. Details of any model used are given.
21. The choice of model used and the key
parameters on which it is based are justified.
22.Analysis and interpretation of results.
23. Time horizon of costs and benefits is stated.
24. The discount rate(s) is stated.
25. The choice of rate(s) is justified.
26. An explanation is given if costs or benefits are
not discounted.
27. Details of statistical tests and confidence
intervals are given for stochastic data
28.The choice of variables for sensitivity analysis
is justified.
29. The ranges over which the variables are
varied are stated.
30. Relevant alternatives are compared
31. Incremental analysis is reported
32. Major outcomes are presented in a
disaggregated as well as aggregated form
33. The answer to the study question is given.
34. Conclusions follow form the data reported.

























Appendix 3: Lothian Stroke Register Protocol
1 Aims
The Register aims to collect information on Stroke, Transient Ischaemic Attack (TIA) and
Retinal Artery Occlusion (RAO) (qualifying 'events') victims presenting at the Western
General Hospital, whether admitted or not. This information will be available for
individual patient care. The primary purpose for collecting this information will be for long
term research.
2 Notification
Any patient showing symptoms consistent with one or more of the qualifying events may
be notified for entry into the database. Notification requires that the patient is examined by
a registering neurologist who completes a notification form. Where a patient is
subsequently shown not to meet required criteria, the information need NOT be removed
from the database, but the patient will not be 'registered'. Once registered, a patient may be
considered for continued observation - 'Follow up'. Criteria for Registration and Follow up
are shown below:
Register Follow up
No base date (a) NO NO
Other diagnosis (b) NO NO
Strokes not seen within 6 months (c) YES NO




Note a) base date is date of first symptoms for stroke, examination for TIA or
RAO;
b) ie not stroke nor TIA nor RAO;
c) from date of first symptoms;
d) from date of last event (updated 29/11/95).
A patient may be notified repeatedly if they fall victim to repeated qualifying events. A
patient may only be followed up on one qualifying event at any one time.
3 Data restrictions
Many investigations may be carried out on patients at any time, but are only of relevance
to our study if conducted within defined time intervals from their event. Ranges
permitted in days from base date are -30 to +30 for blood tests, ECG or CXR, 0 to +99
for CT or Doppler, or -30 to +99 where the diagnosis is NOT stroke, -30 to +99 for
trans-thoracic and trans-oesophageal echo-cardiograms.
341
Appendices












Please PRINTall details in BLACK ink






















Inpatient: Y / N (circle)




Time : Date / /
Examined by (circle)
Time : Date of admission
(ifknown) Date / / of discharge
General medicine / Neurology / Stroke / Neurosurgery / Oncology / Urology / Surgery /
other:
of examination
CPW / MSD / PAGS / other:
Summary of this event
Abnormal neurological signs on examination
Final diagnosis Stroke ( > 24 h )
Transient Ischaemic Attack (< 24 h )
Retinal Artery Occlusion (RAO)
Other (specify):
due to : Cerebrovascular disease at any time
Other
No residual signs
Code 1 = possible (not permittedfor RAO)
2 = probable (not permittedfor RAO)
3 = definite
9 = not applicable
Include events within the last 6 months only. You may code multiple cerebrovascular diagnoses. Leave no blanks.
Patient history Code boxes 1 = Yes, 2
Patient able to give adequate history
Previous Myocardial Infarction
Previous stroke with residual disability
Previous stroke without residual disability
Previous TLA of the brain
Code TIA/ROA: L = left, M = Mid, R = right, B= both, 1
Previous carotid endarterectomy
(Code side of CEA 1 = R, 2 = L, 3 = both, 9 = not known)
Hypertension (history or treatment at any time)
Angina pectoris known before stroke
Atrial fibrillation known before stroke
Breathless walking on an incline
Cardiac surgery (e.g angioplasty)^?^).-
Intermittent claudication
Peripheral vascular surgery
Diabetes mellitus known before stroke
Epilepsy known before stroke
History of migraine with aura













Alcohol > 2 units daily
Smoker (inch Given up < 12 months)
Ex-smoker > 12 months
Employed until this event




0 = no symptoms
1 = minor symptoms which do not interfere with life style
2= some restriction to lifestyle but look after themselves
3= significant restriction to lifestyle, preventing total
independence
4 = severe handicap preventing independent existence but
not requiring constant attention
5 = severe handicap, totally dependent, requiring constant
attention day and night.
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Treatment Code boxes 1 = Yes, 2 = No, 9 — unassessable, Blank = may be completed later.
At time of event Started since event
Antiplatelet
Anticoagulant
Antihypertensive (ifhistory of hypertension)










Clinical heart failure (i.e. signs ofLVF / RVF, not just on Rx, specify)
Clinical valvular heart disease (not simple flow murmur < 2/6, specify)





Sections 1-6 (above) must be completed for all patients.
? Stroke - If a patient has exhibited Brain Symptoms for more than 24 hours (i.e. a Stroke), section 7 must be
completed. Before finalising the Stroke Diagnosis part of this section, you may find it useful to complete section 9 -
Persistent neurological signs. Code duration of symptoms only when symptoms are resolved at examination. If not,
code 'U'.
? TIA / RAO - If a patient exhibited episodes with Brain Symptoms resolved within 24 hours, or with Eye Symptoms
(i.e. Transient Ischaemic Attack - TIA, or Retinal Artery Occlusion - RAO), section 8 must be completed. Note that a
patient may have a definite TIA, but distribution may be probable or definite etc.
? multiple events - You may record more than one type of event on this form. You may record a series of TIAs in
each distribution and a series of RAOs and a stroke on one form. However, you may only record one stroke on this
form. You must record all relevant cerebrovascular diagnoses in section 3. If any cerebrovascular diagnosis is made,
ignore Other diagnoses.
If a patient shows any Abnormal neurological signs on examination, regardless of diagnosis section 9 must be
completed. This applies even if none of the features specifically mentioned are abnormal. Please record residual
neurological signs from previous events and / or other diagnoses. If present, specify in narrative.
Sections 10-11 must be completed for all patients.
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Brain Symptoms > 24 hours Completefor patients exhibiting brain symptoms longer than 24h i.e. STROKES
History of ictus
Time is by 24 hour clock,
dates are dd/mm/yy
Symptoms present on waking
Headache within 2 hours of onset
Vomited since symptom onset
Loss of consciousness at onset





/ / symptoms first noticed
II ofmaximum deficit
Seizure(s) since symptom onset

















Recognise 2 people (e.g.Dr. & Sr)
Date of birth
Dates ofWorld War I or II
Present Monarch — , ,total
(Code '88' if clinically unassessable)
Duration of symptoms,
if resolved at examination






















Scale - see p2, 6 = dead)
£
Brain Symptoms lasting < 24h or any Eye Symptoms
Complete this section for patients exhibiting Brain Symptoms lasting less than 24 hours or Eye Symptoms i.e. TIAs or RAOs





























Persistent Neurologi cal Signs regardless of diagnosis
Complete this page for patients exhibiting Abnormal Neurological Signs at Examiitation
















Gaze palsy to this side
Abnormal swallowing
Motor deficit (ifyes, code next column)
Sensory deficit (ifyes, code next column)
Cerebellar limb deficit
Truncal ataxia (including gait)
Definite brainstem signs
Incontinence since stroke (incl catheter)
Able to sit independently
Able to sand independently












Motor deficit code: Neglect /











Sensation - spinothalamic (pain and touch)
Face
Arm / hand
nornuil, 2 ■= reduced, 3 = severely
^Cerebellar function and co-ordination
1 = normal, 2 = reduced, 3 = severely impaired 1 absent
Code all boxes 1 = Yes, 2 = No, 9 = unassessable, Blank = may be completed later
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Registration Code boxes 1 = Yes, 2 = No, Blank = may be completed later.
Trials
Food
Enter patient into Register
Eligible Rando
mised





























Atrial fib / flutter
LBBB, RBBB, LAD1






1 Left Bundle Branch Block, Right Bundle Branch Block, Left Axis Deviation
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Appendix 5: Breakdown of the cost associated with having a carotid duplex





Capital Room 1019 0.85
Ultrasound machine 23 500 19.58
Human Radiographer (full-time) 46 405 38.67
resources Radiologist (30%)
Consumables Gel, colour and black and 7 400 6.17
and white printer paper, paper







Appendix 6: Carotid endarterectomy cost description study data collection forms.
Patient registration
Section I: PATIENT REGISTRATION

























Date of first symptom:











Patient Operation d d m m y y Study no
name date
Section 2: ADMISSION AND DISCHARGE DETAILS
Was the patient admitted for an initial Yes
assessment of carotid stenosis
If yes, for how many days
Date admitted for angiogram
Date discharged after angiogram
Date admitted for CEA
Date discharged (or died)
Date of surgery
Date admitted to ITU
Date discharged from ITU
Date admitted to HDU
Date discharged from HDU
Date admitted to surgery ward
Date discharged from surgery ward






Status on discharge: Alive Dead











Drug name Dose/unit Frequency
During hospitalisation
Drug name Dose/unit Route Doses given
On Discharge (only changes from admission drugs)




































Patient Operation date d d m m Y Y Study
name no
Section 5: OPERATION TIME;
Time of arrival in anaesthetic room
Time of start of anaesthetic procedures
Time of departure from theatre

















Grade A Grade B
Grade C Grade D


























Vessel retractor x 1
Number INSTRUMENTS:





Gowns (disp) x 1
Gowns (disp) x 3
Gowns (linen) x 1

























Patient Operation d d rn m y y Study no
name date
Section 8: MEDICATIONS IN THEATRE:
(to be completed by anaesthetist please)
REGIONAL CERVICAL BLOCK:





Drug name Dose / % per ampoule No of amps used
Propofol 200mg
Propofol pre-filled syringes 500mg




























TYPE VOLUME OF UNITS NUMBER GIVEN
Hartmanns Solution 500 ml
Normal Saline 500 ml
Gelofusine 500ml
PPS 400 ml
Dextran 70 500 ml






























Appendix 7: League table of costs and quality-adjusted-life-years (QALYs) for
selected health care interventions.
Cost /QALY
(£ Aug 1990)
Cholesterol testing and diet therapy only (all adults, 220
aged 40 - 69)
Neurosurgical intervention for head injury 240
GP advice to stop smoking 270
Neurosurgical intervention for subarachnoid 490
haemorrhage
Anti-hypertensive therapy to prevent stroke 940
Pacemaker implantation 1100
Hip replacement 1180
Valve replacement for aortic stenosis 1140
Cholesterol testing and treatment 1480
CABG1 (left main vessel disease, severe angina) 2090
Kidney transplant 4710
Breast cancer screening 5780
Heart transplantation 7840
Cholesterol testing and treatment (incrementally) of all 14 150
adults aged, 25 -39 years
Home haemodialysis 17 260
CABG1 (one vessel disease, moderate angina) 18 830
CAPB2 19 870
Hospital haemodialysis 21970
Erythropoietin treatment for anaemia in dialysis patients 54 380
(assuming a 10% reduction in mortality)
Neurosurgical intervention for malignant intracranial 107 780
tumours
Erythropoietin treatment for anaemia in dialysis patients 126 290
(assuming no reduction in survival)
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Appendix 8: My contribution to this thesis.
This work was carried out at the Departments of Public Health Sciences and
Clinical Neurosciences at the University of Edinburgh.
I designed the study under the supervision ofDr John Forbes and Prof. Charles Warlow.
I performed a situation analysis of carotid endarterectomy in Scotland. This constitutes
the largest historical cohort analysed to date over the longest time period and in excess
of 12 500 patient-years of observation. The systematic review was entirely my own
work. This is the first systematic review on the literature assessing the costs and benefits
of carotid endarterectomy and not only the cost of the procedure. This is also the first
economic review that has been conducted using a standard evaluation protocol
recommended to authors, referees and editors for the review of economic submissions to
journals.
«
I performed the first prospective study in Scotland and the United Kingdom estimating
the cost of carotid endarterectomy. I designed the data collection forms, collated and
analysed the data. Data were collected by the personnel in the Vascular surgery theatres
under the supervision of Sr. Grace Ross at the Royal Infirmary Edinburgh and Dr
George Welsh at the Southern General Glasgow. 1 performed a sensitivity analysis to
address the uncertainty associated with cost analysis of this nature.
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Alan Finlayson compiled the data set of all patients who had a CEA over the last sixteen
years in Scotland form the national database at ISD. Chris Povey and Brian Reid, also
from ISD, attached the cost data for these patients to the data set. The data so obtained
allowed me to describe CEA over 16 years in Scotland and to assess the transferability
of the efficacy results of the European Carotid Surgery Trial in a "real" patient
population over the same study period. I performed all the analysis including the
survival analysis for this data set.
I extracted all the Scottish patients who were randomised into the ECST from the ECST
data set, linked these patients to the ISD database and performed the analysis to test
various hypotheses.
I analysed the cost data from ISD and described the use of resources of the Scottish
surgical and medical cohorts in the ECST using generic cost measures as well as
Healthcare Resource Groups. These cost estimates in conjunction with the cost estimates
form the carotid endarterectomy cost description study allowed cost effectiveness
analysis.
It is hoped for that the findings of this thesis might provide more definitive answers to
the uncertainty associated with the cost-effectiveness of CEA as reported by previous
modelling studies addressing this issue.
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Appendix 9: Publications so far.
Benade MM, Warlow CP, Forbes JF. Carotid endarterectomy: What does it really
cost? Poster presentation 8th European Stroke conference, Venice April 1999)
Benade MM, Warlow CP, Forbes JF. Carotid endarterectomy: Survival in a
Scottish cohort and randomised controlled trials
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